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Abstract 
Healthcare associated infection confers a significant burden of morbidity and mortality to 
renal patients and to renal dialysis patients in particular.  Sepsis is second only to 
cardiovascular disease as the leading documented cause of death in patients requiring renal 
replacement therapy.  Gram positive bacteraemia is common in the renal replacement 
therapy population and is highly associated with indwelling haemodialysis catheter use.  
Optimal prevention and management of bacteraemia in this setting has not been fully 
determined and requires a multidisciplinary and multifaceted approach.   
 
Each of the studies in this thesis investigates an aspect of healthcare associated infection in 
nephrology within the theme of exploring clinical problems arising from the development 
of antibiotic resistance or antibiotic associated infections in renal patients.   
 
Initially we examined risk factors and outcomes of acute kidney injury requiring renal 
replacement therapy in a tertiary renal unit and critical care population prior to and 
subsequent to a change in antimicrobial guidelines in response to an outbreak of 
Clostridium difficile associated disease. We performed this study to address concerns that 
the increase in the empiric use of gentamicin may have led to an increased incidence of 
acute kidney injury and a greater requirement for emergency renal replacement therapy.   
 
Secondly we explored the clinical implications of gram positive infection in a renal unit 
population by performing a retrospective review of Staphylococcus aureus and coagulase 
negative staphylococcal bacteraemia over a 2 year period with particular attention to 
admission rates, vascular access intervention, antibiotic resistance, metastatic infection and 
mortality.   
 
Thirdly we have analysed S. aureus toxin genes and assessed the epidemiology of S. 
aureus colonisation and infection to improve our understanding of the virulence of S. 
aureus in different patient populations including a large haemodialysis unit in Glasgow.     
 
Finally we undertook a prospective double blind randomised controlled trial of probiotic 
milk drink and placebo in renal unit inpatients commencing antibiotic therapy to assess if a 
probiotic was effective in the prevention of antibiotic associated diarrhoea and Clostridium 
difficile associated diarrhoea.  We performed this study as patients with chronic kidney 
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disease are at increased risk of infection and have a significant antibiotic burden, which 
can lead to antimicrobial resistance, antibiotic associated diarrhoea and 
pseudomembranous colitis due to Clostridium difficile infection.  
 
The study of healthcare associated infection is an evolving field and involves complex 
interactions between colonisation and infection.   There is increasing emphasis on 
prevention of infection and minimising complications and side effects associated with 
standard antimicrobials.  The rising incidence of multiresistant bacterial infections is likely 
to result in increasing focus on preventive bundles of care and alternatives to antimicrobial 
therapy such as the use of probiotics.  The findings of this thesis contribute to the goal of 
prevention of antibiotic resistance and multiresistant infections in renal patients although 
further research is required. 
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Definitions/Abbreviations 
ACE Angiotensin converting enzyme 
AAD Antibiotic associated diarrhoea 
ARB Angiotensin 2 receptor blocker 
AKI Acute kidney injury 
ARF Acute renal failure 
AVF Arteriovenous fistula 
AVG Arteriovenous graft 
BBE Bare below the elbows 
BMI Body Mass Index 
BURP Based Upon Repeat Pattern 
CA-MRSA Community acquired methicillin resistant Staphylococcus aureus 
CDAD Clostridium difficile associated disease 
CFU Colony Forming Units 
CI Confidence Interval 
CKD Chronic Kidney Disease 
CRBSI Catheter-Related Blood Stream Infection 
CRP C-Reactive Protein 
CRRT Continuous renal replacement therapy 
CVC 
 
Central Venous Catheter 
CVVH 
 
Continuous veno-veno filtration 
 17
CVVHDF Continuous veno-veno diafiltration 
eGFR Estimated Glomerular Filtration Rate 
EPR Electronic Patient Record 
ESRF End-stage renal failure 
ETA Exfoliative toxin A 
ETB Exfoliative toxin B 
GGC Greater Glasgow and Clyde 
HCAI Healthcare associated infection 
HD Haemodialysis 
HPS Health Protection Scotland 
HR Hazard Ratio 
ITU Intensive Treatment Unit 
IRRT Intermittent renal replacement therapy 
KDIGO Kidney Disease Improving Global Outcomes 
KIM Kidney Injury Molecule 
HCAI Healthcare associated infection 
HD Haemodialysis 
HD Haemodialysis 
HPS Health Protection Scotland 
HR Hazard Ratio 
ICU Intensive Care Unit 
IRRT Intermittent renal replacement therapy 
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KDIGO Kidney Disease Improving Global Outcomes 
MRSA Methicillin Resistant Staphylococcus Aureus 
MSSA Methicillin Sensitive Staphylococcus Aureus 
NCEPOD National Confidential Enquiry into Patient Outcome and Death 
NGAL Neutrophil gelatinase-associated lipocalin 
NTCVC Non-Tunnelled Central Venous Catheter 
OR Odds Ratio 
PCR Polymerase chain reaction 
PPI Proton pump inhibitor 
RIFLE Risk, Injury, Loss, Failure, Endstage renal disease 
RRT Renal Replacement Therapy 
SAB Staphylococcus aureus bacteraemia 
SD Standard Deviation 
SLED Sustained low efficiency dialysis 
SSS Scalded skin syndrome 
TSS Toxic shock syndrome 
TSST Toxic shock toxin 
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Chapter 1: Background 
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1.1  Acute kidney injury 
1.1.1 The evolution of acute kidney injury as a 
diagnosis 
Identification of an acute decline in renal function was first mentioned as a clinical entity 
in the 18th century although Hippocrates correctly identified that the presence of bubbles in 
the urine could indicate renal disease in the 4th century BC.  In the 2nd century AD, Galen 
of Pergamos first observed that blood is filtered by the kidneys and urine is transported to 
the bladder by the ureters.  He identified a basic differential diagnosis of a reduction of 
urine output based on the presence or absence of a distended urinary bladder based on 
clinical examination (1).  Later that century, Rufus Ephesius studied the changes associated 
with initial oliguric then polyuric acute renal dysfunction.   Non oliguric acute renal 
dysfunction had not been recognised.  By the 4th century AD, it was well established that if 
oliguria or anuria persisted, then death would follow.  Treatment was supportive with 
dietary measure and improved sanitation although laxatives were sometimes used in a 
primitive method of water and toxin removal.        
 
The 19th century English physician Richard Bright first connected the historical illness of 
“dropsy”, observed as a clinical triad of widespread oedema, pathological renal 
abnormalities at postmortem examination, and proteinuria (found by heating the urine and 
denaturing the protein) (2).  He published detailed drawings of dissected kidneys with 
granular changes under the renal capsule with loss of some anatomical landmarks and also 
described pericardial effusions and cerebral haemorrhage.  It is thought that these 
descriptions and drawings are the first visual representations of glomulonephritis.  Bright’s 
disease may be the first regularly used English eponymous disease.  Later, Richard Bright 
was involved in the identification of elevated blood urea levels in Bright’s disease.  He also 
describes abnormalities in the pulse of patients with Bright’s disease that are felt to 
represent hypertension, which had not yet been identified as devices measuring blood 
pressure came into use in the 1890s.      
 
Military medicine in the 20th century resulted in more detailed pathological examination of 
the diseased kidney following trauma and crush injury leading to the identification of 
pigmented casts and tubular damage, potentially as a result of rhabdomyolysis.  This was 
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initially termed “war nephritis”.  The term “acute renal failure” was first introduced by 
Homer W Smith in his textbook “The Kidney: Structure and Function in Health and 
Disease” (2).  Knowledge progressed during the remainder of the 20th century with the 
development of haemodialysis, renal transplantation and further pathological diagnoses, 
however a clinical definition of acute renal failure and formal diagnostic criteria remained 
elusive.  This resulted in wide variations in the reported incidence of acute renal failure and 
heterogeneity of studies leading to difficulty with comparison between populations and 
huge variations in reported clinical outcomes.  The first haemodialysis machine was built 
by Williem Kolff in the Netherlands in 1944 (3).  He used cellophane tubing as a conduit 
to carry the patient's blood through an extracorporeal circuit in contact with an electrolyte 
bath of known composition, equivalent to the concentration of electrolytes and glucose in 
normal plasma.  Comments made in these early experiences of what at the time, was 
termed “ lower nephron nephrosis“ remain pertinent to the management of a patient with 
AKI today: 
 
 “Clinical management of acute renal insufficiency is usually difficult and at times 
discouraging but a majority of patients will respond to conservative measures. 
The causes of death in the remaining minority are pulmonary edema, extreme 
uremia, fulminating potassium intoxication and overwhelming sepsis from 
infection usually introduced at the time of the original trauma, which in turn 
precipitated the lower nephron nephrosis. Conservative therapy with special 
emphasis on proper hydration of each individual patient (scrupulously avoiding 
overhydration) is the keystone of the therapeutic arch.” 
 
1.1.2  Defining acute kidney injury 
Evidence from the early 21st century demonstrated that small rises in serum creatinine 
associated with acute illness resulted in significant increases in mortality(4).  As a result, 
the term ARF was replaced with acute kidney injury (AKI).  The RIFLE criteria were 
developed by the Acute Dialysis Quality Initiative (AQDI) in order to incorporate the 
spectrum of the clinical syndrome (risk, injury, failure, loss, end stage kidney disease 
(ESRD)) (5).  This pyramid of diagnostic criteria are illustrated below (Figure 1-1)   
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Figure 1-1 The RIFLE classification separates criteria for serum creatinine and urine 
output (5) 
 
The severity of AKI is graded based on changes in serum creatinine or urine output with 
the worst of each criterion used.   A retrospective observational study of over 8000 
intensive care unit inpatients showed clear separation by 60 days survival according to the 
RIFLE criteria with the difference persisting to 1 year (Figure 1-2).  Progressing through 
the RIFLE stages is associated with increasing length of stay in the ICU and hospital and 
decreased renal recovery(6).   
 
The RIFLE criteria were limited by its requirement for retrospective information and a 
baseline serum creatinine.  Accurate urine output monitoring can be difficult out of a 
critical care setting and can be affected by diuretics and abnormalities in ADH (anti 
diuretic hormone) secretion such as diabetes insipidus.      
 
The RIFLE criteria have been applied to various patient groups including burns (7), 
decompensated heart failure (8), and in brain deceased kidney donors where the risk and 
injury groups were associated with delayed graft function (9).   
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Figure 1-2 One-year survival after stratification with the RIFLE criteria (6) 
   
Recognition of AKI and stratification of its severity was further refined by the Acute 
Kidney Injury Network (AKIN).  Their criteria were based on the RIFLE criteria and first 
proposed in 2007.  The major addition was the broadening of the “risk” category of RIFLE 
to include smaller changes in serum creatinine.  Change in serum creatinine was to be 
documented over a 48 hour window.  A statement was added that criteria were to be used 
after “optimum hydration and easily reversible causes were excluded”. 
 
 Both the RIFLE and AKIN criteria have been used in several large trials and are well 
validated tools in predicting prognosis in AKI although evidence of superiority of AKIN 
over RIFLE is lacking (10).     
 
Initially, AKI staging criteria were predominantly used in research and audit or in highly 
monitored environments such as the intensive treatment unit (ITU), however, increasingly 
they have been identified as triggers for specific forms of clinical assessment or 
investigations or as part of early warning scoring systems.   
 
Most recently, the KDIGO have further refined diagnostic criteria with the staging criteria 
as defined below (Table 1-1).  It is hoped that this will translate to improved outcomes and 
reduction in severity of AKI.  
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Table 1-1 KDIGO staging criteria for severity of AKI 
 
Stage  Serum creatinine Urine output 
1 1.5-1.9 times baseline 
OR 
≥ 26.4micromol/l increase 
 
<0.5ml/kg/h for 6-12 hours 
2 2.0-2.9 times baseline <0.5ml/kg/h  
for ≥ 12 hours 
3 3.0 times baseline 
OR 
Increase in serum 
creatinine to ≥ 
353.6micromol/l 
OR 
Initiation of renal 
replacement therapy 
 
<0.3ml/kg/h for  
≥ 24 hours 
OR 
Anuria ≥ 12 hours 
 
 
Any staging criteria for AKI require initial recognition that the patient is suffering from or 
at risk of AKI and appropriate alteration in their management with regular monitoring of 
biochemistry, fluid balance and clinical assessment.  
 
1.1.3 Recognition of AKI 
Despite the now well known increase in mortality associated with AKI, recognition and 
appropriate management of patients with AKI can be difficult.  The National Confidential 
Enquiry into Patient Outcome and Death (NCEPOD) held an enquiry into management of 
patients who died at least in part secondary to AKI and identified deficiencies in 
management of this patient group. (11)  A total of 587 patients had case notes and 
questionnaires returned to the reviewers.  90% of patients included had been admitted to 
hospital as an emergency and 60% of patients were under the care of general or medicine 
for the elderly physicians.  88% patients had evidence of kidney disease on admission with 
46% of these patients being diagnosed with AKI.         
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The NCEPOD team attempted to evaluate by means of retrospective case note review, 
whether care of such patients was adequate and identified several areas of deficiency 
including lack of recognition of AKI, delayed management and in some cases, lack of 
referral to tertiary services when in retrospect this was appropriate.  They detailed a 
number of main recommendations relating to prompt checking of electrolytes on 
emergency admissions, early senior review of all acute admissions, appropriate access to 
nephrology and critical care settings and 24 hour access to imaging and emergency urinary 
tract decompression of urinary tract obstruction.  The NCEPOD review also stressed the 
requirement for robust assessment of the patient who acquires AKI while in hospital and 
that there is a means of recognising and highlighting the acutely unwell patient and 
instituting an appropriate plan for review and monitoring as recommended in the National 
Institute for Clinical Excellence (NICE) guideline 50.   
Overall, only 50% patients were considered to have experienced good clinical care.  A 
much smaller proportion, (<10%), were considered to have had deficiencies in 
organizational aspects of their admission. Only 30% of those who developed AKI while 
inpatient in hospital were considered to have experienced good quality care.  64% patients 
had a definitive diagnosis made to explain the episode of AKI.  43% of patients who 
developed AKI while an inpatient had an unacceptable delay in the recognition of AKI in 
the opinion of the advisors.  20.6% cases of AKI occurring while inpatient were 
determined as being predictable and avoidable in the opinion of the assessors.  In total, 
60% patients were in stage 3 AKI when their renal failure was recognised.  113 patients 
were transferred to renal units or critical care.  Forty-four of the 273 remaining patients 
with available case notes who were not transferred to a renal unit or critical care setting 
were judged as potentially benefiting from transfer to a higher level of care.   
Access to nephrology advice has been identified as impacting on the level of care a patient 
with acute kidney injury receives.  The NCEPOD found that 14% hospitals did not have 
access to an on call nephrologist for telephone advice.   
The NCEPOD report concluded that deficiencies in the management of a patient with AKI 
are likely to be representative of deficiencies in the general management of the acutely 
unwell hospital inpatient.    
Timing of admission to hospital has also been found to impact on treatment for AKI (12).  
Retrospective database analysis of 963,730 admissions with a diagnosis of AKI within 
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acute care, nonfederal U.S. hospitals found that 22.3% patients were admitted at a 
weekend.  They had similar baseline characteristics and length of stay, however there was 
significantly increased odds ratios for death when adjusted for age, gender, race, Charlson 
comorbidity index, and use of mechanical ventilation at 3 days; 1.22 (1.15 to 1.30) and in 
hospital; 1.07 (1.02 to 1.12).  This large dataset is limited by its retrospective data where 
AKI was identified by means of clinical coding.  These findings from a large clinical 
database highlight the need for further investigation of the availability of senior clinicians 
and diagnostic services outwith normal working hours.  
1.1.4 Timing of renal replacement therapy in acute 
kidney injury 
There is no consensus on the optimum time to commence renal replacement therapy (RRT) 
for AKI.  Indications for emergency RRT are well established, however the exact timing is 
controversial.  It is conventional to initiate RRT when oliguria persists despite correction 
of precipitating factors in order to prevent and treat the complications of AKI, including 
hyperkalaemia, fluid overload, metabolic acidosis and symptomatic uraemia.  Timing of 
RRT in the non oliguric patient is less obvious with no definite benefit to early initiation of 
RRT or well conducted studies in this area.    
 
Observational research has suggested a U shaped curve between the timing of the initiation 
of RRT and in hospital mortality and that staging criteria in this context is unhelpful.  The 
heterogenous nature of patients requiring acute RRT results in difficulties in comparison 
between patients and study groups (13) (14).  Meta analysis is also limited due to 
variations in parameters used in the initiation of RRT although the lack of a specific trigger 
such as serum creatinine or urea has been highlighted(15).  
 
The only randomised controlled study investigating the impact of the timing of RRT on 
outcomes originated in the Netherlands where 106 patients in an intensive care unit (ICU) 
setting were randomised to early versus late initiation of RRT.  The early initiation group 
started RRT within 12 hours of oliguria or at a creatinine clearance (CrCl) of 20ml/min. 
The late-initiation group started RRT when classic indications were met. There was no 
significant difference in ICU or in hospital mortality, and no difference in renal recovery 
although it is limited by its small size (16).  
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1.1.5 Mode of renal replacement therapy in acute 
kidney injury 
The indications for emergency renal replacement therapy are well recognised, being 
refractory hyperkalaemia, metabolic acidosis, fluid overload resistant to medical therapy, 
symptoms or signs of uraemia and toxicity with certain poisonous substances (17, 18).  
Each modality has advantages and evidence of superiority of one modality over another in 
the acute setting is lacking in part due to the heterogenous nature of the populations 
involved.  A Cochrane review found that there was limited evidence of continuous veno 
veno filtration resulting in a more stable mean arterial pressure in haemodynamically 
unstable patients although this has not been shown to translate into improved mortality 
(19).  The optimum dose of renal replacement therapy in AKI is also yet to be determined.  
There is no convincing evidence of a mortality benefit to high doses of renal replacement 
therapy (20).   
 
RRT in the acute setting can be delivered in a variety of different environments and modes.  
Haemodialysis (HD) is predominantly delivered in a nephrology setting.  HD has the 
benefit of providing intermittent RRT allowing the patient to mobilise and does not require 
systemic anticoagulation.  It allows the diffusion of solutes across a semipermeable 
membrane.  The dialysate flows in the opposite direction to blood in the extracorporeal 
circuit, thus maintaining the concentration gradient and increasing dialysis efficiency.  
Ultrafiltration results from an alteration of the hydrostatic pressure across the membrane 
allowing free water to move out of the blood compartment.  
 
 Continuous veno veno haemofiltration (CVVH) is delivered in a critical care setting.  In 
CVVH there is movement of solutes across a semi permeable membrane using convection 
which are then drained with isotonic fluid added to the resulting blood to replace water and 
solutes.  There is limited evidence that CVVH provides greater haemodynamic stability, 
however evidence of superiority of one mode of RRT against another is lacking with 
similar outcomes reported (19) (18).   
 
Continuous veno veno haemodiafiltration (CVVHDF) is a combination of HD and CVVH.  
Blood is pumped through the blood compartment of a high flux dialyser with a high rate of 
ultrafiltration, resulting in the movement of water and solutes from blood to dialysate.  
These are replaced by substitution fluid that is infused directly into the blood line. 
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However, dialysis solution is also run through the dialysate compartment of the dialyser. 
The combination is theoretically useful because it results in good removal of both large and 
small molecular weight solutes.  It is increasing used in an ESRF population although hard 
outcome data suggesting benefit is currently lacking.  It was available in 50% critical care 
units in 2008 and used first line in 16% of units (21).  Intermittent haemodiafiltration was 
compared to intermittent HD in a small randomised non blinded study of 39 patients with 
acute kidney injury with similar outcomes and biochemical parameters (22).  CVVHDF 
and intermittent HD were compared in a randomised controlled trial of 360 patients in 
French intensive care units between 1999 and 2003 (23).  There was no significant 
difference in death between the 2 groups with survival at 60 days being 32% in the 
intermittent HD group and 33% in the CVVHDF group (95% CI -8.8 to 11.1).  There was 
significantly more hypothermia in the CVVHDF group (p=0.0005).    
 
A hybrid technique named sustained low-efficiency dialysis (SLED) is employed in some 
units providing RRT to critically ill patients.  The first published data was from a single 
centre in Arkansas, USA where 145 SLED treatments were performed in 37 patients where 
intermittent HD had failed due to intradialytic hypotension, failure to meet solute clearance 
goals or been withheld as a result of predicted haemodynamic intolerance by the treating 
clinician (24).  The inpatient mortality of 62.2% was not significantly different to that 
predicted by APACHE II scores at admission to the ICU or at initiation of RRT.   
Retrospective database analysis comparing haemodynamically unstable patients who 
received CVVH between January 2002 and January 2004 and those who received SLED 
between February 2004 and August 2006 has suggested that mortality was improved in the 
SLED group.  This has the disadvantage of a retrospective observational analysis with 
those receiving SLED requiring RRT 2 years after the initial cohort with significant 
difference in inotrope use and creatinine level at initiation of RRT.  An economic 
advantage to SLED has been suggested when a prospective randomised study designed to 
compare clinical outcomes between SLED and CVVH showed significantly reduced 
nursing and consumables costs associated with SLED saving €1300 per patient (25).  
There was no significant difference between the pre-specified outcome measures and in 
particular, no difference in mortality between these 2 groups.          
 
Peritoneal dialysis can be used in an AKI setting, however this is extremely uncommon in 
the adult environment in the UK, although is utilised in the Middle East and developing 
countries. (26)  (27) (28) 
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1.1.6 Mortality associated with acute kidney injury 
Prior to the development of the RIFLE criteria, mortality associated with AKI was not 
clearly defined due to differing definitions between studies.  Although the RIFLE criteria 
were developed in order to standardise AKI diagnosis and severity rather than predict 
prognosis, systematic review has suggested a strong relationship between AKI severity and 
mortality with progression through the stages of the RIFLE criteria associated with 
increasing relative risk of death.  It is notable that the populations studied are almost 
exclusively ITU patients as shown below in the forest plot below (Figure 1-3).     
 
 
Figure 1-3 Forrest plot showing RR for death with respect to non-AKI patients (29).  
(a)Risk (RR 1⁄4 2.40; 58 073 participants included in meta- analysis), (b) Injury (RR 1⁄4 
4.15; 55 351 participants included in meta-analysis), and (c) Failure (RR 1⁄4 6.37; 53 758 
participants included in meta- analysis). Cr, creatinine; UO, urine output. 
 
AKI after myocardial infarction comparing the RIFLE and KDIGO criteria was studied 
retrospectively in 1050 patients (30).  AKI defined by RIFLE and KDIGO occurred in 
14.8% and 36.6% of patients respectively.  There was a significant association between 
patients with AKI as defined by either criteria and mortality at 30 days and at 1 year.  
Patients diagnosed with AKI with the KDIGO criteria but not RIFLE criteria also had 
significantly increased mortality (p<0.001).  Patients were not stratified by stage of AKI.  
38% and 26% of patients with AKI identified by RIFLE and KDIGO criteria respectively 
died within 30 days compared to 8% and 4.7% of the cohort not identified to have AKI by 
RIFLE and KDIGO criteria respectively.     
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Evaluation of 101 patients with acute myocarditis and preexisting normal renal function 
recorded in the National Taiwan University Hospital Study Group on Acute Renal Failure 
database (NSARF) found that, AKI defined as AKIN stage 3 and elevated Sequential 
Organ Failure Assessment score were independent risk factors of in-hospital mortality 
using multivariate logistic stepwise regression (31).  Decreased left ventricular ejection 
fraction and elevated cardiac enzymes were not associated with an increased risk of 
mortality.   
 
Retrospective analysis of patients with diffuse proliferative lupus nephritis suggested that 
the RIFLE criteria could predict short-term prognosis of AKI in this population (32).  
Patients at a more advanced stage of AKI were less likely to achieve complete renal 
recovery and more likely to have progressive renal impairment.  The short follow-up 
duration of 24 weeks, lack of data on baseline serum creatinine, no availability of activity 
index from renal biopsy and the small sample size of 79 patients limit the study.         
 
A prospective study of 200 patients newly diagnosed with high grade haematological 
malignancies compared remission rates in those with and without AKI as defined by the 
RIFLE criteria (33).  68.5% patients developed AKI.  91.4% of cases were as a result of 
hypoperfusion, tumour lysis syndrome, acute tubular necrosis, nephrotoxic agents, or 
hemophagocytic lymphohistiocytosis.  50% of the AKI patients required RRT and 14.6% 
received sub optimal chemotherapy.  AKI was associated with a significantly lower 6 
month complete remission rate (39.4% vs. 68.3%, P<0.01).  The proportion of patients 
achieving complete remission fell with progression through the RIFLE stages.       
 
Electronic results reporting identified AKI in a hospital-wide prospective study of AKI 
incidence over a 9 month period (34).  This allowed data collection on AKI incidence and 
outcomes in the UK in an unselected hospital inpatient population albeit in a tertiary 
referral centre.  3202 AKI episodes in 2619 patients were identified using the AKIN 
diagnostic criteria.  This represented 5.4% of hospital admissions (both elective and non 
elective). Of these patients, 435 had >1 episode of AKI and 1970 (61.5%) episodes were 
classified as stage 1 AKI, with similar numbers in stage 2 (638; 19.9%) and stage 3 (594; 
18.6%).  The in-hospital mortality rate for the entire AKI population was 23.8% (624 
patients) with hospital wide mortality rate for emergency admissions at 3.2%. Patients with 
normal pre-existing renal function had increased risk of mortality as they progressed 
through the AKI stages.  Significantly higher mortality rates were observed in those with 
hospital-acquired AKI: 28.9% compared to 20.6% in those with community-acquired AKI 
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(P<0.001).   This study is notable due to the broad spectrum of patients included and large 
patient population with prospective data collection.      
 
1.1.7 Outcomes in patients following AKI 
Renal outcomes in an adult ICU population of 2164 patients were evaluated in the North 
East Italian Prospective Hospital Renal Outcome Survey on Acute Kidney Injury 
(NEiPHROS-AKI) trial (35).  10.8% patients developed AKI as defined by the RIFLE 
criteria.  19% were classified as risk (R), 35% as injury (I), and 46% as failure.  3.3% of all 
patients required RRT.  Overall mortality for patients with AKI was 36.3%, significantly 
higher than the remainder of the cohort (p<0.001).  Patients with class F AKI had a 
mortality of 49.5%.  36% of patients with AKI recovered renal function by the time of 
death or ICU discharge.  No data was available for renal recovery in survivors. 
 
Health-related quality of life (HRQOL) was assessed in 397 patients following ICU 
admission (36).  73 patients required RRT for AKI.  Patients or a proxy completed the 
Short-Form 36 (37) within 48 hours of ICU admission and followed up survivors for 6 
months following ICU discharge.  Although patients had significantly lower HRQOL after 
ICU admission, there was no significant difference between patients who required RRT 
and those who did not.   
 
A population based cohort study evaluated AKI outcomes from a provincial claims registry 
in Alberta, Canada with patients having been admitted to the hospital between November 
1, 2002 and December 31, 2007 (38).  3.7% participants (7014 patients) experienced AKI 
during the study period.  AKI in this study was defined as an increase in serum creatinine 
by ≥100% and/or requirement for acute dialysis during the index hospitalisation.  4400 
patients (62.7%) survived 90 days after hospital discharge.  3231 of these patients were 
available for follow up for a median of 34 months.  30.8% of these patients died and 2.1% 
(85 patients) progressed to requiring long term renal replacement therapy.  Baseline renal 
function was lower in patients who developed AKI (p< 0.01).  Patients with complicated 
diabetes and congestive cardiac failure were less likely to recover renal function (p<0.01), 
as were patients with CKD at baseline (p<0.01).  Patients who did not fully recover renal 
function had increased hazard ratios for death at 1.23 (95% CI 1.08, 1.40), which persisted 
when adjusted for age and comorbidities.    
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Meta analysis of AKI outcomes in 2009 included 49 studies although only 15 of these 
reported data relating to non-AKI controls (39).  The incidence rate of mortality was 8.9 
per 100 person-years in survivors of AKI and was 4.3 per 100 patient-years in survivors 
without AKI (RR 2.59, 95% CI 1.97-3.42). AKI was associated independently with 
mortality risk in 6 of 6 studies that performed multivariate adjustment (adjusted RR 1.6-
3.9) and it was associated with myocardial infarction in 2 of 2 studies (RR 2.05, 95% CI 
1.61-2.61). The incidence rate of CKD after an episode of AKI was 7.8 per 100 patient 
years and the rate of ESRD was 4.9 per 100 patient-years.   
 
 
1.1.8 Economic impact of AKI 
The cost of renal replacement therapy varies depending on the environment it is delivered 
(renal unit v critical care), staffing, consumables and treatment modality.  The Beginning 
and Ending Supportive Therapy for the Kidney (BEST Kidney) study performed a post-
hoc analysis of costs associated with RRT (40).  Overall costs were not quoted.  Nursing 
costs were higher with intermittent RRT (IRRT), however dialysate, extracorporeal 
circuits, and replacement fluid costs were higher with continuous RRT (CRRT).  There 
was significant variation between centres and when all costs were combined cost 
differences ranged between $3629.80 more per day with CRRT to $378.60 more per day 
with IRRT.  RRT for AKI in the Belgian multi-centre Stuivenberg Hospital Acute Renal 
Failure 4 study cost on average €30 447 for CRRT and € 25 176 for IRRT (41).   
 
1.1.9 Gentamicin associated AKI 
Gentamicin is the most widely used of the aminoglycoside antibiotics and has synergistic 
antimicrobial activity against gram negative bacilli and gram positive cocci.  In line with 
other aminoglycosides, it has the potential for nephrotoxicity and ototoxicity.  99% of 
aminoglycoside administered parenterally is excreted via the kidney (42). 
 
The precise pathophysiology of gentamicin-associated nephrotoxicity is not completely 
understood.  It is well recognised that after filtration, gentamicin is absorbed into the 
proximal convoluted tubule by endocytosis leading to fusion with lysosomes and myeloid 
body formation, and movement into the golgi apparatus with movement into the 
endoplasmic reticulum before being released into the cytoplasm (43) (44).  Thereafter, a 
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number of mechanisms for aminoglycoside-induced nephrotoxicity have been postulated.  
Various studies have identified renal abnormalities including decreased protein synthesis, 
induction of apoptosis, tubular necrosis and abnormal cell respiration although the relative 
importance of each is yet to be determined (45) (46) (47) (48) .  Gentamicin-associated 
AKI is characteristically non-oliguric before glomerular filtration falls.  Tubular 
regeneration marks renal recovery.  
 
The reported incidence of gentamicin associated AKI varies due to differences in study 
design and definition.  A historical review of available literature in 1984 found that 14% 
patients experienced gentamicin associated AKI although this is limited by a lack of 
consensus on the definition of AKI.  Various risk factors for gentamicin-associated AKI 
have been identified, including abnormal baseline renal function (49), liver disease (50) 
and frequent dosing interval (51).  The optimal dosing regimen is yet to be determined.          
 
A retrospective observational study of gentamicin-associated AKI defined by the RIFLE 
criteria included all patients treated with gentamicin over a 1 month period.  24.4% patients 
had AKI defined by the RIFLE criteria although only 2.4% patients reached the “Failure” 
category.  There was increased risk of in hospital mortality in patients with AKI, rising 
with progression through the RIFLE stages (p<0.001) (52).  
 
High cumulative gentamicin dose increases the risk of development of AKI with prolonged 
duration of therapy and elevated plasma drug concentration being associated with 
deterioration in renal function (53) (54).  Repeated short courses of gentamicin have also 
been shown to be nephrotoxic (54).  It is unclear whether elevated peak or trough 
gentamicin levels are most toxic to the kidney.  Increased age may result in inaccurate 
estimation of creatinine clearance and inadvertent excessive dosing.     
 
Severe sepsis increases the risk of aminoglycoside toxicity.  Volume depletion as a 
component of sepsis reduces the effective circulating volume resulting in renal ischaemia.  
Endotoxin is also directly toxic to the proximal convoluted tubule resulting in 
aminoglycoside accumulation (55).    
 
Patients with advanced liver disease are a particular subset at high risk for gentamicin-
associated AKI.  They have reduced effective circulating volume with activation of the 
renin-angiotensin-aldosterone system (50).  Obstructive jaundice gives increased risk of 
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gentamicin-associated AKI via unknown mechanisms (56).  Hypoalbuminaemia is an 
independent risk factor for AKI (57).  
 
The data presented in Chapter 2 adds to the existing body of research suggesting that 
gentamicin is a safe component in the management of sepsis provided there is sufficient 
monitoring and antimicrobial stewardship.  The subset of patients with RRT dependent 
AKI is under represented in existing literature.  
 
1.1.10 Pathophysiology of acute kidney injury in 
sepsis 
The underlying causative mechanism of acute kidney injury in sepsis has not been fully 
determined.  Histological information is limited as renal biopsy is potentially hazardous 
and impractical in such patients.  The majority of historic animal models were based on 
ischaemia-reperfusion models, however small studies of larger animals suggest an increase 
in renal blood flow in the context of sepsis associated AKI(58).  Monitoring of renal blood 
flow during an observational study of 8 septic intensive care unit inpatients found normal 
renal blood flow in the presence of acute kidney injury(59).   Inflammatory cytokines have 
also been implicated.  Renal endothelial dysfunction in sepsis is suggested by albuminuria 
indicating loss of integrity of the glomerular filtration barrier(60).  There is evidence that 
mice deficient in tumour necrosis factor are resistant to the effects of lipopolysaccharide 
associated acute kidney injury with the absence of morphological changes in endothelial 
cell fenestration(61).   
 
Programmed cell death or apoptosis is provoked by brief periods of renal ischaemia, 
however the role of apoptosis in sepsis associated AKI is unclear.  Human proximal tubule 
cells underwent apoptosis when treated with tumour necrosis factor, interleukin 1 and 
lipopolysaccharide in one model of sepsis associated acute kidney injury(62).  Apoptosis 
of renal cells was also induced when incubated with plasma from a rabbit model of acute 
respiratory distress syndrome suggesting interaction with other organ systems affected in 
the critically ill(63).          
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1.1.11 Role of urinary biomarkers in acute kidney 
injury 
The identification of acute kidney injury prior to a rise in serum creatinine has been the 
subject of considerable research.  Urinary biomarkers have been identified as non invasive 
indicators of acute kidney injury and can identify high risk patients, particularly in the 
context of a specific potential cause of AKI such as surgery or iodinated contrast 
administration(64) (65).   
 
The urinary biomarkers neutrophil gelatinase–associated lipocalin (NGAL) and kidney 
injury molecule (KIM) have been used to identify undifferentiated patients with impending 
AKI in the accident and emergency department.  NGAL is a small secreted polypeptide.  It 
has been shown to be upregulated in the proximal tubular cell after an episode of renal 
ischaemia(66).  KIM is a transmembrane protein.  It is not usually expressed in renal 
tissue, however is present in high numbers in renal tissue following ischaemic or toxic 
injury(67).  Urinary NGAL had increased sensitivity and specificity in one large study of 
over 1600 patients compared to other urinary biomarkers.  Patients with elevated urinary 
biomarkers and AKI were found to be at increased risk in hospital mortality and requiring 
renal replacement therapy(68).  There is also evidence that the underlying cause of AKI 
affects urinary NGAL concentration with a small study showing that patients with AKI 
secondary to sepsis had significantly increased urinary NGAL levels.  There were the 
potential confounders of increased burden of illness and increased prevalence of 
malignancy in the sepsis group(69).  
 
Despite promising results from observational studies, randomised controlled trials of the 
application of urinary biomarkers of AKI in clinical practice are lacking.  The only 
published randomised controlled study evaluating the effects of intervention based on 
urinary biomarkers was terminated early due to adverse events in both study arms(70).                 
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1.2   Role of Staphylococcus spp. bacteria in 
infection and disease  
1.2.1 Taxonomy of staphylococcal bacteria 
The term staphylococcus is from the Greek work staphyle meaning bunch of grapes due to 
the tendency of staphylococci to form microscopic grape-like clusters.  They were first 
identified by Koch in 1878 who recognised that diseases such as abscesses correlated with 
the presence of clusters of Gram-positive cocci.  
 
The Staphylococcus spp. and Streptococcus spp. bacteria constitute the family of Gram-
positive cocci.  The genus Staphylococcus are members of the Micrococcacae family.  
Over 60 species and subspecies of Staphylococcus are currently recognised (71).  At least 
18 staphylococcal species have been isolated from human skin although S. epidermidis 
accounts for at least half of the bacterial burden (72).  
 
Gram-positive refers to the violet staining of the bacterial wall on Gram staining due to 
presence of a thick peptidoglycan layer in the cell wall.  Staphylococcal bacteria are 
ubiquitous in their presence on the skin and mucosal surfaces of almost all animals 
including humans.  S. aureus and the S. hyicus-intermedius group produce coagulase.  S. 
intermedius are zoonotic organisms which can be  associated with human disease (73). S. 
aureus causes more severe disease and can be distinguished genetically by the presence of 
the coagulase gene, clinically by its characteristic appearance and golden pigmentation, 
confirmed by latex agglutination testing and increasingly, using polymerase chain reaction 
testing (PCR) to detect the presence of the thermonuclease gene nuc. 
 
Relationships between staphylococcal species can be estimated by DNA analysis using 
single or multiple genes and illustrated by a phylogram evolutionary tree as shown in 
Figure 1-4 below (71).  
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Figure 1-4 Summary phylogram showing Staphylococcal species combined into six 
species groups and 15 cluster groups.  Cluster groups have been colour-coded to 
represent: blue, species that are novobiocin resistant, coagulase negative, and oxidase 
positive; green, species that are novobiocin susceptible, coagulase negative, and oxidase 
negative; orange, species that are novobiocin resistant, coagulase negative, and oxidase 
negative; purple, species that are novobiocin susceptible, coagulase positive, and oxidase 
negative; and red, species that are novobiocin susceptible, coagulase variable, and oxidase 
negative. Colour scheme exceptions are: #S. schleiferi schleiferi is coagulase negative; *S. 
simiae is coagulase negative; ‡S. hominis novobiosepticus is novobiocin resistant; and †S. 
equorum linens is novobiocin susceptible. 
 
1.2.2 Role of S. aureus colonisation in disease 
S. aureus is persistently present in the anterior nares of 30% of the population and 
transiently found in 70% of the population.  There is evidence that there is increased nasal 
carriage of methicillin resistant S. aureus (MRSA) in those with frequent contact with 
domesticated animals, which suggests that they may be vectors in its spread (74).   
Although S. aureus shows preference for the anterior nares, there is an increase in carriage 
rates at extra-nasal sites in nasal S. aureus carriers.  People colonised with community 
acquired MRSA (CA-MRSA) in particular, may be colonised in the throat or skin but not 
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the anterior nares (75). This forms the basis of MRSA screening of multiple sites in 
hospital inpatients.   
 
 
Figure 1-5 S. aureus carriage rates per body site in adults (76) 
 
Carriers of S. aureus have increased risk of infection secondary to the S. aureus strain they 
carry.  Rates of S. aureus carriage in healthcare workers are similar to adults in the general 
public.  Longitudinal studies suggest that only around 20% people are persistent carriers of 
S. aureus.  These individuals have a higher total burden of S. aureus on their skin (77).  
Studies of persistent carriers after attempted decolonisation suggest that they will select out 
their previous strain even after artificial inoculation with alternative strains (78).  
Observational studies show that insulin dependent diabetics and patients requiring renal 
replacement therapy (RRT) are more likely to be carriers of S. aureus (79) (80).  There is 
also an association with S. aureus carriage and increased risk of relapse with ANCA- 
associated vasculitis with granulomatosis (previously termed Wegener’s granulomatosis) 
(81) although there is no evidence that S. aureus eradication reduces the risk of relapse.  
Environmental factors cannot fully explain the variation in carrier states in humans with a 
genetic component being postulated.  Evidence from twin studies is conflicting (82) (83).              
 
S. aureus infection occurs either by self inoculation or by direct or indirect contact.  
Common risk factors for S. aureus infection include prior colonisation, poor hygiene, 
intravenous drug abuse and comorbidities such as chronic skin conditions, cystic fibrosis 
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and renal dialysis.  The density of nasal colonisation and associated secondary colonisation 
of the skin appears to be important in the risk of staphylococcal infection.   
 
There is specific evidence that elimination of the S. aureus carrier state in some 
populations may reduce the incidence of infection, however the role of S. aureus 
colonisation eradication in populations with a long-term increased risk of S. aureus 
infection, such as dialysis patients is less clear.  Any eradiaction therapy utilising 
antimicrobials such as mupirocin has the potential to promote resistance.  Bacterial 
interference may be a more attractive option where the pathogenic S. aureus is replaced 
with an avirulent version (84).       
 
Attention to hand hygiene is important in reducing healthcare-associated infection 
including the transmission of S. aureus.  Compliance with hand hygiene can be notoriously 
low.  A large longitudinal observational study found hand hygiene rates increasing from 
48% to 66% over a 3-year period with an associated fall in MRSA colonisation and 
nosocomial infection (85).  This observation is correlation rather than causation in this 
population of hospitalised patients.  There were other confounding variables during this 
time period including variations in antimicrobial prescribing.       
 
The evidence for the relationship of hand hygiene and nosocomial infections was reviewed 
further with 31 original studies identified by 2008 on systematic review (86).  Over half of 
these originated from the USA.  Deficiencies in study methodology were identified with 
the lack of a control group being raised as a particular issue.  The authors of this systematic 
review concluded that research linking hand hygiene and HCAI is present, but it has not 
been fully quantified.   
 
The “bare below the elbows” advice in the prevention of HCAI has been criticised due to 
its minimal evidence base.  One study randomized 157 doctors and medical students to 
“bare below the elbows” (BBE) or conventional dress (non BBE) with a white coat tailored 
to the carpometacarpal joint of the thumb (87).  There was no significant difference in the 
percentage area of the hands missed during hand washing between the BBE group and the 
non-BBE group (P = 0.281) (BBE mean: 9.3% ± 9.2; non-BBE mean: 11.1 ± 7.2%).  The 
non-BBE group missed significantly more of the wrist compared with the BBE group 
(P = 0.002).  The mean percentage area missed on the wrists in both groups was 
significantly higher than on the hands (P < 0.001).  The authors recognised that the act of 
observation may have influenced participants although this is likely to be similar in both 
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groups.  BBE therefore had no discernable effect on the effectiveness of hand washing.  
The significance of improved wrist washing with BBE is difficult to translate into 
improved clinical outcomes against HCAI.  Wristwatch wearers have also been shown to 
have an increased bacterial load on their wrists but not their hands in contradiction with 
standard infection control advice (88).    
 
1.2.3 The environment and bed occupancy in S. 
aureus transmission 
Hospital environment, high bed occupancy and patient movement between clinical areas 
may increase transmission of bacteria in a hospital or healthcare trust wide model (89) (90) 
(91) (92) (93).  Unfavourable staff-to-patient ratios have been associated with decreased 
hand hygiene and overcrowding of the ward area has also been associated with an increase 
in MRSA transmission and infection despite an increase in beds available, perhaps due to 
higher bacterial contamination of surface areas with increased patient density. 
 
The patient environment is a common reservoir for bacteria.  Hygiene on 2 UK surgical 
wards was monitored by weekly screening of 10 hand-touch sites during an observational 
study (94).  S. aureus was isolated from lockers, overbed tables and beds.  Recovery of S. 
aureus at any site was significantly associated with aerobic colony counts of > 2.5 cfu/cm2 
which in turn were significantly associated with weekly bed occupancy >95%  (p = 0.0004; 
OR: 2.94 [95% CI 1.44, 6.02]).  This was true for both methicillin sensitive S. aureus 
(MSSA) and methicillin resistant S. aureus (MRSA). 
 
This observation was taken further by an intervention study where a cleaner was 
introduced with the sole job specification of cleaning of common hand-touch sites such as 
those discussed above (95).  Two wards were included with each ward receiving enhanced 
cleaning for six months in a cross-over design. Ten hand-touch sites on both wards were 
screened weekly and patients were monitored for methicillin-resistant S. aureus infection 
throughout.  Molecular analysis assessed the relationship of any MRSA infection to that 
found in the environment.  Enhanced cleaning was associated with a 32.5% reduction in 
levels of microbial contamination at hand-touch sites when wards received enhanced 
cleaning (P < 0.0001: 95% CI 20.2%, 42.9%).  The two wards were well matched for 
demographics with the exception of Ward A being predominantly male and Ward B 
female.  There were no changes to hospital antimicrobial policy or to MRSA screening 
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policy during the period studied.  The authors found that there were fewer new MRSA 
infections during enhanced cleaning at 26.6% (95% CI 7.7%, 92.3%) of the rate during 
normal cleaning (P = 0.032).  Molecular epidemiological methods supported the possibility 
that patients acquired MRSA from hand-touch sites.  
 
1.2.4 Active surveillance of MRSA colonisation 
The screening for MRSA and subsequent isolation of colonised individuals is a widespread 
practice in the healthcare setting.  The National MRSA Screening Programme utilises a 
Clinical Risk Assessment (CRA) designed to identify high risk individuals.  All admissions 
with the exception of obstetrics, paediatrics and psychiatry are assessed by the 3 questions: 
 
• Has the patient ever had a previous positive MRSA result? 
• Has the patient been admitted from a care home/institutional setting or another 
hospital? 
• Does the patient have a wound/ ulcer or invasive device that was present prior 
to admission?   
 
If the answer to any of these questions is yes, the patient undergoes a full MRSA screen.  
This involves swabbing of the anterior nares and perineum in addition to skin lesions, 
wounds and invasive devices if there are any signs of infection.  High impact specialities 
including critical care, orthopaedics, nephrology, vascular and cardiothoracic surgery are 
exempt from the CRA and patients require MRSA screening regardless of any other risk 
factors.   
 
A 12-month prospective trial of universal screening for MRSA in acute care in Scottish 
hospitals found that 3.39% patients (2717/69 445 patients) were identified as colonised 
with MRSA on admission (96). The initial colonisation prevalence of 5.5% significantly 
decreased to 3.5% by month 12 of the study (P < 0.0001).  Multivariate analysis found that 
elderly patients, those with more than a single hospital admission during the year, those 
admitted from another hospital, care home or institution, in addition to those admitted 
under medicine, orthopaedics, ICU, care of the elderly or oncology were more likely to be 
colonised with MRSA.  A total of 422 MRSA infections were identified during the study 
period.  It is notable that the odds of developing an MRSA infection among patients who 
screened positive on admission and who were previously known to be positive for MRSA 
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colonisation was 18.3 (95% CI: 13.0–25.9) times greater than those screened negative for 
MRSA.  The odds of developing infection for those who were screen positive on admission 
and who were not previously known positive were 11.9 (95% CI: 8.1–17.6) times greater 
than for those who screened negative.  These data suggests that universal screening for 
MRSA may be of benefit, especially in hospital settings with a high overall prevalence of 
MRSA.  It would be important to consider the resource implications of this before such a 
programme is implemented (97).  
 
1.2.5 MRSA  
The number of penicillinase-producing S. aureus was very low in the 1940s and this 
rapidly increased when penicillins were introduced.  Methicillin (the first penicillinase 
resistant β-lactam antibiotic) was introduced in 1959 and the first MRSA strains appeared 
2 years later and were rapidly established in places of high antibiotic use.  The European 
Antimicrobial Surveillance System (EARSS) monitors MRSA prevalence in European 
countries.  It maintains a comprehensive surveillance and information system that provides 
comparable and validated data on the prevalence and spread of major invasive bacteria 
such as MRSA. 
 
Methicillin resistance is conferred due to the acquisition of the staphylococcal 
chromosomal cassette mecA gene (SCCmec).  This is confirmed by polymerase chain 
reaction (PCR) testing.  The coagulase negative Staphylococcus epidermis is frequently 
methicillin resistant and carries SCCmec genes with associated theoretical interspecies 
transfer of this gene to S. aureus.      
 
1.2.6 MRSA and MSSA bacteraemia surveillance and 
monitoring 
It is mandatory to report all cases of S. aureus bacteraemia to Health Protection Scotland 
(HPS).   Health Protection Scotland was established by the Scottish Government in 2005 to 
strengthen and co-ordinate health protection in Scotland.  It is organised into three 
specialist groups: Healthcare Associated Infections and Infection Control; Blood Borne 
Viruses and Sexually Transmitted Infections, Immunisation, and Respiratory and Vaccine 
Preventable Diseases; Gastrointestinal and Zoonoses, Travel, and Environment and Health.  
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 HPS has published quarterly reports on the numbers of MRSA bacteraemias in 
Scotland since April 2002. The programme was extended to include reporting of MSSA 
bacteraemias from July 2006. 
  
 Renal units accounted for nearly 5% of all epsodes of methicillin sensitive 
Staphylococcus aureus (MSSA) bacteraemia between 1 April 2005 to 31 March 2009 and 
5.5% methicillin resistant Staphylococcus aureus (MRSA) bacteraemia between 1 January 
2003 to 31 March 2009 in Scotland (98).  It is clear that central venous catheters are a 
specific risk factor for bacteraemia in such patients and have been associated with an 
increased risk of mortality (99).   
 
 The HEAT targets are well defined as: 
• Health Improvement for the people of Scotland - improving life expectancy 
and healthy life expectancy 
• Efficiency and Governance Improvements - continually improve the 
efficiency and effectiveness of the NHS 
• Access to Services - recognising patients' need for quicker and easier use of 
NHS services 
• Treatment Appropriate to Individuals - ensure patients receive high quality 
services that meet their needs 
 
 
Figure 1-6  MRSA and MSSA bacteraemias per 100 000 acute occupied bed days in 
Scotland from March 2006 until March 2013 (100). 
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Figure 1-6 above shows national performance on MRSA and MSSA infections from March 
2006 until March 2013.  For the quarter ending July 2013, the rate of MRSA/MSSA cases 
across NHS Scotland was 0.31 per 1,000 acute occupied bed days. The current HEAT 
target is to further reduce SAB (including MRSA) cases to 0.24 or fewer per 1000 acute 
occupied bed days by March 2015.  Although MRSA cases have consistently fallen, 
MSSA bacteraemia rates are static and efforts to reduce MSSA bacteraemia will be 
required for this target to be reached.     
 
There appear to be differences in the patient populations affected by MSSA and MRSA 
bacteraemia (101).  MRSA bacteraemia is associated with 2.2 fold increased mortality, 
increased duration of hospital admission and increased healthcare costs.  MRSA 
bacteraemia in HD patients is 100x that of the general population (45.2 vs 0.4 
episodes/1,000 patient-years) (102).  HD patients account for up to 15% of all invasive 
MRSA infections in the USA.   
 
Vancomycin resistant S. aureus (VRSA) remains very rare, with only a few cases reported 
worldwide.  The first European case of VRSA was reported in a Portuguese diabetic HD 
patient in July 2013(103).   
 
1.2.7 Staphylococcus aureus virulence and 
pathogenicity  
S. aureus possesses a number of mechanisms which facilitate its persistence in the 
environment and enhance its ability to cause disease.  The accessory gene regulator (agr) 
reacts to bacterial density, allowing the bacteria to shift between a growth phase in areas of 
low bacterial density, to a stationary phase where it expresses virulence genes in order to 
enhance pathogenicity.   The staphylococcal accessory regulator gene (sar) encodes a 
DNA-binding protein, which controls agr.  Inactivation of agr and sar have been shown to 
decrease the pathogenicity of S. aureus in experimental models.   
 
Some S. aureus clones have the ability to form biofilm although this is more of a feature of 
the less pathogenic coagulase negative staphylococci.  The polysaccharide capsule of the S. 
aureus bacteria can increase S. aureus virulence by being anti-phagocytic and is a potential 
target for vaccines against S. aureus.  Enzymes secreted by S. aureus are often proteases 
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and lipases which promote bacterial pathogenicity by causing tissue destruction and 
providing nutrition to the invading bacteria.   
 
The role of the toxin genes including the Panton Valentine Leucocidin toxin in causing 
disease is discussed in Chapter 4.       
 
1.2.8 Coagulase-negative staphylococcal disease 
The coagulase-negative staphylococci are the most abundant microbes on normal human 
skin and mucous membranes.  They are mostly regarded as non-pathogenic commensals.  
However, they have been associated with disease, particularly in nosocomial infections 
involving implanted vascular devices, prosthetic joints and prosthetic heart valves.  S. 
epidermis is most commonly isolated in humans and is the most prevalent species on 
human skin with the average person carrying more than 10 different strains.  S. lugdunesis 
is rarer, but can result in a clinical syndrome more in keeping with S. aureus infection and 
therefore requires more aggressive treatment.  S. epidermidis is responsible for 50-70% of 
catheter associated infections caused by coagulase negative staphylococci(104).  This has 
been attributed to its ability to form biofilm.  Different species of coagulase negative 
staphylococcus have varying antimicrobial susceptibility, virulence and adhesion 
properties and therefore cause differing patterns of disease(105).  An example is S. 
saprophyticus, which can account for up to 10-15% urinary tract infections with increased 
prevalence in young women(106).  A mechanism for this is a capacity to bind 
preferentially to uroepithelial cells(107).      
 
Coagulase negative staphylococci are often found as components of a biofilm on 
intravascular catheters and this is implicated in its mechanism of causing disease.  It binds 
to the surface then forms an extracellular matrix before forming a “biofilm community”.  
In this environment, the bacteria are in varying states of replication from quiescence to 
active replication.   
 
Despite the ubiquity and persistence of coagulase negative staphylococci, native valve 
endocarditis due to coagulase negative staphylococci is uncommon, accounting for 5-8% 
cases although this rises to 20% of prosthetic valve endocarditis cases.  It remains the most 
common cause of intravascular device infection although it tends to give a less severe 
clinical course than S. aureus.   
Chapter 1  46 
 
1.2.9 Staphylococcal bacteraemia in renal patients 
Renal dialysis patients are at high risk of S. aureus bacteraemia (SAB) due to their frequent 
contact with healthcare services and the high proportion of haemodialysis (HD) who have 
indwelling central venous catheters.  Even patients receiving RRT via arteriovenous 
fistulae (AVF) are at a higher risk of bacteraemia than the general population.  
 
The risk of bacteraemia in HD patients changes according to the form of vascular access 
with AVF conferring the lowest risk of bacteraemia, followed by arteriovenous grafts 
(AVG) and tunneled central venous catheters (TCVCs) and non-tunnelled central venous 
catheters (NTCVC) conferring the highest risk of bacteraemia (99).  The site of dialysis 
catheter is also important with internal jugular NTCVCs imparting a lower risk of 
bacteraemia compared to NTCVCs sited in the femoral vein (99). NTCVC insertion into 
subclavian vein has been found to have a lower incidence of infection compared to internal 
jugular vein (108). However, insertion of catheters into the subclavian vein tends to be 
avoided due to the considerable risk of angiographic stenosis following catheter insertion 
at this site (109).   
 
A bundle of measures are employed in an effort to reduce the risk of infectious 
complications associated with central venous catheter (CVC) insertion.  “Maximal sterile 
barriers” were employed in an effort to reduce CVC related infection in a 500 bed cancer 
referral centre (110).  176 patients were randomized to maximal sterile precautions 
consisting of mask, cap, sterile gloves, gown and large drape and compared to 167 control 
patients who received standard precautions at the time consisting of sterile gloves and 
small sterile drapes.  Patients were followed up for 3 months or until the catheter was 
removed.  There was a significant fall in catheter related infection in the group randomised 
to maximal sterile barriers with a total of 4 catheter infections in the test group and 12 in 
the control group (p=0.03).  It is impossible to know which of the several interventions 
above provided most impact on the reduction of CVC related infection.  It is notable that 
the study population were not patients requiring renal replacement therapy.      
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1.2.10 Antimicrobial line locks 
Catheter lock solutions have been shown to reduce the incidence of catheter related 
bloodstream infection (CRBSI) in some settings although there is no consensus for their 
use in routine clinical practice (111) (112).  Antibiotic line locks have been used with 
some effect with gentamicin, vancomycin, minocycline, cefazolin and cefotaxime all being 
used either alone, in combination with another antibiotic or in combination with another 
antimicrobial agent.  The majority of studies included patients with TCVCs only.  
Alternative antimicrobials such as citrate and taurolidine have also been used to prevent 
CRBSI and these have the advantage of not promoting antibiotic resistance.  The 
mechanism of action of an antimicrobial line lock is the limitation of biofilm formation and 
this may explain their effectiveness against coagulase negative staphylococcal bacteria in 
particular.  Heparin was used as the control line lock in the majority of clinical studies and 
is the standard agent for the locking of TCVCs and NTCVCs. Some studies included 
additional measures such as povodine- iodine application at the catheter exit site or nasal 
mupirocin and as a result are difficult to compare directly.            
 
1.2.11 Treatment of haemodialysis catheter related 
infection 
Haemodialysis (HD) patients with CRBSI present a challenge due to their ongoing 
requirement for access to the intravascular tree.  Any attempt made to salvage the HD 
catheter should be balanced against the risk of inadequately treated infection and metastatic 
complications and therefore management of CRBSI must be tailored to the requirements of 
the individual.   
 
It is convention that the initial empirical antimicrobial in CRBSI is intravenous 
vancomycin(113, 114).  Coagulase negative staphylococci commonly exhibit methicillin 
resistance, therefore vancomycin is a logical choice while a pathogen is cultured.    Once a 
pathogen is cultured, the antibiotic therapy should be rationalized.  If MSSA is cultured, 
the current recommendation is for therapy to be altered to flucloxacillin in the UK, or 
cefazolin in the USA.  Cefazolin utilizes intermittent dosing which allows outpatient 
treatment in the HD unit and has been shown to provide a mortality benefit in MSSA 
compared to vancomycin (115).  Flucloxacillin is considered to have superior efficacy 
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against MSSA compared to vancomycin although research studies confirming this are 
lacking (116).            
 
S. aureus bacteraemia (SAB) secondary to NTCVC insertion requires NTCVC removal.  
TCVCs should also be removed in the event of S. aureus CRBSI due to the risk of 
metastatic infection, which increases if TCVC removal is delayed.  Removal of the 
intravascular device has been associated with more prompt resolution of infection and 
higher cure rate.  It is recommended that repeat TCVC should not be reinserted until blood 
cultures are negative where feasible.  Persistently positive blood cultures are a sign of 
haematogenous spread and should prompt further investigation.  The optimum duration of 
antimicrobial therapy has not been the subject of a randomized controlled trial.   
 
CRBSI secondary to coagulase negative staphylococcal infection characteristically gives 
rise to a less severe illness and therefore the HD catheter can often be salvaged.  A 
NTCVC should still be removed where possible and replaced once blood cultures are 
negative for 72 hours.  An exception to this is Staphylococcus lugdunesis bacteraemia 
which, despite being a coagulase negative Staphylococcus, gives rise to a clinical 
syndrome similar to SAB with a relatively high incidence of metastatic infection and 
therefore should be treated more aggressively (117).  Diagnosis of CRBSI secondary to 
coagulase negative Staphylococcus is difficult in the absence of clinical signs as it is 
commonly viewed as a contaminant and depends on multiple positive blood cultures from 
multiple sites.  The optimal duration of antimicrobial therapy in uncomplicated CRBSI 
secondary to coagulase negative Staphylococcus remains uncertain and evidence is based 
on expert opinion only.  Antibiotic line locks have been used as an adjunct in the treatment 
of CRBSI with some success, particularly in the treatment of coagulase negative 
staphylococcal bacteraemia (118).     
 
1.2.12 Typing of Staphylococcus aureus strains 
The epidemiology of S. aureus infection relies on typing methods based on their genotypic 
characteristics.  This helps to establish clonal relationships between strains and to trace the 
geographic dissemination of bacterial clones.  Pulsed-field gel electrophoresis after Smal 
digestion of total bacterial DNA was originally proposed for outbreak investigation was 
used widely(119) (120).  It is time consuming and expensive therefore limiting its use in 
routine clinical practice.     
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Multilocus sequence typing relies on the sequences of the internal fragments of seven 
housekeeping genes(121).  It is also expensive compared to spa typing.  Spa typing is 
based on the sequence of an internal fragment of the spa gene, which is the polymorphic X 
region of the protein A gene on the cell wall of the S. aureus bacterium.  The region 
consists of a variable number of repeat units with each new base composition of a repeat 
being assigned an alpha-numerical code.  The repeat success determines the spa type(122).  
These DNA sequence-based typing methods have the benefit of generating unambiguous 
and portable data, allowing comparison to be made between different geographical 
areas(123). 
 
Relationships between different spa gene polymorphisms are visually represented using 
Based Upon Repeat Pattern (BURP) diagrams.  They are used to infer clonal relatedness 
from spa repeat regions(124) and therefore construct a population snapshot as illustrated 
below(124). 
 
 
Figure 1-7 Population snapshot of the 400 S. aureus strains after BURP grouping 
(124) 
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The Discriminatory Power (D) is the average probability that the typing system will assign 
a different type to two unrelated strains randomly sampled in the microbial population of a 
given taxon.  It con be expressed by the formula of Simpson’s index of diversity which 
reads- 
 
 
Where D is the index of discriminatory power, N the number of unrelated strains tested, S 
the number of different types, and xj the number of strains belonging to the jth type, 
assuming that strains will be classified into mutually exclusive categories. Thus, a D value 
of 1.0 would indicate that a typing method was able to distinguish each member of a strain 
population from all other members of that population. Conversely, an index of 0.0 would 
indicate that all members of a strain population were of an identical type. An index of 0.50 
would mean that if one strain was chosen at random from a strain population, then there 
would be a 50% probability that the next strain chosen at random would be 
indistinguishable from the first(125) (126). 
 
The data presented in Chapter 3 describes the incidence, management and outcomes of 
staphylococcal bacteraemia in renal inpatients with particular attention to treatment and 
outcomes in HD patients.  
 
1.3 Antibiotic associated diarrhoea and probiotics 
1.3.1 Development of the human intestinal microbiota 
The human intestinal microbiota is absent at birth but rapidly develops over the first 2 
years of life.  The mode and location of delivery influences its development in the very 
early stages, however the sequence of colonisation with various bacteria is well established 
with initial colonisation with aerobic bacteria, followed by faculatitive anaerobes such as 
enterobacteria spp followed by aerobes including bifidobacteria spp.  Bifidobacteria spp 
were first identified in the 1900s by Tissier, who linked their numbers in the faeces to the 
ability to resist bacteria and first discovered their presence in the stools of breast fed 
infants.  It has been established that the intestinal microbiota is an important aspect of the 
immune system.   
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Germ free mice reared in sterile environments have a poorly developed immune system 
with defined immune deficiencies, reduced number and distribution of certain immune 
cells and failure to thrive.  They carry no microorganisms in their intestines and body and 
therefore exposure to bacterial stimuli can be manipulated for research purposes.   They 
have reduced numbers and size of Peyer’s patches, decreased IgA secreting plasma cells, 
decreased lamina propria CD4+ T cell numbers and altered intra-epithelial T cell contents 
with abnormal cytokine production (127) (128).  Ito found that when germ free mice were 
colonised with the flora of normal healthy mice in a process termed conventionalization, 
there were measurable improvements in their immune response (129).   
 
The Nurmi concept took this further with “competitive exclusion” cultures selected from 
the mucosa of healthy birds given orally in order to prevent salmonella infection (130).  
They hypothesised that the abnormally hygienic environment of a poultry farm resulted in 
impaired development of the intestinal flora and therefore reduced resistance to infection.  
This was implicated in an outbreak of Salmonella infantis in humans with poultry acting as 
a reservoir of infection.  They compared 1-2 day old chicks given 0.5ml gut contents from 
adult cocks diluted with 0.9% saline to control animals reared.  The groups were reared 
separately and each bird was held in isolation.  Both groups were given S. infantis and 
began a standard feeding regimen free from antibiotics and chemotherapeutics.  Chicks 
were killed when they were 8-22 days old and bacteriological examination was performed.  
All chicks who did not receive gut contents were colonised with S. infantis compared to the 
chicks with pretreatment of adult gut contents where 23% of those given 103 S. infantis and 
31% of those 106 S. infantis were colonised.  This demonstrated the importance of the gut 
microbiota in the protection of the body against pathogenic bacteria.     
 
Various mechanisms within the gut prevent the adhesion and translocation of pathogens.  
Gut-associated lymphoid tissue (GALT) is present throughout the gut, particularly in the 
small intestine.  Peyer’s patches are aggregates of lymphoid tissue located in the ileum.  
These are covered by a protective layer of mucus, which in addition to its barrier function, 
contains antimicrobial peptides originating from the commensal microbiota and the host.  
Abnormal functioning of the GALT can result in increased risk of infection and bacterial 
translocation.  It also has a role in the pathogenesis of autoimmunity involving coeliac 
disease and inflammatory bowel disease   
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The intestinal microbiota affects the innate and acquired immune response using toll-like 
receptors expressed on epithelial cells, microfold cells (M cells) transporting bacterial and 
antigens from the gut lumen to lymphoid tissue and dendritic cells in the lamina propria 
sampling luminal antigens.  All of these processes have been the subject of research with 
regards to the influence of probiotics on the gut microbiota and immune system.   
 
A normal adult gut microbiota comprises 1014 microbes and greater than 1 kg bacteria.   
This results in a genome 150x the size of the adult human host with up to 1500 bacterial 
species with complex metabolic interactions and relationships.  Bacterial colonisation 
density is greatest in the large bowel and least in the upper gastrointestinal tract as 
demonstrated below.  Bacterial distribution depends on the available nutrients including 
oxygen in addition to gut transit time and pH.  The most hospitable environment is the 
colon which contains more than 90% bacteria due to its low luminal oxygen concentration, 
slow transit time, less acidic pH and favourable nutrient availability.    
    
 
  
Figure 1-8 Distribution and abundance of bacteria in the human gastrointestinal tract 
(131)  
 
The number of species comprising the intestinal microbiota result that some are likely to be 
beneficial to the host although some bacteria have obvious pathogenic potential.  The 
beneficial activity of the intestinal microbiota are those bacteria with saccharolytic 
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properties rather than those that possess proteolytic properties or have putrefying activities.  
Disruption of the intestinal microbiota, for example, with antibiotic therapy, can increase 
disease susceptibility. 
 
1.3.2 Role of probiotics and prebiotics in 
manipulation of the intestinal microbiota 
Probiotics and prebiotics have been used in clinical research in an attempt to promote the 
integrity of the intestinal microbiota in health and when it is interrupted as a result of 
disease, in particular due to antibiotics or inflammatory bowel disease.  Probiotics have 
been defined by the Food and Agriculture Organisation of the United Nations, (FAO), and 
the World Health Organisation (WHO) (132), as live microorganisms which when 
administered in adequate amounts confer a health benefit on the host.  There is no 
necessity for these beneficial effects to be gut related.    Prebiotics are non-digestible 
substances that when consumed provide a beneficial physiological effect on the host by 
selectively stimulating the favourable growth or activity of a limited number of indigenous 
bacteria (133).  These can be dietary carbohydrates known to have a selective metabolism, 
for example, oligosaccharides and fructooligosaccharides.  Synbiotics are less clearly 
defined but tend to be a combination of prebiotic and probiotic which may have synergistic 
properties.   
 
Probiotics may exert a beneficial effect on the host via various mechanisms of action 
which are similar to that described above for the commensal gut bacteria.  Specific 
immune effects are more likely to be strain specific whereas the effects of competitive 
exclusion for lactobacilli and bifidobacteria as they transit through the gut are likely to be 
more species specific.    
 
In general, the gut effects of a probiotic are in the maintenance and restoration of the 
intestinal microbiota with specific effects on gut barrier function.  They increase numbers 
of short chain fatty acids and decrease luminal pH.  They also increase mucus production 
resulting in improved barrier function.  More subtle effects on immune modulation in the 
gut and elsewhere are in the process of being determined and are not fully understood.  
There is some evidence of a therapeutic benefit of probiotics in the reduction of duration of 
upper respiratory tract infections, particularly in the elderly and in athletes (134) (135) 
(136), who have increased susceptibility to such infections  although this is not a consistent 
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finding (137) (138).  Mechanistic studies suggest that salivary IgA and natural killer cells 
may have a role here (139) (140) (141).  There has also been investigation into the role of 
probiotics in functionally immunocompromised patients such as those at risk of ventilator 
associated pneumonia (142).  
 
Synbiotics have been used in research into the reduction of postoperative infections, in 
particular, one small study of 50 living liver transplant recipients randomised to 
Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides or control resulted 
in a reduction in postoperative infections up to 2 weeks after surgery.  This is limited by 
lack of blinding (143).    
 
1.3.3 Clinical trials of prebiotics and probiotics 
Probiotic use in critically ill patients must still be viewed with caution.  Although there are 
case reports only of lactobacilli causing symptomatic bacteraemia, one large randomized 
controlled trial was discontinued early due to excess mortality in the treatment arm (144).  
Besselink et al recruited 298 patients predicted to have acute severe pancreatitis into a 
double blinded comparison of six different strains of freeze-dried, viable bacteria: 
Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius, Lactococcus 
lactis, Bifidobacterium bifidum, and Bifidobacterium lactis against placebo.  It was stopped 
early after an interim analysis showed excess mortality in the probiotic group shown in 
Figure 1-9 below.  A follow-up of longer than 90 days was obtained in 266 (90%) patients. 
Three deaths occurred after 90 days: two in the probiotics group (day 112 and 125) and one 
in the placebo group (day 140). 
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Figure 1-9 Kaplan–Meier time-to-event analysis for mortality in the first 90 days 
after randomisation  
  
Relative risk for mortality in the probiotic group was 2·53 (95% CI 1·22–5·25). The 
majority of the deaths in each group were due to multi organ failure.  There was bowel 
ischaemia at surgery or post mortem examination in 9 patients in the probiotic group with 
8 of these patients dying as a result.  There was no bowel ischaemia in the placebo group 
(p=0.004).  It has been postulated that the mechanism behind the mesenteric ischaemia was 
increased enteric blood demand due to the presence of probiotic or metabolic stress of gut 
epithelial cells due to increased bacterial load.   
 
It is estimated that between 5 and 39% patients experience diarrhoea as a consequence of 
antibiotic treatment depending on the population and type of antibiotic used.  This can 
result in a more prolonged hospital admission and in the most extreme cases, clostridium 
difficile associated diarrhoea, which significantly increases morbidity and mortality.   
 
The elderly are more susceptible to antibiotic associated diarrhoea.  It has been postulated 
that a mechanism behind this is that the gut microbiota in the elderly are less efficient with 
evidence of immune senescence (145).  There are changes in the composition of the 
intestinal microbiota with lower numbers of bifidobacteria and bacterioides, with 
decreased species diversity and increased numbers of enterobactericae.  This was taken 
further by Van Tongeren in 2005 where they investigated the relationship between faecal 
microbiota composition and frailty in the elderly (146).  They found that subjects with high 
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frailty scores had x26 reduction in lactobacilli with very frail subjects having a x7 increase 
in Enterobacteriaceae (facultative anaerobes).   
 
Probiotics have been used with very limited success in the treatment of norovirus.  There is 
a single open label case controlled study of Lactobacillus casei Shirota (LcS) in elderly 
patients resident in a care home (147).  There was a reduction in fever but no difference in 
diarrhoea and vomiting duration or incidence.  Faecal acetic acid concentration before, 
during and after LcS administration was measured and found to increase, and was 
correlated with increasing bifidobacterium concentration, however this is difficult to 
interpret in the clinical context of recent infectious diarrhoea.    
 
1.3.4 Antibiotic associated diarrhoea and Clostridium 
difficile associated disease 
The effect of even a short course antibiotic on the bowel flora in otherwise healthy patients 
can be significant.  Dethlefsen et al investigated faecal bacteria as a surrogate for large 
bowel bacteria before and after a 5 day course of oral ciprofloxacin at its usual therapeutic 
dose (148).  They found that there was a reduction in bacterial species with some strains 
not recovering within 6 months.  This is limited study population of only 3 patients but has 
been followed up in larger scale studies, mostly investigating the effects of probiotic 
administration.     
 
Antibiotics are known to disrupt the colonic microbiota by two main mechanisms.  They 
reduce the metabolism of fermentable carbohydrates resulting in a reduction in the number 
of short chain fatty acids and increased amount of non-absorbable carbohydrate in the gut 
lumen, leading to osmotic diarrhoea.  They also lead to a reduction in the resistance of the 
gut flora to the overgrowth of pathogenic bacteria such as C. difficile, C. perfringens, 
Salmonella, S. aureus and yeast such as C. albicans as a result of a reduction of 
competitive exclusion.   
 
Clostridium difficile associated disease (CDAD) is the most severe form of antibiotic 
associated diarrhoea.  Clostridium bacteria are rod-shaped spore-forming bacteria that live 
under anaerobic conditions.  It was first discovered in 1935 (149) and first associated with 
disease in 1978 (150).  It is an opportunistic pathogen and common environmental 
reservoirs include soil, water, hay, and sand.  Eradication of C. difficile from the 
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environment is difficult because of its spore forming properties and that it can be carried 
asymptomatically in the bowel in approximately 3% of adults in health (151).  This is 
significantly more after an insult to the intestinal microbiota by antibiotic therapy and in 
hospital inpatients.   
 
Mortality associated with CDAD can be as a direct result of bowel perforation or surgery 
required for toxic megacolon or the more insidious effects of diarrhoea including poor 
nutrition, volume depletion and general increasing frailty. Studies of outcomes in CDAD 
are difficult to compare due to different end points with not all reporting absolute 
mortality.  McGowan et al reviewed all patients diagnosed with CDAD in a specific UK 
NHS hospital trust between 2002 and 2008 and reported absolute mortality at 30 days of 
32.7% (152).  There was no significant difference between the study years or between 
hospitals.  Increasing age, increasing comorbidity, renal impairment, hypoalbuminaemia, 
leukocytosis and leucopaenia have all been associated with increased risk of mortality in 
CDAD (153) (154) (155) (156) (157) (158).   
 
Acute kidney injury (AKI) was found to be associated with adverse outcomes with a 
retrospective review of over 1 million patients entered into the National Hospital Discharge 
Summary database (159), which provides data on demographics, diagnoses, procedures, 
length of stay, discharge, and funding.  They found that patients with CDAD and AKI had 
nearly 3 times higher all-cause in-hospital mortality on univariate and multiple variable 
logistic regression analysis in addition to increased risk of colectomy, length of hospital 
admission and increased likelihood for discharge to a facility providing further short or 
long-term care.  An Austrian prospective cohort study of 185 patients admitted to a 
community hospital with CDAD found that 13% died during their hospital stay compared 
to 2.7% of controls.  After adjustment for age, sex and co-morbidity the relative risk of 
pre-discharge death was 2.74 (95 % CI 1.82–4.10; p < 0.0001) for patients with CDAD 
(160).  Furthermore, analysis of the same cohort suggested that patients with underlying 
chronic kidney disease (CKD) may also have increased risk of adverse outcomes although 
there was no significant difference in patients requiring renal replacement therapy (RRT) 
to the remainder of the CKD cohort.          
 
Antibiotic use is intrinsically associated with Clostridium difficile associated disease 
(CDAD).  Antibiotic choice is crucial in the reduction of C. difficile with some broad 
spectrum antibiotics resulting in an increased risk of CDAD compared to others as 
discussed in Chapter 5.     
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Increasing age is a risk factor for antibiotic associated diarrhoea and CDAD and the 
changes in the gut microbiota associated with increasing age have been discussed above.  
Proton pump inhibitor (PPI) use has been associated with antibiotic associated diarrhoea in 
multiple large studies (161) (162).  These increase the gastric pH and can affect gut flora 
in many ways.  Tanner et al investigated risk factors associated with CDAD in two UK 
hospitals and found an elevated Waterlow score to have a positive predictive value of 
16.8% and negative predictive value of 99% (163).  33% of patients who developed 
CDAD (32/98) came from the 5% of patients with a Waterlow score of ≥20.  The 
Waterlow score is a well-validated risk assessment tool for predicting pressure sore risk 
using several risk factors including body mass index (BMI), continence and mobility (164) 
(165).  
 
A large American retrospective cohort study compared outcomes of 41 000 patients with 
CDAD to 4 000 000 propensity score matched controls (166).  Average length of stay was 
longer for CDAD patients by 5 days (p < 0.001) with higher overall mortality albeit with 
small absolute differences (9.4% vs. 8.6%; p < 0.001).   Hospital costs were 56% higher for 
CDAD patients with a mean hospital admission cost of $23 350 (p < 0.001).  
 
CDAD occurs as a result of disruption of the protective bowel flora allowing C. difficile 
spores to germinate resulting in toxin damaging the epithelium.  Injured epithelial cells 
result in the leakage of neutrophils and erythrocytes into the gut.  Severe CDAD can result 
in pseudomembranous colitis.  The pseudomembrane is as a result of a viscous collection 
of fibrin, inflammatory cells and necrotic epithelial cells.  CDAD is pathognomonic of 
pseudomembranous colitis although very rarely it can also occur in diarrhoea caused by 
other bacterial infections.  Toxic megacolon can occur and in some cases, colectomy is 
required.  
 
A hypervirulent strain of CDAD termed NAP-1/ ribotype 027 was identified in 2005 (167) 
(168).  It was associated with increased toxin and spore production and is highly 
transmissible.  It has a higher mortality and is more difficult to eradicate.  It has been 
associated with outbreaks in the healthcare setting and was associated with severe 
complications such as pseudomembranous colitis and toxic megacolon in addition to 
increased mortality and lower cure rates (169, 170).  A case controlled study has now 
suggested that this association was overstated and found no evidence of increased mortality 
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or complications with this ribotype when adjustments were made for other severity 
markers although this is not a consistent finding across all studies.    
 
Initial therapy of CDAD is predominantly with antimicrobial therapy, particularly 
metronidazole or oral vancomycin in addition to discontinuing other antimicrobials where 
possible. (171)  Vancomycin may be more effective in severe or recurrent CDAD (172).  
This is successful in the majority of cases, however CDAD can recur in around 25% cases 
with 45-65% of these patients experiencing further and sometimes multiple recurrences 
(173-175).  CDAD can be problematic to eradicate completely and prolonged courses of 
vancomycin are prescribed with limited efficacy.  Pulsed or tapered vancomycin therapy 
aims to eradicate any vegetative C. difficile cells that have germinated from spores since 
the last antibiotic exposure.   
 
Fidixamicin is the first in a new class of macrocyclic antibiotics and has targeted activity 
against C. difficile.  There is evidence that it has a less profound effect on the gut 
microbiota and can also limit C. difficile spore release.  Oral fidixamicin, like oral 
vancomycin, has limited systemic absorption and is not metabolised via cytochrome p450 
(176).  Meta analysis of 2 trials of fidixamicin against vancomycin in CDAD suggested 
that there was a reduction in recurrent CDAD in those randomised to fidixamicin although 
initial cure rates were similar  (8) (177).  Of note, patients requiring parenteral treatment 
were not eligible for recruitment into trials of fidixamicin as it is administered orally only.      
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Figure 1-10 Time to recurrence by treatment group in patients with a prior episode of 
Clostridium difficile infection. Kaplan–Meier analysis of the probability of recurrence 
according to treatment group (per-protocol population). Day 0 is defined as the day the 
patient received the last dose of either fidaxomicin or vancomycin. The difference between 
treatment groups was statistically significant by both log rank (P = .02) and Wilcoxon (P = 
.01) tests (177). 
 
CDAD in Scotland is monitored by HPS and has been falling rapidly between 2007 and 
2012 from 37.4 to 29.2 per 100 000 total bed days in those aged >65 years as illustrated in 
Figure 1-11 below.  There was also a reduction in the 027 ribotype.  A range of measures 
are likely to account for this including increased awareness of CDAD as a cause of 
diarrhoea, antimicrobial stewardship and early isolation of suspected cases with strict 
attention to hygiene in the healthcare setting.  There has been a reduction in the use of 
broad spectrum antibiotics in particular cephalosporins and quinolones as discussed in 
Chapter 2.     
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Figure 1-11 Incidence rates of CDAD in patients aged ≥65 and 15-64 years in 
Scotland per 100 000 bed days, October 2006 to December 2012 (Data courtesy of 
Health Protection Scotland (178)) 
 
Faecal transplantation is an extreme but logical method of restoring the intestinal 
microbiota and was first described by Eismen et al in 1958.  Published case series have 
varied in the method of administration (nasogastric tube, gastroscopy, colonic delivery), 
donor characteristics (related vs anonymous, fresh v frozen the thawed specimen), type of 
suspension (sterile water, milk or saline) and indication (recurrent CDAD, refractory 
CDAD or both).  
 
Case series and systematic reviews generated encouraging results, however controlled trial 
evidence was lacking until van Nood et al from the Academic Medical Centre in 
Amsterdam randomized 43 patients with recurrent CDAD (defined as relapse of C. difficile 
infection after at least one course of adequate antibiotic therapy) in an open labeled study 
to one of 3 different study groups: the infusion of donor faeces preceded by an abbreviated 
regimen of vancomycin and bowel lavage, a standard vancomycin regimen, or a standard 
vancomycin regimen with bowel lavage (179).  Heavily immunosuppressed recipients, 
those with concurrent antibiotic use, pregnancy or critical care admission were excluded.  
Donors were anonymous and donor faeces specimens were screened for parasites and other 
faecal pathogens.  Donor blood was screened for human immunodeficiency virus (HIV) in 
addition to other viral and bacterial infections.  The primary end point was cure without 
relapse within 10 weeks after the initiation of therapy.  Cure was defined as an absence of 
diarrhoea or persistent diarrhoea that could be explained by other causes with 3 
consecutive negative stool samples for C. difficile toxin.  Faecal microbiota was examined 
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for diversity before and after donor faeces infusion.  The study was terminated early as 
most patients from both control arms had evidence of a relapse.  There were significantly 
increased cure rates in those who received donor faeces compared to the vancomycin alone 
or vancomycin with bowel lavage groups as shown by Figure 1-12 below.   
 
 
Figure 1-12 Rates of Cure without Relapse for Recurrent Clostridium Difficile 
Infection. 
 
Shown are the proportions of patients who were cured by the infusion of donor faeces (first 
infusion and overall results), by standard vancomycin therapy, and by standard 
vancomycin therapy plus bowel lavage.  
 
Diversity of faecal microbiota was analysed from 9 patients prior to and within 2 weeks 
after donor faeces infusion using Simpson’s Reciprocal Index of Diversity.  Diversity of 
the faecal microbiota was low before the infusion compared to donor faeces and compared 
to faecal microbiota following infusion of donor faeces.  Taxa of faeces from donors and 
that 2 weeks following faecal transplant was indistinguishable (Figure 1-13 below).   
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Figure 1-13 Microbiota diversity in Patients before and after Infusion of Donor 
Faeces, as Compared with Diversity in Healthy Donors 
     
Microbiota diversity is expressed as Simpson’s Reciprocal Index of diversity in faecal 
samples obtained from nine patients before and 14 days after the first infusion of donor 
faeces, as compared with their donors. The index ranges from 1 to 250, with higher values 
indicating more diversity. The box-and-whisker plots indicate interquartile ranges (boxes), 
medians (dark horizontal lines in the boxes), and highest and lowest values (whiskers 
above and below the boxes). 
 
This well conducted study is limited by its small sample size.  35 of the 43 patients were 
recruited after a 2nd or greater relapse and it is known that the efficacy of antibiotic is 
reduced after each relapse.  The nature of the intervention resulted in blinding being 
impossible.  There is no recognized optimum antibiotic regimen for recurrent CDAD.  It 
was reassuring that the adverse event profile was low.  Research is ongoing in this field, 
particularly into synthetic stool (180), with a theoretical advantage of a reduction in 
pathogen transmission.  
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Probiotics and the yeast Saccharomyces boulardii were postulated as less invasive and less 
expensive methods of restoring the bowel flora and thereby preventing antibiotic 
associated diarrhoea, although well-designed randomised controlled studies were lacking 
until very recently.   
 
 
1.3.5 Rationale for performing a double blind trial of 
probiotics in the prevention of AAD in renal inpatients   
 
Hickson et al recruited 135 patients to Lactobacillus casei DN-114 001 (L. casei imunitass) 
(1.0×108 colony forming units/ml), S. salivarius (1.0×108 cfu/ml), and L. bulgaricus 
(1.0×107 cfu/ml) (Actimel) or placebo milkshake with striking differences in the incidence 
of antibiotic associated diarrhoea as illustrated by table 1-2 below (181).     
 
Table 1-2  Total number of cases of antibiotic associated diarrhoea (including cases 
positive for C. difficile toxin) and proportion who were positive or negative for toxin 
(all patients followed up in hospital and after discharge) 
 
 
This study has been criticized for its exclusion of high risk antibiotics and potential 
difficulties with blinding.  Staff administering the milk drinks and monitoring for loose 
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stool were not blinded.  Proton pump inhibitor administration was not recorded and this is 
a potential confounding variable.     
 
Sampalis randomised a total of 437 patients to a probiotic BIO K+ CL1285® or placebo 
(182).  BIO K+ CL1285® is a commercially available probiotic with a patented formula 
containing the L. acidophilus CL1285® strain of human origin, registered at the Pasteur 
Institute, and a L. casei strain.  Placebo was an identical capsule containing sterile 
lactoserum with similar texture and taste to the probiotic.  Patients were given a lower dose 
for the first 2 days in order to ensure tolerance of the product, followed by full dose for the 
remainder to the period.  Both the probiotic and placebo preparations were administered 
within 24 hours after the first dose of antibiotic and continued once daily within ± 2 hours 
of the administration of the antibiotic treatment and for 5 days following the termination of 
antibiotic regimen.  The incidence of antibiotic associated diarrhoea was reduced in the 
probiotic arm although this did not reach statistical significance (Table 1-3 below).    
 
Table 1-3 Efficacy outcomes of probiotic against placebo in the prevention of 
antibiotic associated diarrhoea (Sampalis et al 2010) 
  
       
 
This study did not reach its recruitment target of 500 patients and therefore was 
underpowered.  A Cochrane Review in 2013 concluded that more research is required in 
probiotics prevention of AAD and CDAD (183) and is discussed further in Chapter 5.     
 
The PLACIDE study completed recruitment in 2012 and was published in August 2013 
(184).  This is the first large multicentre randomised controlled trial of probiotics against 
placebo and was conducted in 3 hospitals in Wales and 2 hospitals in the north of England.  
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They screened 17 420 patients, with 2981 patients recruited in total.  1493 were randomly 
assigned to the probiotic group and 1488 to the placebo group.  The probiotic preparation 
was a lyophilised powder in a vegetarian capsule containing 6 × 1010 live bacteria: two 
strains of Lactobacillus acidophilus and two strains of bifidobacterium.  Incidence of AAD 
in this study was relatively low at 10.6% with no significant difference between the 
probiotic and placebo groups.  Interpretation of this study in the context of other positive 
studies is discussed further in Chapters 5 and 6.    
 
Meta-analysis of available literature in the prevention of AAD with probiotic 
administration has taken this new research into account.  Studies are difficult to compare 
having used different probiotic and yeast preparations, children and adults and a variety of 
clinical settings.  The forest plot below (Figure 1-14) suggests a small benefit of probiotic 
in the prevention of AAD in older patients.  Substantial statistical heterogeneity (I2=90%) 
was recognised which undermines the reliability of this analysis.  
 
 
Figure 1-14 Meta-analysis of trials of lactobacilli or bifidobacteria, or both, in the 
prevention of antibiotic-associated diarrhoea in older inpatients (184) 
 
Publication bias in probiotic related research has been noted on previous metanalysis with 
the funnel plot below (Figure 1-15) showing asymmetry with the Egger regression test 
(p.0.0001) and the Begg rank correlation test (p.0.0001) giving significant evidence of 
publication bias despite overall positive results for gastrointestinal diseases in general and 
antibiotic associated diarrhoea in particular.  
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Figure 1-14 Funnel plot asymmetry used to determine publication bias. Log of the risk 
ratios were plotted against the standard error of the risk ratio of each study to identify 
asymmetry in the distribution of trials. Gaps in the funnel plot suggest potential publication 
bias. The synthesis estimate and the 0.01 limit are shown to distinguish asymmetry  (185) 
 
The data presented in Chapter 5 adds to the existing body evidence on the role of probiotic 
milk drink in the prevention of antibiotic associated diarrhoea.  It is limited by its small 
sample size which did not reach that required by the power calculation.  The study 
population of inpatients within a renal unit are a heterogenous group which have not been 
represented before in a trial of this nature.  
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1.4 Summary of hypotheses 
This thesis examines four hypotheses in relation to infection in renal patients.   
Chapter 2 hypothesises that a change in antibiotic policy resulting in increased gentamicin 
use would lead to a higher incidence of acute kidney injury requiring renal replacement 
therapy in Glasgow intensive therapy and renal units.  Patients requiring emergency renal 
replacement therapy in the 6 months before the change in antibiotic policy and 6 months 
after the change in policy were compared.  Gentamicin use in these patients was 
determined by patient casenote review and laboratory gentamicin levels.    
In Chapter 3, staphylococcal bacteraemia in the Glasgow Renal Unit is examined utilising 
a 2 year cohort comprising renal unit inpatients and outpatients requiring regular 
haemodialysis.  The hypothesis that patient outcomes are improved with the use of 
flucloxicillin compared to vancomycin in S. aureus bacteraemia is explored, as it’s the 
hypothesis that S. aureus bacteraemia results in poorer patient outcomes compared to 
coagulase negative staphylococcal bacteraemia.  
Chapter 4 evaluates toxin gene positivity in S. aureus isolates from four different patient 
populations with the hypothesis that S. aureus isolates causing disease will have a higher 
prevalence of toxin gene positivity.  PCR testing was utilised to confirm toxin gene 
positivity and spa typing was performed with the hypothesis that there would less variety 
in S. aureus clones in haemodialysis patients.   
Finally, Chapter 5 discusses a placebo controlled randomised controlled trial evaluating the 
effect of probiotic milk drink on the incidence of antibiotic associated diarrhoea.  It 
hypothesises that the addition of twice daily probiotic milk drink within 48 hours of 
commencing antibiotics, continued for 7 days after antibiotic cessation will reduce the 
incidence of antibiotic associated diarrhoea.    
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Chapter 2:  Acute kidney injury in the context of 
a restrictive antibiotic policy 
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2.1 Background 
In August 2008, following a rise in Clostridium difficile infection, antibiotic guidelines in 
Greater Glasgow and Clyde health board were revised, restricting cephalosporins, co-
amoxiclav and quinolones whilst promoting narrow spectrum agents and short term use of 
the aminoglycoside, gentamicin. As a consequence, gentamicin use doubled from 
approximately 20 to 40 defined daily doses / 1000 bed days as illustrated in Figure 2-1, 
below (p=0.002).   
 
 
Figure 2-1 Gentamicin use by defined daily dose in Greater Glasgow and Clyde 
hospitals comparing 1st August 2007 until 31st January 2008 with 1st August 2008 
until 31st January 2009 (p<0.05). 
 
Acute kidney injury (AKI) affects up to 20% of hospitalised patients and is associated with 
increased mortality (186) (187).  Gentamicin is an important cause of AKI as a result of a 
complex interaction of renal tubular dysfunction, tubular obstruction and reduced 
glomerular filtration (188).     
 
Various mechanisms of aminoglycoside toxicity have been discussed in Chapter 1, 
however a clinical definition of gentamicin associated AKI has not been formally 
determined.  Reported incidence of gentamicin associated AKI varies due to differences in 
study design and patient risk factors.  The difficulties in defining AKI prior to the 
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development of validated staging criteria are discussed in Chapter 1.  A rise in serum 
creatinine by 0.5mg/dl (44 micromol/ml) was used by Sweileh in a non critical care 
population with baseline normal renal function in a study designed to evaluate the 
nephrotoxicity of gentamicin and amikacin (189).  They found that 35.6% patients 
prescribed gentamicin developed nephrotoxicity as defined above compared to 16.3% of 
those prescribed amikacin (p=0.003).  Bartal et al defined nephrotoxicity as a rise in serum 
creatinine of greater than 25% from baseline or to a serum creatinine of greater than 
1.4mg/dl (123micromol/l) in their study of different aminoglycoside dosing regimens and 
concluded that individualised dosing using an immunoassay resulted in reduced 
nephrotoxicity with the incidence of nephrotoxicity in the individualised dosing regimen 
being only 5% compared to 21% of the once daily dosing group (p=0.03).  This study is 
limited by its small sample size with only 51 patients in total being prescribed gentamicin 
(190).     
 
Cosgrove et al examined low dose gentamicin as adjuvant therapy in S. aureus 
endocarditis and defined an adverse renal outcome as a decrease in creatinine clearance to 
<50 mL/min if the baseline creatinine clearance was  50 mL/min or a decrease in 
creatinine clearance of  10 mL/min if the baseline creatinine clearance was <50 mL/min 
(101).  They found that 22% of those who received gentamicin developed a deterioration in 
renal function compared to 8% of those who did not receive gentamicin.  Several 
confounders were identified, in particular, three times daily dosing of gentamicin and 
potential nephrotoxic effects of other antibiotics such as vancomycin and high dose 
flucloxacillin. 
 
Oliveira studied aminoglycoside associated nephrotoxicity in a critical care population 
with a baseline eGFR >30ml/min/1.73m2 (191).  They defined aminoglycoside associated 
nephrotoxicity as a decrease in the eGFR of 20% or more from the baseline eGFR during 
aminoglycoside use.  They found that 58% of the 360 patients meeting inclusion criteria 
developed acute kidney dysfunction in association with an aminoglycoside as defined 
above.    
 
In this population of patients with established acute kidney injury we have defined 
gentamicin associated AKI as the development of AKI requiring renal replacement therapy 
associated with the initiation of gentamicin between 1 and 10 days prior to the requirement 
for renal replacement therapy.  There is no formal definition of gentamicin associated AKI 
and the optimal time interval for identification of gentamicin associated AKI is unclear.  It 
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is well known that nephrotoxicity secondary to gentamicin often takes several days to 
manifest and therefore, given the end point of commencing RRT, the definition above 
would capture most patients with gentamicin associated AKI requiring RRT. This would 
associate gentamicin use with AKI requiring RRT although causation would be impossible 
to ascertain.  The retrospective nature of this review necessitated an unequivocal end point 
such as dialysis dependence.     There was no requirement for high or toxic gentamicin 
levels.  The retrospective nature of this analysis made defining gentamicin toxicity 
unreliable as the time relationship between administration and therapeutic drug monitoring 
would not be ascertained accurately.  
 
We investigated whether this change in antibiotic guidelines promoting the use of 
gentamicin resulted in any change in the incidence of, or mortality associated with, AKI 
with a secondary end point of residual renal impairment.  
 
2.2 Methods 
2.2.1 Data collection 
A retrospective audit of all patients requiring emergency renal replacement therapy for 
AKI within all Greater Glasgow and Clyde Health Board hospitals over two time periods 
was performed. The first period, (Period 1), before the change in antibiotic guidelines from 
01/08/2007-31/01/2008, and the second, (Period 2), after the change in antibiotic 
guidelines 01/08/2008-31/01/2009.  The audit periods were separated by 6 months 
allowing a run in period for the change in antibiotic guidelines and to minimise seasonal 
bias.  
 
All general intensive therapy units (ITUs) and renal units in GGC were included. Patients 
undergoing renal replacement therapy in an intensive therapy unit were identified using the 
“Wardwatcher” software used by all intensive therapy units in Greater Glasgow and Clyde 
(GGC).  This records prospectively collected data of all ITU inpatient interventions 
including use of RRT.  Date of first dialysis session in an inpatient renal unit, or outlying 
area such as a coronary care unit, during the study period was initially identified using the 
renal unit electronic patient record then confirmed where possible using paper case notes.   
Patients commencing dialysis as a consequence of progressive chronic kidney disease 
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(CKD) were identified by a pre-existing eGFR of <15ml/min/1.73m2 prior to this acute 
presentation and excluded from the analysis.          
 
Paper case notes, electronic clinical portal, electronic renal database and biochemistry 
results were reviewed for each patient to assess co-morbidities, likely causes of AKI, dates 
of gentamicin use, duration of renal replacement therapy, mortality and extent of renal 
recovery.  Patients with primary glomerulonephritis were included in this population.  
Vascular disease was defined as the presence of ischaemic heart disease, cerebrovascular 
disease or peripheral vascular disease affecting large of small vessels.  Immunosuppression 
includes high dose corticosteroids, in addition to antiproliferatives, and other drugs 
affecting the immune response.  
 
Patients with pre-existing Stage 5 chronic kidney disease (including those patients with 
functioning renal transplants but eGFR<15ml/min/1.73m2 ) were excluded. Patients 
already requiring dialysis, patients transferred from hospitals outside GGC Health Board 
and patients developing AKI following cardiac surgery were all excluded as antimicrobial 
guidelines in these patients differed from those in NHS GGC and the population of interest 
was those with AKI in general, and gentamicin-associated AKI in particular.   
 
In time period 1, recommended gentamicin dosing was based on a 24 or 48 hourly dosing 
system (approximately 5mg/kg) utilising body weight with creatinine clearance estimated 
using the Cockcroft-Gault calculation.  After auditing compliance with these guidelines, 
and estimating pharmacokinetic profiles, the gentamicin dosing regimen was simplified 
prior to Period 2.  The dose range was 180mg every 48hours to 400mg every 24 hours, 
with a 2.5mg/kg (maximum dose 180 mg) recommended for patients with a 
CrCl<20ml/min.  This ensured either 24 or 48 hourly dosing and uniformity of prescribing 
guidance across all hospitals.  An intranet-based gentamicin dosage calculator, dosing 
chart (according to Cockroft and Gault creatinine clearance calculation) and plot to guide 
sampling time, target trough levels and subsequent dosage (Figure 2-2, illustrated below) 
was introduced to further simplify dosing. 
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Figure 2-2 Gentamicin dose adjustment plot 
 
Demographic, comorbidity, gentamicin usage and outcome data from patients with AKI 
requiring RRT from Period 1 and Period 2 were compared.  Following this, patients 
identified as having gentamicin-associated AKI from either time period were compared to 
the rest of the cohort.   
 
2.2.2 Statistical analyses 
The Mann Whitney U test was used to compare data that were not normally distributed.  
The binomial comparison of 2 distributions and binary logistic regression analysis were 
utilized where appropriate using Minitab 13.1 software. A univariate binary logistic 
regression analysis, to identify factors associated with a higher risk of death, was 
performed using the entire cohort.  Those with p<0.15 were entered into multivariate 
analysis using a backwards selection model.   
 
2.3  Results 
No change in the incidence of AKI requiring RRT was identified. 191 patients who 
received emergency renal replacement therapy were identified during Period 1 
(01/08/2007-31/01/2008) and 184 identified during Period 2 (01/08/2008-31/01/2009).   
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2.3.1 AKI: Comparison between Period 1 and Period 2 
 
There was no significant difference in patient age, length of hospital stay, incidence of 
sepsis or mortality comparing the 2 periods.  43% of patients in both populations received 
gentamicin at any time during their admission.  There were no significant differences in 
patient comorbidity comparing the patients identified in the 2 periods (Table 2-1).   
 
Table 2-2 compares patient outcomes and gentamicin use in Period 1 compared with 
Period 2. There was no significant difference in mortality or length of patient admission 
between the 2 groups.  Duration of gentamicin use was significantly more prolonged 
during Period 1 before the change in antibiotic guidelines (p=0.046) although this was not 
maintained when gentamicin use was censored for death (p=0.097).  This may represent 
increased antimicrobial stewardship and increased awareness of gentamicin-associated 
AKI during Period 2.  There was no significant difference in mortality or in the incidence 
of patients alive but with a deterioration in baseline serum creatinine comparing the 2 
periods studied.   
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Table 2-1 Baseline characteristics and comorbidities of patients with AKI requiring 
RRT comparing Period 1 (before change in antibiotic guidelines) and Period 2 
(following change in antibiotic guidelines).   
Data are expressed as value (%) or median (interquartile range) as appropriate  
 
 Period 1  
01/08/2007-31/01/2008 
(n=191) 
Period 2 
01/08/2008- 
31/01/2009 (n=183) 
p value 
Age (years)  66 (54, 74) 63 (51, 74) 0.393 
Male 115 (60.2) 110 (60.1) 0.984 
 
   
AKI risk factors    
ITU admission 138 (72.25) 129 (70.49) 0.707 
Renal unit admission only  50 (26.2) 51 (27.9) 0.713 
Sepsis  145 (75.92) 129 (70.49) 0.236 
Hypotension  102 (53.40) 89 (48.63) 0.356 
Volume depletion  129 (67.54) 114 (69.30) 0.288 
Urinary tract obstruction  6 (3.14) 6 (3.28) 0.940 
Surgery   41 (21.47) 47 (25.68) 0.337 
Iodinated contrast  15 (7.85) 20 (10.93) 0.308 
 
   
Comorbidities    
Diabetes mellitus  36 (18.85) 38 (20.77) 0.642 
Vascular disease  61 (31.94) 58 (31.69) 0.960 
Acute myocardial infarction  12 (6.28) 16 (8.74) 0.367 
 
   
Medications    
Gentamicin at any time during admission  76 (39.79) 77 (42.08) 0.653 
 ACE-I*/ARB ** 52 (27.23) 57 (31.15) 0.404 
NSAID§  14 (7.33) 9 (4.92) 0.329 
Diuretic  51 (26.70) 50 (27.32) 0.892 
Immunosuppression  17 (8.90) 15 (8.20) 0.808 
 
*    Angiotensin-converting enzyme inhibitor 
**  Angiotensin 2 receptor blocker 
§      
 Non steroidal anti inflammatory drugs 
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Table 2-2 Comparison of outcomes and gentamicin use between Period 1 (before 
change in antibiotic guidelines) and Period 2 (after change in antibiotic guidelines).   
Data are expressed as value (%) or median (interquartile range) as appropriate 
 Period 1   
01/08/2007- 
31/01/2008 
n=191 total 
n= 89 alive at discharge 
Period 2  
01/08/2008- 
31/01/2009  
n= 183 total  
n= 99 alive at discharge 
p value 
Length of stay in days: all 20  (8, 38.5) 20 (9, 34.5) 0.598 
Length of stay in days: those 
who survived to discharge  
28 (18.25, 50) 27 (17, 43) 0.588 
Duration of gentamicin in 
days: all  
N= 61 
4.5 (0, 9) 
N=73 
3(1,7) 
0.046 
Duration of gentamicin in 
days : those who survived to 
discharge  
N=27 
5.5 (2, 9.75) 
 
N=29 
2 (1,7.5) 
0.097 
Alive: no renal recovery  
 
5/89 5/99 0.863 
Alive with >20% 
deterioration in baseline 
serum creatinine at hospital 
discharge 
13/89 (14.6) 21/99 (21.21) 0.235 
In Patient Mortality  
 
102/191 (53.4) 84/183 (45.9) 0.146 
Mortality: 1 year  
 
112/191 (58.6) 101/183 (55.2) 0.501 
 
 
2.3.2 Comparison of gentamicin-associated AKI to 
the remainder of the cohort 
Overall, 40.5% (61 patients) of patients who received gentamicin were classified as 
gentamicin-associated AKI, having started gentamicin therapy between 1 and 10 days prior 
to requiring renal replacement therapy.  27 of these patients (44.3%) were admitted during 
Period 1 and 34 patients (55.7%) during Period 2.     
 
The gentamicin-associated AKI group was more likely to have undergone surgery and had 
a higher number of cumulative AKI risk factors defined as the number of risk factors, 
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comorbidities and predisposing medications as illustrated in Table 2-3.  The gentamicin 
associated AKI group had a relatively short duration of gentamicin therapy with a median 
of 2 days.  In those who survived to discharge from hospital, there was no significant 
difference in the duration of gentamicin therapy (p=0.44).  Patients with gentamicin 
associated AKI had a more prolonged hospital stay (p=0.16) although clearly the increased 
incidence of ITU admission is a major confounder here.  
 
Despite the higher proportion of ITU admission, greater number of risk factors and longer 
duration of stay, there was no evidence of increased inpatient or 1 year mortality in the 
gentamicin associated AKI group.  The gentamicin associated AKI group and all other 
AKI had 1 year mortality of 57.4% and 55.4% respectively.  This is in keeping with data 
for those requiring acute renal replacement therapy in previous research (5, 192).  Data 
illustrated in Tables 2-3 and 2-4 underwent Bonferroni correction for multiple comparisons 
and therefore the P value for statistical significance was adjusted from <0.05 to <0.003 in 
Table 2-3 and corrected to <0.005 in Table 2-4.     
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Table 2-3 Baseline characteristics and AKI risk factors comparing those with 
gentamicin associated AKI to the remainder of the cohort.   
Data are expressed as value (%) or median (interquartile range) as appropriate.  Statistical 
significance was defined at p<0.002 after Bonferroni correction for multiple comparisons 
 Gentamicin-
associated AKI n=60 
All other AKI 
n=315 
p value 
Age (years) 65.0 (57.0-71.5) 65.0 (51.0-74.0) 0.93 
Sex (male %)   37 (60) 186 (60) 0.96 
AKI risk factors    
ITU admission  51 (83.6) 220 (70.1) 0.004 
Renal unit admission 
only  
9 (14.8) 91 (30.0) 0.008 
Sepsis  58 (95.1) 220 (70.1) 0.000 
Hypotension  36 (59.0) 156 (49.7) 0.33 
Volume depletion  44 (72.1) 200 (63.7) 0.53 
Urinary tract obstruction 1 (1.6) 11 (3.5) 0.80 
Surgery  27 (44.3) 62 (19.7) 0.000 
Iodinated contrast  10 (16.4) 26 (8.3) 0.39 
Comorbidities    
Diabetes mellitus  11 (18.0) 63 (20.1) 0.59 
Vascular disease  20 (32.8) 99 (31.5) 1.00 
Acute myocardial 
infarction 
6 (9.8) 22 (7.0) 0.75 
Medications    
ACE-I/ARB  20 (32.8) 89 (28.3) 0.77 
NSAID  4 (6.6) 19 (6.1) 0.99 
Diuretic  17 (27.9) 84 (26.8) 0.93 
Immunosuppression 10 (16.4) 23 (7.3) 0.063 
Number of AKI risk factors  7.0 (5,8) 5.0 (3,6) 0.000 
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Table 2-4 AKI outcomes comparing those with gentamicin associated AKI to the 
remainder of the cohort.   
Data are expressed as value (%) or median (interquartile range) as appropriate.  
Statistical significance was defined at p<0.005 after Bonferroni correction for 
multiple comparisons 
 Gentamicin-
associated AKI n=60 
All other AKI 
n=315 
p 
value 
Length of stay in days: all 24.0 (14.0-42.5) 19.0 (8.0-34.8) 0.016 
Length of stay in days: those 
who survived to discharge 
37.0 (26-74) 25 .0 (16-44.8) 0.003 
Duration of gentamicin use 
in days: all 
2.0 (1.0-7.0) 4.0 (1.0-9.0) 0.048 
Duration of gentamicin use 
in days: those who survived 
to discharge  
5.0 (2.3-10.0) 5.0 (2.5-9.5) 0.44 
Survived with new residual 
renal impairment  
5 (8.20) 30 (9.5) 0.762 
Survived with no renal 
recovery 
0 6 (1.9) 0.013 
Mortality (inpatient)  32 (52.5) 154 (49.0) 0.72 
Mortality (1 year)  35 (57.4) 174 (55.4) 0.81 
 
2.3.3 Outcomes and regression analyses using the 
entire cohort 
327 of 374 patients (87.4%) had information on baseline renal function.   Renal outcomes 
are summarised in Figure 2-3.   
 
181 (48.3%) of these patients survived until discharge from hospital and 153 (46.8%) were 
alive at 1 year.  Of those 181 patients who survived to discharge, 115 patients (63.5%) had 
normal renal function at presentation, 38 patients (20.1%) had stage 3 CKD and 15 patients 
(8.2%) had stage 4 CKD.  13 of the patients who survived to discharge had no recent 
biochemistry results therefore their baseline level of renal function was unknown.  As 
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would be expected, increasing age was associated with pre-existing CKD in patients 
surviving to hospital discharge (OR 2.25 for every 10 year increase in age, 95% confidence 
intervals 1.63, 3.12, p=0.000) and in the entire cohort (OR 2.31 for every 10 year increase 
in age, 95% confidence intervals 1.82, 2.93, p=0.000).     
 
At the time of discharge, 31 of 181 (18.1%) patients had a decline in renal function 
compared to baseline including 10 patients (5.8%) remaining dialysis dependent. 17 of 
these patients (54.8%) had pre-existing CKD with 11 patients (35.4%) having stage 3 CKD 
and 6 patients (19.4%) stage 4 CKD.  7 patients of the 53 with known baseline CKD who 
survived to hospital discharge became dialysis dependent (11.3%).  3 of these patients had 
pre-existing stage 3 CKD and the remainder had stage 4 CKD.     
 
47 patients from the total population had no pre-existing biochemistry.  13 of these patients 
survived to hospital discharge.  6 patients in this group did not recover to an eGFR of 
>60ml/min/1.73m2 and 6 patients were dialysis dependent.  It is likely that a proportion of 
patients had unrecognised CKD prior to presentation with an acute illness.     
 
To determine factors associated with a deterioration in renal function or dialysis 
dependence after the episode of AKI a univariate analysis was performed on the entire 
cohort.  Gentamicin administration had no impact on renal outcome.  A higher premorbid 
serum creatinine (p=0.002), increasing age, location of RRT (renal unit) and death at 1 
year were associated with an increased risk of deterioration in renal function after the 
episode of AKI (Table 2-4).  Multivariate analysis confirmed that poorer baseline renal 
function was highly associated with residual renal impairment.  Patients were also more 
likely to have residual renal impairment if they received RRT in a renal unit only.  There 
were 7 patients with acute glomerulonephritis in this cohort.  One of these patients died 
during the follow up period, 1 patient fully recovered renal function, 2 required long term 
dialysis and 3 had residual renal impairment at hospital discharge and at 1 year with 1 of 
these patients requiring RRT at some point during their admission.    
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Figure 2-1 Hierarchy plot of renal outcomes in surviving patients 
 
Entire cohortn= 374
Alive at hospital discharge (n=181)
No baseline renal function (n=13)
Normal renal function at discharge from hospital (n= 2)
Stage 3 CKD at hospital discharge(n=2)
Stage 4 CKD at hospital discharge (n=3 )
Remained dialysis dependent (n=6)
Previously normal renal function (n=115)
Normal renal function at hospital discharge (n= 101)
New stage 3 CKD (n=9)
New stage 4 CKD (n=2)
Remained dialysis dependent (n=3)
Pre-existing stage 3 CKD (n=38)
Renal function returned to baseline at hospital discharge (n=27)
Serum creatinine >20% higher than baseline (n=8)
Remained dialysis dependent (n=3)
Pre-existing stage 4 CKD (n= 15)
Renal function returned to baseline at hospital  discharge (n=9)
Serum creatinine >20% higher than baseline (n=2)
Remained dialysis dependent (n=4)
Died as hospital inpatient (n=193)
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Table 2-5 Univariate and multivariate binomial regression analysis of factors associated with residual renal impairment at discharge from 
hospital.  Multivariate analysis was performed using a backwards selection model.   
  
Variable Univariate analysis  
Odds Ratio 
95% CIa P value Multivariate 
analysis  
Odds Ratio 
95% CI P value 
Ageb 1.54 1.15, 2.05 0.002    
ITU admission 0.14 0.06, 0.33 0.000 0.18 0.08, 0.44 0.000 
Renal Unit admission only 6.06 2.67, 13.77 0.000 4.66 1.98, 10.99 0.000 
Baseline serum creatinine 
(micromol/l)c 
1.13 1.04, 1.02 0.002 1.11 1.01, 1.21 0.000 
Gentamicin use at any time 0.27 0.10, 0.68 0.003    
Death at 1 year 4.40 1.63, 11.88 0.005    
 
aConfidence Interval 
bPer 10 year increase in age  
cPer 10 micromol/l rise in serum creatinine 
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There was no trend towards more prolonged hospital admission according to age in those 
surviving to discharge (Pearson correlation coefficient -0.11, P value 0.123).  This did not 
change when the renal unit population only was studied (Pearson correlation coefficient 
0.187, P value 0.11).   
 
To determine factors associated with inpatient mortality, univariate binary logistic 
regression analysis was performed on the entire cohort.  ITU admission, increasing age, 
sepsis, immunosuppression and gentamicin use at any time were associated with an 
increased risk of in hospital mortality.  A prior diagnosis of diabetes mellitus and ACE- 
inhibitor or ARB use were associated with decreased risk of in hospital mortality.  An 
increased burden of AKI risk factors was not associated with increased mortality (Odds 
ratio 1.08, 95% confidence intervals 0.98, 1.20).  
 
Multivariate analysis was subsequently performed using a backwards selection model.  
ITU admission and increasing age were associated with increased risk of death whereas 
angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker use prior 
to renal replacement therapy was associated with decreased risk of death.  There was no 
association with increased in hospital mortality with gentamicin exposure prior to renal 
replacement therapy (gentamicin-associated AKI) or with gentamicin exposure at any time. 
Univariate and multivariate analyses are illustrated in Table 2-6.  
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Table 2-6 Binary logistic regression analysis of factors associated with in-hospital mortality.  Multivariate analysis was performed using a 
backwards selection model.   
 
Variable Univariate analysis  
Odds Ratio 
95% CIa P value Multivariate 
analysis  
Odds Ratio 
95% CI P value 
ITU admission 3.81 2.32, 6.27 0.000 4.87 2.65, 8.23 0.000 
Age 1.16b 1.01, 1.32 0.03 1.44 b 1.22, 1.70 0.000 
Sepsis 1.53 0.90, 2.61 0.116   ns 
Diabetes mellitus 0.46 0.27, 0.79 0.004   ns 
Immunosuppression 2.28 1.07, 4.86 0.028   ns 
Gentamicin use at any time 1.60 1.05, 2.43 0.028   ns 
Prior ACE I/ARBc 0.49 0.31, 0.78 0.002 0.45 0.24, 0.82 0.01 
 
aConfidence Interval 
bPer 10 year increase in age  
cAngiotensin 2 receptor blocke
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2.4 Discussion 
This large dataset from a single health board has investigated patients requiring RRT for 
AKI before and after a change in antimicrobial policy that resulted in a doubling of 
gentamicin use. We have found no evidence of increased requirement for RRT for AKI, no 
change in mortality associated with requiring RRT for AKI and no change in renal 
outcomes.  Patients who received gentamicin during Period 1 had a more prolonged overall 
duration of therapy, however this may reflect specific advice to limit gentamicin therapy 
duration in Period 2 and increased antibiotic stewardship.    
 
Patients with gentamicin-associated AKI were defined as those receiving gentamicin 
between 1 and 10 days prior to RRT requirement.  There was no evidence of increased 
mortality in this patient group compared to the remainder of the cohort.  This was despite a 
higher burden of AKI risk factors in this patient group.  It is notable that 94 of 314 (29.9%) 
patients in the non-gentamicin associated AKI group also received gentamicin.  
Gentamicin use at any time was associated with increased risk of death on univariate 
analysis but not multivariate analysis, and may simply be a surrogate marker for sepsis, 
especially in the ITU setting.      
 
Gentamicin prescribing increased as a consequence of restricted prescribing of co-
amoxiclav, cephalosporins and quinolones due to their association with C. difficile 
associated disease (CDAD).  CDAD incidence has fallen as a result of this and other 
interventions as discussed in Chapters 1 and 5.  Antimicrobial prescribing is measured by 
defined daily dose (DDD).  There was a significant increase in gentamicin prescribing 
between the 2 study periods (p=0.002) but no corresponding increase in RRT requirement 
or mortality giving a favourable risk: benefit ratio despite concerns at implementation of 
the change in guidelines of increased gentamicin associated AKI by virtue of increased 
gentamicin prescribing.      
 
Multivariate analysis was consistent with previous data showing that increasing age and 
requiring RRT in an ITU environment are associated with an increased risk of mortality.  
The suggestion that a diagnosis of diabetes could be a positive prognostic marker should be 
viewed with caution.  This has not been observed in other research and it is important to 
recognise that the population studied are a highly selected group who were felt appropriate 
for critical care admission or emergency renal replacement therapy.  
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The presence of proteinuria has been associated with increased risk of requiring RRT post 
cardiac surgery, although there was no evidence of diabetes mellitus being implicated in a 
large observational study (193).  This is contrasted with retrospective data from nearly 450 
000 patients undergoing coronary artery bypass grafting suggesting that diabetes, treated 
with either oral agents or insulin, increased the risk of postoperative dialysis with Odds 
Ratios of 1.42 and 2.17 respectively (194).     
 
Prior use of an ACE inhibitor or angiotensin 2 receptor blocker also appeared to be 
associated with decreased mortality on multivariate analysis.  This has not been observed 
in previous literature and should be explored further.  There may be an argument that 
patients with AKI with ACE inhibitor or ARB as an exacerbating factor are less unwell at 
presentation, however in this cohort, potential confounders such as concomitant sepsis and 
ITU admission were included in the multivariate analysis.    These agents are highly 
reversible contributing factors to AKI that have been associated with increased mortality in 
a cardiac surgery population in retrospective series (195).  There may also be an increased 
risk of AKI when ACE inhibition is associated with iodinated contrast administration 
although prospective research is lacking and existing data is contradictory (196, 197).     
 
The size of the dataset has allowed further analysis into risk factors associated with hard 
outcomes such as residual renal impairment.  20.3% patients were discharged from hospital 
with residual renal impairment and 5.3% became dialysis dependent.  This is a lower 
proportion than that observed in other critical care populations (198), and in a meta-
analysis of AKI in adults, which also recognised the heterogenous nature of available 
research (199).  They found that increased age was associated with non recovery of AKI 
requiring RRT, with 31.3% of surviving elderly patients not recovering kidney function 
compared with 26% of younger patients (pooled relative risk, 1.28, 95% confidence 
interval, 1.06 to 1.55; P < 0.05). 
 
Patients who received RRT in a renal unit only were more likely to have residual renal 
impairment at discharge from hospital.  This may relate to other patient characteristics not 
captured by this analysis including the underlying cause of renal impairment and the 
decreased overall mortality in this population.       
 
These data are limited by the definition of AKI as dependence on renal replacement 
therapy and its retrospective nature.  It is well recognised that very small rises in serum 
creatinine are associated with significant morbidity and mortality and therefore further 
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research into gentamicin and AKI not requiring dialysis is required.  Prospective data 
collection would help to capture a full dataset ensuring that, for example, single doses of 
gentamicin not followed up by levels are recorded.  Ongoing surveillance of outcomes in 
gram negative bacteraemia in NHS GGC with research in press suggests that there has 
been a fall in mortality in those with hospital associated infection with associated reduction 
in resistant organisms since the change in antibiotic guidelines.  As seen in these data, 
there was no change in the incidence of acute RRT.      
 
A very large sample size would be required to identify an increase in AKI requiring RRT 
as a result of gentamicin use.  If we assume that 10% of patients admitted to an ITU 
require RRT, in order to identify a 20% increase in RRT requirement with 80% power and 
type 1 error rate 0.05, we would require a minimum sample size of 7700 patients.  Such a 
prospective study would be difficult to recruit, an alternative antibiotic to gentamicin be 
required for ethical approval and blinding would be impossible due to the requirement for 
drug level monitoring.  Therefore such a trial would be unlikely to proceed to a recruitment 
stage.  This raises the potential for the current study to be a false negative result as it is 
underpowered.       
 
2.5 Conclusion 
In summary, in this retrospective cohort, we have found no evidence of an increase in 
gentamicin-associated AKI requiring renal replacement therapy despite doubling of 
gentamicin use in the hospital population.  Our concern that increased gentamicin use may 
result in a significant increase in AKI requiring emergency renal replacement therapy was 
unfounded.   
 
Continued vigilance is required to ensure that gentamicin is used safely and appropriately, 
particularly through careful therapeutic drug monitoring, avoidance of other co-
administered nephrotoxic agents and restriction in duration of therapy.  
 
2.5 Suggestions for further research 
Further research in this field should focus on the prevention of gentamicin-associated AKI 
by adjusting gentamicin dosing regimens in order to adequately treat sepsis while reducing 
the potential for toxic levels with limitation of gentamicin course duration.   
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Further prospective research into the early recognition of AKI and addressing its 
precipitants with the aim of improving outcomes is required.  Methods to facilitate the 
detection of early acute kidney injury using automatic electronic alerts from the 
biochemistry laboratory are already underway with promising results (34).  A need for a 
more robust and consistent assessment of patients with AKI was highlighted by the 
NCEPOD Report(11) and prospective research may include a bundle of measures similar 
to that recommended in the assessment of the patient with possible sepsis (200).  These 
measures may help to increase awareness of gentamicin-associated AKI in this era of 
restricted antimicrobial prescribing.   
 
Global surveillance by the World Health Organisation has identified very high rates of 
resistance in common bacteria including S. aureus (201).   A post antibiotic era during the 
21st century is becoming a very real possibility with significant associated health and 
economic implications.  Alternative approaches, such as improved and more rapid 
diagnostics and non-antimicrobial approaches to the prevention and treatment of infection 
may help to delay or avert this potential disaster. 
    
Chapter 3: A Retrospective Study of 
Staphylococcal Bacteraemia in a Renal Unit. 
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3.1. Background 
Staphylococcus spp. bacteraemia is a significant cause of morbidity and mortality in renal 
failure populations. Metastatic infective complications are relatively common e.g. 
endocarditis can occur in over 10% of episodes of S. aureus bacteraemia (202). 
Endocarditis associated with coagulase negative staphylococcal spp is much less common, 
developing in fewer than 3% cases (203).    
 
HD access is often implicated as the route of inoculation, especially where central venous 
catheters have been used.  It is well recognised that regular HD patients with tunnelled and 
non tunnelled central venous catheters have an increased incidence of bacteraemia and 
increased risk of mortality (99).  Antimicrobial line locks may reduce the risk of catheter-
associated bacteraemia, however there are concerns regarding the promotion or selection of 
resistant organisms (204).  Cannulation of arteriovenous fistulae via the buttonhole method 
is also associated with an increased incidence of bacteraemia despite an overall reduction 
in radiological and surgical interventions required to maintain a functional fistula (205) 
(206). 
 
Sepsis is reported to account for 18% of all cause mortality in prevalent dialysis patients 
(207).  Renal units account for nearly 5% of all of the episodes of methicillin sensitive 
Staphylococcus aureus (MSSA) bacteraemia reported to Health Protection Scotland (98).  
Staphylococcus spp. are the predominant organisms causing bacteraemia in a HD 
population as discussed in Chapter 1.   
 
Previous research has suggested that patients with established renal failure and MSSA 
bacteraemia have higher hospitalisation and mortality rates when treated with vancomycin 
instead of the beta lactam antibiotic, cefazolin (208). However there is no consensus on the 
optimal antibiotic duration or antibiotic choice in treatment of MSSA bacteraemia in the 
HD population as discussed in Chapter 1.  The majority of coagulase negative 
staphylococci causing disease are S. epidermidis, however no species-specific information 
was available for the purposes of this research.      
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This study was performed to: 
a) determine the effect of Staphylococcus aureus and coagulase negative Staphylococcus 
spp. bacteraemia on mortality, metastatic infection and hospitalisation rates in patients with 
established renal failure. 
b) compare different antimicrobial regimens in the treatment of MSSA bacteraemia.   
c) evaluate the epidemiology of the Staphylococcus aureus species with respect to spa gene 
typing and diversity of the species involved.   
 
3.2 Methods  
3.2.1 Data collection 
All positive blood cultures of Staphylococcus aureus and coagulase negative 
Staphylococcus spp. from patients who were receiving outpatient HD therapy or were a 
renal inpatient under care of the Glasgow Renal and Transplant unit between 01/01/2010 
and 31/12/2011 were obtained from the microbiology laboratories in Greater Glasgow and 
Clyde and Forth Valley health boards.  Details of HD access type at the time of 
bacteraemia, hospitalisation, evidence of metastatic infection and mortality were recorded.  
Where available, data on antibiotic therapy were recorded from the Glasgow Renal and 
Transplant Unit Electronic Patient Record.   
 
In this cohort, the definition of bacteraemia was entirely microbiological with no 
requirement for evidence of localised infection, metastatic infection or a systemic 
inflammatory response.  Positive blood cultures for the same organism within 14 days were 
considered the same episode of bacteraemia.     
 
All demographic and admission data was obtained from the Glasgow Renal and Transplant 
Unit Electronic Patient Record and NHS Greater Glasgow and Clyde Clinical Portal.  
These collate admission data, blood test results, radiology reports and records of 
procedures performed for all patients under the care of the Glasgow Renal and Transplant 
Unit, Western Infirmary, Glasgow.  
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Spa gene typing of all S. aureus positive blood cultures was performed as standard in the 
Scottish MRSA Reference Laboratory (209).  PCR amplification was performed in house 
using Ridom primers prior to Spa testing by GATAC Biotech (Germany) (210). 
 
3.2.2 Statistical analyses 
The Mann Whitney U test, binomial comparison of 2 distributions and binary logistic 
regression analysis were utilized where appropriate using Minitab 13.1 software.  The 
continuous data were not normally distributed by the Anderson-Darling test for normality.   
 
3.3 Results 
3.3.1 Staphylococcus spp. bacteraemias 
248 renal inpatients with 362 episodes of staphylococcal bacteraemia were identified 
during the two year study period.  
• Eleven (3.0%) episodes were in renal transplant recipients 
• Forty-seven (13.0%) were in HD patients dialysed via arteriovenous fistulae 
• Two hundred and twenty-five (62.2%) were in HD patients dialysed via tunnelled 
central venous catheters 
• Fifty-one (14.1%) were in HD patients who dialysed via non tunnelled central 
venous catheters 
• Twenty-eight (7.7%) were in renal inpatients not receiving RRT and with no 
indwelling central vascular access 
 
Sixty-five of the 248 (26.2%) patients died within 6 months of a first episode of 
staphylococcal bacteraemia.  Renal transplant recipients were less likely to die in the 6 
months after a first episode of staphylococcal bacteraemia (p = 0.04) compared to patients 
requiring regular HD.  
 
Eighteen of the 248 (7.3%) patients had evidence of metastatic infection.   
• Eleven patients (4.4%) had endocarditis 
• Three patients (1.2%) had discitis       
• Two patients (0.8%) had osteomyelitis 
• Two patients (0.8%) had mycotic abscess formation 
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There were an average of 1.32 admissions per 6 months before a first episode of 
staphylococcal bacteraemia and 1.67 admissions per 6 months after the first episode of 
staphylococcal bacteraemia (p = 0.01).  Patients who developed bacteraemia had an 
average of 9.59 inpatient days per 6 months before the first episode of staphylococcal 
bacteraemia and 14.59 inpatient days per 6 months after the first episode of staphylococcal 
bacteraemia (p = 0.00).   
  
There was no significant difference between the number of vascular access procedures in 
the 6 months before (1.02 procedures) or after (1.10 procedures) developing a first episode 
of staphylococcal bacteraemia.  
 
3.3.2 Staphylococcus aureus bacteraemia (MSSA and 
MRSA combined) 
There were 84 renal inpatients with 102 S. aureus bacteraemias (SAB) (including 16 
MRSA bacteraemias).   
• Four (3.9%) SAB were in renal transplant recipients 
• Nineteen (18.6%) SAB were in HD patients dialysed via arteriovenous fistulae 
(AVF) 
• Sixty-one (59.8%) SAB were in HD patients dialysed via tunnelled central venous 
catheters (TCVC) 
• Fourteen (13.7%) SAB were in HD patients dialysed via non tunnelled central 
venous catheters (NTCVC) 
• Four (3.9%) SAB were in renal patients who were not undergoing HD and were not 
renal transplant recipients 
 
Twenty-three (27.4%) of the patients died within 6 months after first developing S. aureus 
bacteraemia.  None of these patients were renal transplant recipients (p=0.04).  Seven 
(14.6%) of the patients had metastatic infection and only 1 of these patients dialysed via an 
AVF.        
  
There were an average of 1.41 admissions per 6 months before and 2.08 admissions per 6 
months after first developing SAB (p < 0.01).  Patients had an average of 11.26 inpatient 
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days per 6 months before and 15.79 inpatient days per 6 months after developing SAB (p < 
0.01).   
 
There was no significant difference between the number of vascular access procedures in 
the 6 months before (average of 1.19 procedures) or after (average of 1.71 procedures) 
developing SAB (p= 0.17).   
 
MSSA and MRSA bacteraemias were compared in Table 3-1.  15.7% of SAB were caused 
by MRSA.  There were no MRSA bacteraemias in renal transplant recipients  (p=0.04 
compared to MSSA bacteraemias).  There was no significant increase in MRSA 
bacteraemia in patients with TCVC or NTCVC dialysis access.  Patients with MRSA 
bacteraemia had significantly fewer hospital admissions (p=0.002) and significantly fewer 
inpatient days (p=0.011) during the first 6 months following first bacteraemia compared to 
those with MSSA bacteraemia (Table 3-1).  
 
Chapter 3 96
 
Table 3-1 Comparison of MSSA and MRSA bacteraemia.  Data are expressed as value 
(%) or mean (standard deviation) as appropriate.  1 patient had MSSA and MRSA 
bacteraemia therefore was excluded from the analysis 
Patient group MSSA bacteraemia 
n=69 patients 
n=85 bacteraemias 
MRSA bacteraemia 
n=14 patients 
n=15 bacteraemias 
P value 
Renal Transplant 4 (4.7) 0 0.040 
HD with AVF 15 (17.6) 4 (26.7) 0.458 
HD with TCVC 51 (60.0) 8 (53.3) 0.632 
HD with NTCVC 
 
13 (15.3) 1 (6.7) 0.252 
Peritoneal dialysis 
 
1 (1.2) 0 0.314 
No IV access 
 
1 (1.2) 2 (13.3) 0.170 
Average no. of admissions 
in 6 months before first 
SAB 
1.5 (1.3) 0.86 (0.77) 0.113 
Average no. of admissions 
in 6 months after first 
SAB 
2.3 (1.6) 0.93 (0.73) 0.002 
Inpatient days in 6 months 
before first SAB 
 
10.8 (11.8) 13.8 (26.8) 0.524 
Inpatient days in 6 months 
after first SAB 
 
17.5 (16.8) 8.0 (9.7) 0.011 
Average no. of procedures 
in 6 months before first 
SAB 
 
1.3 (1.3) 0.9 (1.6) 0.163 
Average no. of procedures 
in 6 months after first 
SAB 
 
1.7 (1.9) 1.4 (1.6) 0.796 
Metastatic infection 
 
11 (15.9) 1 (7.1) 0.396 
Death 17 (24.6) 6 (40.0) 0.135 
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Table 3-2 Comparison of flucloxacillin monotherapy and vancomycin monotherapy 
in MSSA bacteraemia.  Data are expressed as value (%) or mean (standard deviation) as 
appropriate 
Patient group Flucloxacillin 
monotherapy: 
n = 13 patients 
Vancomycin 
monotherapy: 
n = 18 patients 
P value 
Renal Transplant 
 
2  (15.4) 2  (11.1) 0.73 
HD with AVF 
 
3  (23.0) 3  (16.7) 0.66 
HD with TCVC 
 
4  (30.8) 11  (61.1) 0.08 
HD with NTCVC 
 
4  (30.8) 2 (11.1) 0.18 
Average no. of 
admissions in 6 months 
before first SAB 
1.77 (0.83) 1.53 (1.29) 0.50 
Average no. of 
admissions in 6 months 
after first SAB 
2.54 (1.98) 2.07 (1.43) 0.58 
Inpatient days in 6 
months before first SAB 
 
11.15 (8.35) 8.36 (9.74) 0.22 
Inpatient days in 6 
months after first SAB 
 
16.31 (12.94) 13.71 (8.75 0.68 
Average no. of 
procedures in 6 months 
before first SAB 
 
1.58 (1.38) 2.07 (1.44) 0.44 
Average no. of 
procedures in 6 months 
after first SAB 
 
1.08 (1.44) 2.21 (2.05) 0.12 
Metastatic infection 
 
2 (15.4) 3 (16.7) 0.92 
Death 
 
3 (23.1) 3 (16.7) 0.66 
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Table 3-3 Comparison of flucloxacillin based regimen and vancomycin based regimen 
in MSSA bacteraemia.  Data are expressed as value (%) or mean (standard deviation) as 
appropriate 
Variable Flucloxacillin based 
regimen:  
 
n = 29 patients,  
n = 32 bacteraemias 
Vancomycin based 
regimen:  
 
n =23 patients,  
n = 28 bacteraemias 
P value 
Transplant 
 
2  (6.3) 2  (7.1) 0.89 
AVF 
 
6 (18.8) 5  (17.9) 0.92 
TCVC 
 
16  (50.0) 17  (60.7) 0.40 
NTCVC 
 
6   (18.8) 4  (14.3)   0.64 
Average no. of 
admissions before first 
MSSA bacteraemia 
1.48 (1.27) 1.68 (1.56) 0.72 
Average no. of 
admissions after first 
MSSA bacteraemia 
2.62 (1.97) 2.50 (1.47) 0.90 
Average no. of inpatient  
days before first MSSA 
bacteraemia 
10.72 (9.74) 9.36 (10.93) 0.45 
Average no. of inpatient  
days after first MSSA 
bacteraemia 
16.79 (13.82) 13.50 (9.21) 0.57 
Average no. of 
procedures before first 
MSSA bacteraemia 
1.39 (1.32) 1.18 (1.33) 0.53 
Average no. of 
procedures after first 
MSSA bacteraemia 
1.32 (1.59) 2.05 (2.08) 0.17 
Metastatic infection 
 
5 (15.6) 4 (14.3) 0.84 
Death 
 
6 (20.7) 4 (17.4) 0.63 
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Table 3-4 Comparison of MSSA bacteraemia by antibiotic duration.  Data are 
expressed as value (%) or mean (standard deviation) as appropriate 
Variable <14 days Rx 
n= 51 patients 
n=60 bacteraemias  
>14 days Rx 
 n=16 patients 
n= 16 bacteraemias 
P value 
Average no. of 
admissions before first 
MSSA bacteraemia  
1.37 (1.28) 1.50 (1.03) 0.46 
Average no. of 
admissions after first 
MSSA bacteraemia  
  
2.06 (1.59) 3.06 (1.91) 0.04 
Average no. of inpatient  
days before first MSSA 
bacteraemia 
11.01 (17.01) 11.88 (19.79) 0.33 
Average no. of inpatient  
days after first MSSA 
bacteraemia  
14.00 (10.97) 20.63 (13.61) 0.06 
Average no. of 
procedures before first 
MSSA bacteraemia 
 
1.28 (1.46) 1.56 (0.89) 0.12 
Average no. of 
procedures after first 
MSSA bacteraemia 
1.86 (2.07) 12.88 (2.60) 
  
0.16 
Metastatic infection 
 
3/51  (5.9%) 5/16  (31.3%) 0.04 
Death 
 
13/51  (25.5%) 4/16  (25%) 0.97 
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Table 3-5 Comparison of S. aureus bacteraemia and coagulase negative 
Staphylococcus spp. bacteraemia.  Data are expressed as value (%) or mean (standard 
deviation) as appropriate 
Variable  S. aureus 
bacteraemia 
 
n= 84 patients 
n= 102 bacteraemias 
Coagulase negative 
Staphylococcus spp 
bacteraemia 
n= 191 patients 
n= 260 bacteraemias 
P value 
Average no. of 
admissions before first 
bacteraemia 
 
1.42 (2.29) 1.36 (1.38) 0.50 
Average no. of 
admissions after first 
bacteraemia 
  
2.08 (1.64) 1.58 (1.51) 0.008 
Average no. of inpatient  
days before first 
bacteraemia 
  
11.26 (15.13) 9.74 (13.54) 0.29 
Average no. of inpatient  
days after first 
bacteraemia  
15.79 (16.10) 13.87 (16.73) 0.07 
Average no. of 
procedures before first 
bacteraemia 
 
1.19 (1.32) 1.06 (1.23) 0.49 
Average no. of 
procedures after first 
bacteraemia 
1.71 (1.93) 1.05 (1.03) 0.007 
Metastatic infection 
  
12/84  (14.5%) 7/191  (3.7%) 0.009 
Death 23/84  (27.4%) 52/191  (27.2%) 0.98 
 
 
There were no significant differences in demographics or outcomes between patients 
treated with flucloxacillin monotherapy or vancomycin monotherapy (Table 3-2) or 
between those treated with a flucloxacillin-based regimen compared to a vancomycin-
based regimen (Table 3-3).  This data contrasts with the previous clinical viewpoint that a 
vancomycin based regimen reduced inpatient days, although this hypothesis has not been 
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proven by observational research (208).  Patients treated with a prolonged antibiotic course 
for MSSA bacteraemia had more hospital admissions with an increased incidence of 
metastatic infection (p=0.04) (Table 3-4). There was significantly more metastatic 
infection in those with S. aureus bacteraemia compared to coagulase negative 
Staphylococcus spp (p=0.009).  There was no significant difference in mortality rates 
(Table 3-5).  This was surprising, and may be related to the high co-morbidity of the study 
population. 
 
17 patients had more than a single episode of S. aureus bacteraemia.  All of these patients 
required regular HD compared to 54/67 (80.6%) of the remainder of this population (p= 
0.000).  Two (11.8%) of the patients with more than a single episode of bacteraemia had 
metastatic infection compared with nine (16.7%) of the remainder of the S. aureus 
bacteraemia cohort.    
 
3.3.3 Staphylococcus spp. bacteraemia in regular 
haemodialysis patients only 
 
Bacteraemia in regular HD patients can be expressed per 1000 dialysis days or per 1000 
catheter days in those with tunneled central venous catheters (TCVC). From Scottish Renal 
Registry data TCVC use in prevalent HD patients in the Glasgow Renal and Transplant 
Unit was 27% and 26%, in 2010 and 2011 respectively, confirmed by unit specific data 
collection from the vascular access team (personal communication, Emma Aitken).  No 
data were available for NTCVC days.   
 
198 patients from this cohort were receiving long term HD at the time of bacteraemia.  
This accounts for 314 bacteraemias with 88 S. aureus bacteraemias (including 15 MRSA 
bacteraemias) and 215 coagulase negative staphylococcal bacteraemias.  Total bacteraemia 
rate was 0.87 per 1000 dialysis days for all bacteraemias with 0.21 per 1000 dialysis days 
for MSSA bacteraemias, 0.04 MRSA bacteraemias per 1000 dialysis days and 0.62 
coagulase negative staphylococcal bacteraemias per 1000 dialysis days.    
 
TCVC associated bacteraemia prevalence was 2.02/1000 catheter days.  MSSA 
bacteraemia occurred in 0.46/1000 catheter days, MRSA bacteraemia in 0.08/1000 catheter 
days and coagulase negative staphylococcal bacteraemia in 1.48/1000 catheter days.   
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AVF associated bacteraemia was 0.21/1000 AVF days.  MSSA bacteraemia occurred in 
0.06/1000 AVF days, MRSA bacteraemia 0.02/1000 AVF days and coagulase negative 
staphylococcal bacteraemia 0.13/1000 AVF days. 
 
Standard treatment of staphylococcal bacteraemia during the study period was difficult to 
define and depended on the perceived source of infection, bacteria cultured, dialysis access 
and individual clinician preference.      
 
Table 3-6 illustrates bacteraemia rates in the prevalent HD patient population directly 
comparing TCVC and AVF bacteraemia.  Bacteraemia secondary to MSSA and coagulase 
negative staphylococci were significantly increased in those patients dialysing via TCVC.   
 
Table 3-6 Comparison of form of haemodialysis access by Staphylococcus spp. 
bacteraemia  
 All patients 
bacteraemia 
/1000 HD days) 
TCVC patients 
(bacteraemia 
/1000 TCVC 
days) 
AVF patients 
(bacteraemia 
/1000 AVF days) 
P 
value 
MSSA 
 
 
0.21 0.46 0.06 0.000 
MRSA 
 
 
0.04 0.08 0.02 0.024 
Coagulase 
negative 
Staphylococcus 
0.62 1.48 0.13 0.000 
 
All 
Staphylococcus 
spp. 
 
0.87 
 
2.02 
 
0.21 
 
0.000 
 
 
Regular HD via a TCVC was significantly associated with bacteraemia due to all 
staphylococcal species.  Coagulase negative staphylococci rarely cause a sepsis syndrome 
in an AVF population but can be pathogenic in those with indwelling lines, predominantly 
due to the effect of biofilm as discussed in Chapter 1.   
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3.3.4 Spa gene typing of S. aureus bacteraemias 
Spa gene typing was performed as routine for all S. aureus bacteraemia specimens in the 
Scottish MRSA reference laboratory.  This allows relationships between different S. 
aureus strains according to the polymorphic region of the protein A gene to be represented 
visually using a Based Upon Repeat Pattern (BURP) diagram.  The spacing between linked 
spa types and between unlinked spa types provides no information concerning the genetic 
distance between them.  The spa type with the highest founder-score is defined founder of 
the cluster (blue colour). Subfounders are the spa types with the second highest founder-
score and are labelled in yellow. If two or more spa types exhibit the same highest 
founder-score, they are all coloured in blue.   
 
Spa typing was available for 96% of S. aureus isolates.  There were 7 clusters with 11 
singletons.  Clusters 1-3 accounted for 28% of all isolates and all clusters are illustrated in 
Figure 3-1.   Discriminatory Power was 0.97 (95% confidence interval 0.956-0.983).  
There was no difference in Discriminatory Power when samples originating from regular 
HD patients only were analysed.  The Discriminatory Power is the average probability that 
the typing system will assign a different type to two unrelated strains randomly sampled in 
the microbial population.   
 
17 patients had more than a single staphylococcal bacteraemia.  These were all regular HD 
patients.  In 14 of these patients (77.8%) the subsequent spa type was identical to the 
original bacteraemia.   
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Figure 3-1 Population snapshot of the 53 S. aureus strains after BURP grouping.  The 
spa type with the highest founder-score is defined founder of the cluster (blue colour). 
Subfounders are the spa types with the second highest founder-score and are labelled in 
yellow 
 
3.4 Discussion 
Staphylococcal bacteraemia remains common in the renal unit, particularly among our HD 
patients and the highest bacteraemia rates (2.02/1000 days) were observed in HD patients 
dialysing via a TCVC.  This pattern of prevalence of bacteraemia in HD patients is similar 
to the rates documented in the renal patient population in the same unit in 2004-2005 
(0.3/1000 dialysis days in HD patients with arteriovenous fistulae, 1.8/1000 dialysis days 
in patients with TCVC and 6.3/1000 dialysis days in patients with a NTCVC) (99).  Given 
the previously documented high incidence of Staphylococcal bacteraemia in the Glasgow 
HD population a range of measures designed to reduce infection were in place at the time 
of this audit.  TCVC were inserted by a core team of specialist nurses and interventional 
radiologists in a controlled environment under strict aseptic conditions.   Non-tunnelled 
central venous catheter (NTCVC) insertion was mostly performed by renal trainees under 
aseptic conditions in the ward environment or a treatment room.  A chlorhexidine-
impregnated “BiopatchTM” was placed at the catheter exit site.  A single retrospective study 
reported a reduction in exit site infection but no reduction in catheter related bacteraemia 
was associated with this intervention (211). It is disappointing that the bacteraemia rates 
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were not improved in this study in 2010-2011 despite the routine use of a range of 
measures to prevent bacteraemia in HD patients.  
 
In the historic literature a definition of bacteraemia required documentation of a systemic 
inflammatory response as well as positive blood culture results.  This was not a criterion in 
this series as bacteraemia may not be associated with fever or neutrophilia in renal patients.  
Inclusion of all episodes of positive blood cultures as episodes of bacteraemia in this study 
may overestimate the true prevalence of bacteraemia, especially the incidence of coagulase 
negative staphylococcal bacteraemia due to contamination when blood sampling or 
colonisation of the HD catheter due to biofilm formation.     
 
The incidence of coagulase negative Staphylococcus spp. bacteraemia may be difficult to 
correlate with clinical significance in this study population as not all of these episodes were 
associated with clinical evidence of sepsis.  Nevertheless coagulase negative 
Staphylococcus spp bacteraemia, defined as the presence of a positive blood culture only, 
was associated with admission rates, number of inpatient days and mortality rates in this 
study which were not significantly different from S. aureus bacteraemia (Table 3-5). The 
high mortality rate after Staphylococcal bacteraemia in the HD population may be related 
to this patient population’s high cardiovascular and other co-morbidity (99). As expected 
S. aureus bacteraemia was associated with a significantly higher risk of metastatic 
infection than coagulase negative staphylococcal spp bacteraemia (Table 3-5). S. aureus 
bacteraemia is known to confer a major economic burden on renal units, with an estimated 
cost of up to $32000 for each patient who is hospitalised for bacteraemia in the US (212, 
213).   
 
Outcomes with MRSA and MSSA bacteraemia in this cohort contrast with other published 
literature (214) (215).  MRSA bacteraemia accounted for 15.7% of all SAB.  This is lower 
than reported in historical series of HD patients or hospitalized patients.  109 HD patients 
with SAB from 3 German hospitals between 1999 and 2005 were reviewed in an attempt to 
assess variation in demographics and outcomes between community-acquired and 
nosocomial infection.  25.7% patients in this cohort had MRSA bacteraemia.  Mortality 
rates in MRSA and MSSA bacteraemias were 32.1% and 30.9%, respectively and the 
average treatment costs for patients with MSSA bacteraemia were <50% of patients with 
MRSA bacteraemia (€10,573 vs. €24,931, p <0.05).  An American study, in which 37.8% 
of the HD patients had MRSA bacteraemia, reported that there was an increased risk of 
death associated with MRSA bacteraemia.  There were higher adjusted costs for the initial 
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hospitalization for MRSA bacteraemia ($21,251 vs $13,978; p = 0.012) and after 12 weeks 
($25,518 vs $17,354; p = 0.015) (215).  MRSA bacteraemia in general has been falling 
over the past 10 years and therefore the current series may be more comparable with 
present day bacteraemia rates.      
 
There is little information on how best to treat S. aureus bacteraemia in renal patients, 
especially HD patients. The largest available dataset from the USA analysed data from 293 
094 outpatient HD patients over the 4 year period, January 1st 2006 until December 31st 
2010 (208).  In this population, the rate of MSSA bacteraemia was 2.1 per 100 outpatient-
years, and rate of MRSA bacteraemia was 1.9 per 100 outpatient-years.  This retrospective 
data showed that the 1st generation cephalosporin, cefalozin was associated with 
significantly reduced risk of hospitalization or death compared to vancomycin (hazard 
ratio=0.50, 95% CI=0.35–0.73).  This study was limited because it was retrospective and 
so information regarding inpatient care and all additional interventions that were required 
to treat infection such as catheter removal or changes was not available.  In addition, 
vancomycin levels were not consistently recorded raising the possibility that 
subtherapeutic vancomycin titres may have contributed to the poorer outcomes with 
vancomycin.  The increased use of high flux haemodialysis and haemodiafiltration results 
in increased vancomycin removal requiring adjustment of dosage regimens (216).               
 
The MRSA bacteraemia rate for HD patients from this unit is comparable to other large 
renal units in the UK as illustrated by UK Renal Registry Report data (Figure 3-2, below).  
Data are expressed per 100 prevalent HD patients.  The Glasgow Renal and Transplant 
Unit has had approximately 650 regular HD patients throughout 2010 and 2011 and so the 
MRSA bacteraemia rate per 100 prevalent HD patients in 2010 and 2011 was 1.15.   
 
MSSA bacteraemia was also recorded for the first time in the 14th Annual UK Renal 
Registry Report in 2012 and the total MSSA bacteraemia was reported as 1.7 per 100 
prevalent HD patients in X of the total renal units in England (217).  There were 5.61 
MSSA bacteraemias per 100 prevalent HD patients in this Glasgow population but this 
needs to be interpreted in the context of a probable incomplete dataset from the UK Renal 
Registry given the lack of mandatory reporting in this population at the time of data 
collection.    
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Figure 3-2 Figure 3-4 MRSA bacteraemia rate per 100 prevalent HD patients by 
renal centre: 1/4/2009 to 31/3/2010 For each centre the rate per 100 prevalent HD 
patients as reported 31/12/2009 is provided (217). 
The overall rate for England is provided at the top of the graph 
 
Data obtained from spa gene analysis is difficult to interpret on an epidemiological level 
due to the relatively small number of samples.  Recurrent infection with S. aureus 
containing the same spa gene supports existing evidence of individuals predominantly 
carrying a single strain of S. aureus despite attempts at eradication.   
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3.5 Conclusion 
Staphylococcus spp. sepsis is common in the renal unit and predominantly affects regular 
HD patients.  It is strongly associated with the use of central venous catheterisation for 
vascular access and catheter related staphylococcal bacteraemia is associated with a high 
incidence of metastatic infection.  The key objective is therefore to reduce the proportion 
of HD patients using central venous catheters for vascular access. An AVF is the preferred 
mode of vascular access for HD and effective bundles of care are already in place to reduce 
the risk of bacteraemia in patients using an AVF.  Despite long-term efforts at maximizing 
the percentage of HD patients using an AVF for vascular access, many patients 
unfortunately continue to require TCVC for vascular access for HD.   
 
UK guidelines advise a target of 85% prevalence of AVF or arteriovenous graft use, 
however only a minority of renal units are currently achieving this (218).  High quality 
observational data has repeatedly found a clinically and statistically significant increase in 
mortality in patients undergoing haemodialysis via a TCVC compared to AVF.  Registry-
based data over three years with a maximum follow up of 36 months found a increased 
mortality associated with TCVC use.  Survival analysis using unadjusted data and data 
adjusted for comorbidities found significantly increased risk of death with 28.2% patients 
dialysing only via AVF or arteriovenous grafts during follow up compared to 45.2% of 
those dialysing via TCVC (unadjusted) (219).    
 
 3.6 Suggestions for further research 
Further investigation of the optimal bundle of care for prevention of catheter related 
infection is required to reduce hospitalisation and mortality rates in this comorbid 
population.  The optimum duration of antimicrobial therapy and antibiotic choice to 
adequately treat sepsis, limit metastatic infection and minimise antibiotic related side 
effects in renal patients is yet to be determined and should be studied further. 
 
Future research will focus on prevention of infection with alternative methods of vascular 
access such as increased use of arteriovenous grafts and modifications to TCVCs to reduce 
biofilm formation.  Antimicrobial line locks have been studied with evidence of a 
reduction in bacteraemia rates, however there are concerns that antibiotics used in the form 
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of line lock would promote antimicrobial resistance as has been seen in clinical practice in 
the USA(220). 
 
Increased patient involvement in their own management may also improve care of their 
vascular access device or AVF resulting in decreased infectious complications.  Attention 
to self care regimens, patient education and patient empowerment, as part of a wider 
culture, may help to improve outcomes.  Such interventions are underrepresented in the 
current literature.  
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4.1 Introduction 
Staphylococcus aureus isolates carrying the Panton-Valentine leucocidin (PVL) toxin gene 
have been responsible for outbreaks of community acquired severe invasive disease in the 
recent past (221) (222) (223).  It causes cell injury, and therefore disease, by activating 
neutrophils before creating lytic pores damaging the cell membrane (224). Injection of 
purified PVL toxin induces release of histamine, enzymes such as lysozyme, chemotactic 
factors, and oxygen metabolites from neutrophils. Injection of purified PVL toxin 
intradermally in rabbits resulted in severe inflammatory lesions with capillary dilatation, 
chemotaxis, neutrophil infiltration and skin necrosis (225).  Disease resulting from PVL 
positive S. aureus characteristically causes severe skin infections and a necrotising 
pneumonia (226).  Case series of those with pneumonia secondary to PVL positive S. 
aureus found that it was commonly preceded by a viral type illness.  One possible 
mechanism for this is that an initial viral lung infection could result in desquamation of 
ciliated and secretory cells, allowing bacterial adhesion to basal epithelial cells (227).  It is 
known that the prevalence of PVL positive S. aureus colonisation varies in different 
geographical areas (228) (229). 
 
Toxic shock toxin (TSST) has also been implicated in community acquired MRSA and is a 
superantigen.  Superantigens are able to bind directly to the major histocompatibility 
complex on the surface of antigen-presenting cells outside the antigen-binding groove.  
They cross-link with T cell receptors resulting in increased T cells activation (230).  Toxic 
shock toxin is produced by 5-25% of S. aureus isolates.  It causes toxic shock syndrome by 
stimulating the release of large amounts of interleukin-1, interleukin-2 and tumour necrosis 
factor (231).  Toxic shock syndrome (TSS) was first described in 1978 and was in 
association with highly absorbent tampons (232).  Once these were identified as being a 
risk factor for TSS they were removed from the market and the incidence has declined 
since.  It manifests as the development of septic shock with a desquamating skin rash.    
 
Exfoliative toxins A and B (ETA and ETB) mostly cause disease in children and result in a 
spectrum of disease ranging from localised blisters to generalised exfoliation affecting the 
entire body surface area (230).  Around 5% of S. aureus strains produce exfoliative toxin.  
They are responsible for the staphylococcal scalded skin syndrome (SSSS). Although 
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SSSS predominantly affects children, adults with renal impairment are also at increased 
risk.   SSSS in adults carries a greater than 50% mortality (233). 
 
Toxin gene positivity including PVL positivity has been associated with increased 
virulence and disease severity associated with S. aureus, however this is now disputed 
(234).  It has not been a consistent finding in observational human studies, animal models 
and in vitro research and deletion of the genes encoding the PVL toxin gene has not been 
shown to reduce virulence in animal models(224, 225, 235-240).  Recent research suggests 
that PVL may play a role in activation of the innate immune response, and therefore 
function in host recognition of S. aureus infection and facilitate resolution of disease (241).  
 
Prior to toxin gene analysis and epidemiological typing, S. aureus Methicillin resistance 
must be determined.  Methicillin resistance in S. aureus is conferred by the mecA gene, 
which encodes a membrane protein that has a low penicillin-binding affinity (penicillin-
binding protein 2a). mecA is located within a mobile genetic element named 
staphylococcal chromosomal cassette mec (SCCmec).   
 
Isolates of S. aureus can be characterised by spa typing.   This involves DNA sequencing 
of short sequence repeats in the polymorphic X region of the protein A gene (spa) of S. 
aureus. Each new base composition of a repeat is assigned an alpha-numerical code and 
the repeat succession determines the spa type.  BURP (Based upon repeat pattern) 
diagrams– as implemented in the StaphType software v. 1.5 (Ridom GmbH, Würzburg, 
Germany) can be used to cluster spa types and therefore infer their clonal relatedness.  
(124)  Spa typing is used world-wide for reliable, accurate and discriminatory typing of S. 
aureus (both MSSA and MRSA).  In commonly occurring lineages, DNA sequencing of 
the spa gene allows presumptive identification of healthcare- and community-associated 
MRSA strains identified in the UK and multi locus sequence typing (MLST) clonal 
complex designation.  Certain toxin genes have been associated with particular spa types.   
 
The USA300 clone is associated with community acquired MRSA. It has increased 
virulence and transmission and is characteristically spa t008 or t024.  Isolates with the spa 
type t008 are associated with PVL positivity.  The USA300 strain was first reported in 
2000 as causing skin and soft tissue infections amongst American sportsmen and prisoners.  
It is the most prevalent strain of community acquired MRSA and may account for up to 
50% of those colonised with MRSA in the community setting in the US (242) (243).    
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The prevalence of PVL, toxic shock toxin and exfoliative toxins in S. aureus in the 
community and haemodialysis patients is unknown.  In Scotland, these toxin genes are 
screened for in all S. aureus positive blood culture isolates which are routinely submitted 
to the Scottish MRSA Reference Laboratory (SMRSARL). However, not all isolates 
isolated from other sites are submitted, and testing for toxins is performed on request.      
 
This observational cohort study assesses the prevalence of PVL, TSST, ETA and ETB 
toxin genes in S. aureus from 4 different populations.   
• Assessment of nasal carriage of methicillin sensitive Staphylococcus aureus 
(MSSA) and methicillin resistant Staphylococcus aureus (MRSA) from: 
o All regular haemodialysis patients at Glasgow Royal Infirmary and Stobhill 
Hospital, Glasgow  
o “healthy volunteers” from an orthopaedic preoperative assessment clinic at 
Glasgow Royal Infirmary  
• Isolates originating from GP practices of skin infections  
• S. aureus positive blood cultures  
 
Laboratory analysis was at the MRSA reference laboratory for Scotland.  Isolates from the 
GP practices gave an estimate of community based disease.   Spa type was also ascertained 
in order to allow epidemiological analysis of S. aureus specimens.  
 
4.2 Methods 
4.2.1 Laboratory assays 
S. aureus ID (SAID; bioMérieux, La Balme Les Grottes, France) chromogenic agar plates 
were used for rapid and reliable identification of S. aureus species.  On SAID agar, S. 
aureus forms distinctive green colonies due to production of α-glucosidase (Figure 4-1).  
Other staphylococci generally form white colonies but occasionally produce pink colonies 
due to the hydrolysis of a second chromogenic substrate for β-glucosidase (244). 
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Figure 4-1 S. aureus culture on SAID chromogenic agar plate 
 
Latex agglutination testing (Figure 4-2) (Staphaureux Plus, Thermoscientific) confirmed 
the presence of a S. aureus colony.  Yellow latex particles coated with human fibrinogen 
for detection of clumping factor and coated with specific IgG for detection of protein A 
and surface antigens characteristic of MRSA and MSSA strains are visible in the bottom 
left and top middle areas of the card illustrated below.   
 
 
Figure 4-2 Latex agglutination testing kit 
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Standard horse blood agar plates were inoculated with a single colony and the 
susceptibility of the organism against cefotaxime, as a measure of methicillin resistance, 
and mupirocin antibiotic discs was assessed in line with Clinical and Laboratory Standards 
Institute Guidelines.   
 
Polymerase chain reaction testing followed by gel electrophoresis was performed for 
presence via the method described below.  These identify nuc, MecA and MupA genes via 
the method below which detect S. aureus, MRSA and mupirocin resistance respectively.  
The same specimens were tested for the presence of PVL, TSST, ETA and ETB toxin 
genes using the same method using appropriate primers.  
 
 
4.2.2 DNA Extraction method  
• Label the lids of autoclaved 0.5ml microtubes ((1 – x) depending on number of 
isolates on the worksheet) and place the labelled tubes in a polystyrene float 
• Include positive and negative controls with each run  
• Tube 1 should always be a water control 
• Add 50µl NET buffer to each microtube using a pipette and filter tip 
• Add 10µl Achromopeptidase to each microtube using a pipette and filter tip 
• Using a 1µl plastic loop suspend 1-2 colonies of the appropriate culture into each 
tube 
• Place the polystyrene float into the 50˚C waterbath, and incubate for 10-15 minutes 
 
4.2.3 Preparation of PCR Reaction Mix 
• Place multiwell plate on frozen block to ensure reagents remain cool 
• Add 23µl of PCR Master Mix to each well of the multiwell plate as necessary using 
a pipette and filter tip 
• Remove polystyrene float from water bath 
• Add 2µl of lysed cell suspension to the appropriate well of the multiwell plate using 
a pipette and fresh filter tip for each sample 
• Place the multiwell plate onto the MWG plate sealer block 
• Place foil seal on top of the multiwell plate with the white side up/silver side down 
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• Press down on the handle until you feel contact between the upper heated plate and 
the multiwell plate then press down a little further, and hold contact for at least 15 
seconds 
• Release the handle slowly 
• The plate is now ready to be placed in the thermal cycler 
 
4.2.4 Thermal Cycle 
• Place the multiwell plate or individual tubes in the thermal cycler ensuring lids of 
individual tubes are securely closed 
• Press the lid down firmly to close 
• Select the desired PCR cycle  
• When a run has finished, the timer is at zero.  Press the Red STOP button until the 
screen reads 'MY JOB IS DONE', open the lid and remove samples 
 
4.2.5 Electrophoresis Gel Preparation 
• Depending on the number of isolates being tested and the PCR being carried out, 
select the appropriate size of gel  
o Up to 8 isolates:   Mini Gel 
o Up to 14 isolates:   Small Gel 
o Up to 30 isolates:   Large Gel – either a 20 well or 30 well comb can be 
used in large gels 
• Into a 500ml Duran bottle, place the correct weight of agarose, and volume of 
distilled water and x10 TBE (to result in a 1.5% agarose gel) according to the table 
below: 
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Table 4-1 Composition of electrophoresis gel depending on size required 
 Agarose Distilled Water X 10 TBE* Buffer 
Mini 1.5 g 105 ml 5 ml 
Small 1.5 g 105 ml 5 ml 
Large 3.0 g 190 ml 10 ml 
 
* Tris/Borate/EDTA 
 
• Screw the cap onto the bottle very loosely 
• Place in microwave 
• Heat at full power for 2 minutes  
• After 1 minute - stop the microwave by opening the door, and swirl the bottle 
whilst still within the microwave 
• Return the bottle to the microwave and continue heating 
• Cool by placing in 50˚C waterbath for 15 minutes or by running cold water from 
tap over bottle with constant swirling 
• Prepare gel cast by taping both ends with white tape 
• Pour the gel, and then place comb(s) in the notches 
• Allow agarose to set for 20-30 minutes 
 
4.2.6 Electrophoresis Tank Preparation 
• Prepare the appropriate volume of buffer in a 2L measuring cylinder for the tank 
required as follows and pour carefully from the measuring cylinder into the tank 
 
Table 4-2 Composition of buffer required for electrophoresis tank depending on size  
 Tank Distilled Water x 10 TBE* buffer 
Mini Mini Tank 190 10 
Small Horizon 11:14 950 50 
Large Horizon 20:25 1900 100 
 
* Tris/Borate/EDTA 
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• Place the agarose gel into the tank with the wells towards the negative (black) 
electrode and carefully remove comb(s) from the agarose gel 
 
4.2.7 Gel Electrophoresis 
• Starting at the well closest to the front of the tank, load 6µl PCR product to each 
well as appropriate 
• Plug in black lead to black electrode on tank and black lead into black electrode on 
power pack. 
• Plug in red lead to red electrode on tank and red lead into red electrode on power 
pack. 
• Set voltage and running time according to gel size 
• Once complete, switch off the power pack and remove both red and black leads 
from the tank and power pack   
•  
4.2.8 Ethidium Bromide Staining  
This is carried out in designated area due to its carcinogenic and teratogenic 
properties 
• Remove gel and gel cast from tank carefully 
• Slide the gel (not the cast) into an ethidium bromide dedicated staining tray 
• Pour 0.0001% ethidium bromide from brown shatterproof bottle over the gel with 
the gel being completely immersed in stain. 
• Leave to stain for 15-20 minutes 
• Carefully remove gel from ethidium bromide using plastic gel scoop 
• Place gel in a fresh tray containing tap water to remove residual ethidium bromide 
• Return the ethidium bromide to the brown shatterproof bottle by pouring from the 
tray through the dedicated funnel 
• Photograph the gel and store image (Figure 4-3)  
• Discard the gel into a “Solid” toxic waste container 
 
4.2.9 Quality control measures 
• The water control should have no presence of DNA 
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• The positive control band(s) must be present 
• The negative control band(s) must be absent 
• Internal controls should be positive for all isolates.  A negative result may indicate 
extraction failure 
• If there is failure of any control, then the assay must be repeated 
• All batch/lot numbers of reagents should be recorded on the worksheet 
• Work-flow should be unidirectional i.e. from clean areas to contaminated areas, but 
not from contaminated areas to clean areas. 
 
 
Figure 4-3 Example of protein gel electrophoresis confirming PVL positivity of 
samples 2-5 with control samples at position 1 and 14.   
 
Spa testing was performed by GATAC Biotech (Germany) after PCR amplification in 
house using Ridom primers. 
 
The software Ridom StaphTypeTM (Ridom GmbH, Würzburg, Germany) was used for 
spa sequence analysis including the generation of BURP diagrams. 
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4.2.10 Study population 
Group 1:  Haemodialysis patients at Glasgow Royal Infirmary and Stobhill Hospital, 
Glasgow, aged over 18 and able to give informed consent.  These patients were 
prospectively screened using a nasal swab into charcoal medium.  Basic demographic data 
was collected. 
 
Group 2: Patients attending the preoperative assessment clinic for elective orthopedic 
surgery at Glasgow Royal Infirmary who were aged over 18 and able to give informed 
consent.  These patients were prospectively screened using a nasal swab into charcoal 
medium.  Basic demographic data was collected 
 
Group 3: Community skin swabs from GP practices in Greater Glasgow and Clyde were 
cultured in the conventional fashion in the general microbiology laboratory in Glasgow 
Royal Infirmary. If S. aureus was isolated, further analysis as described above was 
instituted.  The origin of the swab and character of the illness was collected.  
 
Group 4: Blood cultures were processed in the conventional fashion by the general 
microbiology laboratory in Glasgow Royal Infirmary.  If S. aureus was isolated they 
underwent further analysis as described above as routine by the MRSA reference 
laboratory 
 
 
4.2.11 Statistical analyses 
Minitab 13.1 TM was used for data analysis.  The data were not normally distributed and 
therefore the Mann Whitney Test for non parametric data and 2 Sample T Test were used 
where appropriate.   
 
4.2.12  Indemnity and ethical approval 
The study was conducted according to the guidelines laid down in the Declaration of 
Helsinki and was healthcare related research covered by NHS indemnity.  It was approved 
by the local Research and Development department and by NHS Greater Glasgow and 
Clyde research and ethics committee, (reference 10/S0701/65), on the 2nd November 2010. 
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4.3 Results 
148 Haemodialysis patients and 125 healthy patients were tested for S. aureus nasal 
colonisation.  58 skin swabs positive for S. aureus were identified from the general 
microbiology laboratory in a 3 month period giving an estimate of community based 
disease and 64 blood cultures were identified as being positive for S. aureus over a 6 
month period from the same geographical area.   
 
4.3.1 Comparison of haemodialysis patients and 
healthy controls 
There was no significant difference in age between the haemodialysis patients and healthy 
controls however there were significantly more males in the haemodialysis population with 
57.9% males in the haemodialysis population compared to 43.2% males in the “healthy” 
population.  There was no significant difference in age between those colonised with S. 
aureus and those without S. aureus colonisation in either the haemodialysis or healthy 
control groups.    Only 4 of 44 haemodialysis patients with S. aureus colonisation were 
colonised with MRSA and only 1 of the healthy controls were colonised with MRSA as 
illustrated by Table 4-3.  
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Table 4-3 Characteristics of prospectively screened patients (Groups 1 and 2) 
 Haemodialysis 
patients (Group 1) 
Healthy patients 
(Group 2) 
P value 
Number of 
patients screened 
 
145 125 n/a 
Mean age (IQR)* 
 
61.17  
(49.21, 74.61) 
58.33  
(47.31, 72.07) 
0.15 
No. (%) males 
 
84 (57.9) 54 (43.2) 0.015 
No. S. aureus (% 
of total screened) 
 
44 (30.3) 34 (27.2) 0.56 
No. MRSA (% of 
S. aureus positive) 
 
4 (9.1) 1 (2.9) 0.24 
Mean age (IQR) 
colonised with S. 
aureus (in years) 
59.06 (52.68, 
73.76) 
61.10 (53.89, 
72.24) 
0.83 
Mean age (IQR) 
not colonised with 
S. aureus (in 
years) 
62.10 (48.16, 
75.34) 
57.11 (46.26, 
71.98) 
0.06 
*Interquartile range 
 
4.3.2 Comparison of community infections and 
bacteraemias 
58 patients were identified as having a skin infection caused by S. aureus during a 2 month 
period in 2011 with 64 patients having S. aureus bacteraemia during a 6 month period from 
December 2010 from the same geographical area.  There was no significant difference in 
age or MRSA infection however there were significantly more males in the bacteraemia 
group as illustrated by Table 4-4. 
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Table 4-4 Characteristics of infected patients (Groups 3 and 4) 
 
 
4.3.3 Staphylococcus aureus colonisation compared 
to infection 
There was no statistically significant difference between the ages of those colonised with S. 
aureus (Groups 1 and 2) compared to those with S. aureus infection (Groups 3 and 4) with 
mean ages being 59.95 years and 61.60 years respectively (Table 4-5).  Distribution of 
ages of those with S. aureus infection is illustrated by  Figure 4-4.   
 
Table 4-5 Comparison of S. aureus colonised patients compared to S. aureus infected 
patients 
 S. aureus 
colonisation 
(Groups 1 and 2) 
S. aureus infection 
(Groups 3 and 4) 
P value 
Number of 
patients 
78 122 n/a 
Mean age (IQR) 
 
59.95 (53.42, 
73.49) 
61.60 (47.79, 
75.99) 
0.57 
No (%) male  
 
45 (57.7) 65 (53.3) 0.54 
No. MRSA (% S. 
aureus positive 
 
5 (6.4) 22 (18.0) 0.009 
 
 
 
 Community S. 
aureus infections 
(Group 3) 
S. aureus 
bacteraemia 
(Group 4) 
P value 
Number of 
patients 
58 64 n/a 
Mean age (IQR) 
 
58.59  
(41.59, 74.29) 
64.33 (53.38, 
73.05) 
0.11 
No (%) male  
 
22 (37.9) 43 (66.1) 0.001 
No. MRSA (% of 
S. aureus positive) 
8 (13.8) 14 (21.9) 0.24 
Chapter 4 
 
124
 
Figure 4-4 Ages of those with S. aureus infection of skin or blood (Groups 3 and 4) 
 
4.3.4 Toxin gene positivity 
There were toxin genes present in 15.0% of all isolates positive for S. aureus and in 7.6% 
of all isolates in total.  There was a single isolate containing the PVL toxin gene from a S. 
aureus positive blood culture.  This S. aureus was methicillin sensitive.  The healthy 
patients (Group 2) tended to have fewer toxin genes compared to the remainder of the 
isolates, however this did not reach statistical significance given the small numbers 
involved.  Table 4-6 summarises toxin gene positivity in all populations.    
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Table 4-6 Summary of toxin gene positivity in all specimens  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.5 Description of disease characteristics of skin 
and soft tissue infections 
Characteristics of community skin and soft tissue infections were taken from the 
information given on the microbiology request form by the requester.  There was no 
information available for 2 specimens.  8 specimens (13.8%) were MRSA positive with the 
same number having toxin gene positivity.  No specimens were both MRSA positive and 
toxin gene positive (see appendix).  There was a wide variation in the source of infection.  
18 specimens (31%) were from a wound or site of medical intervention, for example, a 
chest drain.  This suggests that a proportion of these patients had recently been inpatients 
in a hospital.  This is a potential major confounding variable.  Two of these patients were 
toxin gene positive and four were MRSA positive.     
 
 
4.3.6 Deprivation indices 
There was no significant difference in deprivation index between those colonised and those 
infected with S. aureus (p=0.41) or between those who were colonised with S. aureus 
compared to those not colonised with S. aureus (p=0.99) as illustrated by figures 4-5 and 
 No. S. 
aureus (% 
total 
screened)  
No. 
MRSA (% 
S. aureus 
positive) 
TSST 
positive 
(% 
positive) 
ETA or B 
positive 
(% 
positive) 
PVL 
positive 
(% 
positive) 
Haemodialysis 
patients 
(Group 1) 
43 (29.7) 4 (9.8) 4 (9.8) 3 (7.0) 0 
Healthy 
patients 
(Group 2) 
30 (24.0) 1 (2.8) 0 3 (10) 0 
Community 
swabs 
(Group 3) 
58 (n/a) 8 (13.8) 5 (8.6) 3 (5.2) 0 
Blood cultures 
(Group 4) 
64 (n/a) 14 (21.9) 8 (12.5) 4 (6.3) 1 (1.6) 
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4-6.  The Scottish Index of Multiple Deprivations identifies areas of deprivation within 
Scotland using postcodes.  The Scottish Index of Multiple Deprivation 2009 combines 38 
indicators across 7 domains, namely: income, employment, health, education, skills and 
training, housing, geographic access and crime.    
 
 
Figure 4-5 Boxplot of S. aureus positivity by Deprivation Index Quintile 
 
 
Figure 4-6 Boxplot of S. aureus colonisation compared to no S. aureus colonisation by 
deprivation index quintile 
 
4.3.7 Spa testing and BURP diagrams 
Spa testing was performed on all S. aureus positive isolates.  Based Upon Repeat Pattern 
(BURP) diagrams were created for all positive isolates, for the individual groups and for 
toxin gene positive isolates.  The spacing between linked spa types and between unlinked 
Chapter 4 
 
127
spa types provides no information concerning the genetic distance between them.  The spa 
type with the highest founder-score is defined founder of the cluster (blue colour). 
Subfounders are the spa types with the second highest founder-score and are labelled in 
yellow. If two or more spa types exhibit the same highest founder-score, they are all 
coloured in blue.      
 
Table 4-7 Summary overview of numbers of isolated of MSSA, MRSA and number of 
spa types by study group  
 No. 
isolates 
No. 
MSSA 
No. 
MRSA 
No. spa 
types 
MSSA 
No. spa 
types 
MRSA 
No. not 
typable 
% not 
typable 
Group 1 
Haemodialysis 
patients 
44 40 4 34 4 0 0 
Group 2 
Healthy 
patients 
34 33 1 28 1 0 0 
Group 3 
Community 
infections 
58 50 8 35 6 2 4 
Group 4 
Bacteraemias 
64 50 14 30 9 4 6.3 
 
The diversity of the spa types can be quantified using Simpson’s index of diversity (125) 
(245).  MSSA only was included and the data were combined to represent isolates from 
colonised (Groups 1 and 2) or infected patients (Groups 3 and 4).  Diversity was greater in 
the colonised groups compared to the infected patients however this did not reach 
statistical significance.   
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Figure 4-7 Estimates of genetic diversity expressed as Simpson's index of diversity of 
spa types (as a percentage) for MSSA of colonised patients (groups 1 and 2) and 
infected patients (groups 3 and 4) 
 
BURP analysis of all isolates revealed 13 spa clusters and 17 singletons in total.  This is 
illustrated using the population snapshot below.   
 
 
Figure 4-8 Population snapshot of all S. aureus strains on analysis of all isolates after 
BURP grouping.  The spa type with the highest founder-score is defined founder of the 
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cluster (blue colour). Subfounders are the spa types with the second highest founder-score 
and are labelled in yellow 
 
Isolates were grouped into MSSA isolates from patients colonised (Groups 1 and 2) and 
patients infected (Groups 3 and 4) with S. aureus.  BURP analysis of the MSSA isolates 
from Groups 1 and 2 revealed 7 spa clusters  and 19 singletons with the largest 2 
associated with t012 and t015 (Figure 4-9).  BURP analysis of the MSSA isolates from 
Groups 3 and 4 revealed 10 spa clusters and 13 singletons with the largest 2 associated 
with t032 and t012 (Figure 4-10).   
 
  
  
 
Figure 4-9 Population snapshot of the largest 4 clusters of MSSA isolates from 
Groups 1 and 2 after BURP grouping.  The spa type with the highest founder-score is 
defined founder of the cluster (blue colour). Subfounders are the spa types with the second 
highest founder-score and are labelled in yellow 
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Figure 4-10 Population snapshot of the largest 2 clusters of MSSA isolates from 
Groups 3 and 4 after BURP grouping.  The spa type with the highest founder-score is 
defined founder of the cluster (blue colour). Subfounders are the spa types with the second 
highest founder-score and are labelled in yellow 
 
4.4 Discussion 
Prevalence of S. aureus colonisation from this study was in keeping with previous research 
for haemodialysis patients and the general population (246) although it did not show a 
significantly higher point prevalence of S. aureus colonisation in haemodialysis patients.  
Overall, virulence toxin gene prevalence was low, accounting for 15.0% of all positive 
isolates and 7.6% of all isolates in total.  This is similar to existing data for S. aureus 
bloodstream infections in Europe.  Published data on S. aureus toxin gene positivity of 
colonised patients is sparse.  There was no evidence of increased prevalence of toxin gene 
positivity if the isolates were grouped into those originating from isolated compared to 
infected patients (p=0.51). 
 
These data suggest that although the virulence toxin genes may cause more severe disease, 
they are not more likely to cause disease in a colonised patient.  Observational data from 
elsewhere in the UK suggests that the percentage of MRSA colonisation with PVL toxin 
gene positivity is increasing although MRSA colonisation in general is reducing (228).  
There appears to be significant geographical variation (229).  There is also a potential 
difference in the age of those more likely to experience disease secondary to PVL positive 
S. aureus with paediatric patients more likely to develop the characteristic severe 
necrotising pneumonia associated with PVL positive S. aureus infection.  This may partly 
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explain the absence of PVL positive S. aureus in this study as those under 18 were 
specifically excluded.   
 
There is an ongoing national surveillance study funded by the Department of Health being 
performed by the Health Protection Agency focusing on patients presenting to English 
Emergency Departments or “Walk-in” centres with purulent skin infections (247).  It is 
hoped that this will provide more information on the prevalence of PVL positivity in the 
community.  Clearly, this is limited by the exclusion of isolates originating from General 
Practice, which would provide the majority of community S. aureus specimens. 
 
Spa types of MSSA positive isolates representing infection (Groups 3 and 4) were 
predominately t002, t127 and t084 which were 1st, 2nd and 6th most frequent spa types 
isolated in a recent large European epidemiological study (248).  t6057 was the 
predominant MRSA strain.  This isolate is found mostly in Germany and the Netherlands 
(209).  There was less epidemiological variation in the MRSA positive isolates than has 
been noted in previous research.  Only countries for which spa type information for more 
then ten MRSA isolates were available were included in this figure (Figure 4-11). 
 
 
Figure 4-11 Estimates of country-specific genetic diversity expressed as Simpson's 
index of diversity of spa types (as a percentage) for MSSA (light blue diamonds) and 
MRSA (dark blue diamonds) and 95% CIs (bars) 
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The role of S. aureus colonisation in the development of systemic disease is unclear.  
There is an association between community based S. aureus skin infections and nasal 
carriage (249), however a large prospective population based study using all cause 
mortality as a surrogate end point for significant S. aureus disease found no association 
between persistent S. aureus nasal carriage and death (78).  There is also evidence that 
those who are not colonised with S. aureus have an increased mortality rate if they do 
develop S. aureus bacteraemia compared to those with persistent nasal carriage (75).  
There is some evidence that S. aureus decolonisation using nasal mupirocin could reduce 
S. aureus infection in haemodialysis patients although repeated courses are required.  
There is concern that mupirocin use could promote an increased prevalence of high-level 
mupirocin resistance (250).  There were only 4 cases of high-level mupirocin resistance in 
this dataset with 3 of these isolates being MRSA.  None of these isolates were from 
haemodialysis patients.      
 
The role of toxin gene positivity in S. aureus virulence has not been fully characterised and 
is felt to be part of a complex interplay between regulation of these and other virulence 
factors with the host response and factors influencing bacterial transmission.  There is 
ongoing research into a vaccine against S. aureus and there is evidence of partial efficacy 
in haemodialysis patients in addition to healthy populations (251).   
 
4.5 Conclusion 
These data have demonstrated a similar prevalence of S. aureus colonisation in healthy 
patients and those undergoing hospital haemodialysis.  They have added to existing 
evidence of a low prevalence of toxin gene positivity in the general population and 
haemodialysis patients in particular.  There was no convincing evidence of increased 
virulence associated with toxin gene positivity manifest as skin infection in the community 
or bacteraemia, although numbers involved were small.  Further research is required into 
the prevalence of toxin gene positivity in the general population with regard to 
asymptomatic colonisation and symptomatic infection.   
 
4.6 Suggestions for further research 
Larger scale research is ongoing into the prevalence of toxin gene positivity in community 
skin infections, however the most exciting new direction is whole genome sequencing of S. 
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aureus bacteria.  This method has the potential to revolutionise the investigation of S. 
aureus transmission with particular application to the investigation of hospital-based 
outbreaks.   
 
This method of whole genome sequencing of S. aureus was utilised in an English 
secondary and tertiary referral hospital with a 24 cot special care baby unit(252).  A 
potential outbreak of MRSA colonisation was identified.  Whole genome sequencing 
helped to distinguish between isolates that were part of the outbreak and those that were 
not involved and most importantly, identify a potential source.  It also raised the currently 
unanswered  issue of whether screening of staff for MRSA could be indicated in some 
situations.  The pilot study in question screened staff after consulting with senior clinicians 
and the infection control team.  It is stated that informed consent was obtained, however 
the implications of a staff member being colonised with MRSA were not explicitly stated.       
 
Chapter 5  
 
Chapter 5: Prospective randomised double blind 
study of efficacy of probiotic milk drink (Yakult) in 
reducing the incidence of antibiotic associated 
diarrhoea and Clostridium difficile diarrhoea  
Chapter 5 
 
135
 
5.1 Introduction 
In 2006 there were more than 4000 documented cases of C. difficile infection in Scotland 
and concern was raised by the identification of a more virulent strain - NAP1/027 – which 
was felt to give rise to a more serious infection (253).  A double blind randomised study 
has shown that 100g (97ml) Actimel administered twice daily within 48 hours of starting 
antibiotics and continued for 7 days after antibiotics were stopped reduced AAD and C. 
difficile in the treatment group (181).  It found a 22% risk reduction for antibiotic 
associated diarrhoea (AAD) in the probiotic treated group (NNT = 5) and 17% reduction in 
C. difficile infection in the probiotic treated group (NNT= 6)(181).  The positive results of 
this study are supportive of the use of probiotic drinks to reduce AAD and CDAD but 
require confirmation.  
 
AAD and in particular Clostridium difficile associated diarrhoea (CDAD) are major causes 
of morbidity and mortality in hospitalised patients who are administered broad spectrum 
antibiotics. Cephalosporins, co-amoxiclav and quinolones are the main culprit antibiotics 
and the incidence of AAD may approach 25% of patients who are administered these 
antibiotics (254) (255).  
 
C. difficile is found in up to 5% of the general population (151) (256) and in up to 18% of 
hospital inpatients (257). Its growth is restricted by normal bowel flora and it flourishes in 
the presence of antibiotic treatment. Its heat resistant spores can remain in the hospital 
environment for lengthy periods (258), are resistant to gastric acid (259) and alcohol based 
cleansing solutions (260) and this allows ready spread by the faecal-oral route.  There is 
also evidence that spores can be disseminated via the aerial route (261). 
 
Diarrhoea has been defined by the WHO as the new onset of 3 or more semi-formed or 
watery stools per 24 hours.  The main predisposing factors to AAD in addition to exposure 
to antibiotics are age over 65 years, prolonged hospital stay and proton pump inhibitor 
therapy (161) (162).  AAD usually occurs within 5-10 days of starting antibiotics but may 
develop earlier than 5 days or later than 10 weeks after stopping antibiotics (262) (263). 
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Probiotics are defined as live micro-organisms which confer a health benefit to the host 
when administered in adequate numbers (132). There is some evidence that probiotics may 
be helpful in reducing the incidence of AAD and C. difficile infections.  
  
Further studies are required in high risk clinical settings, such as renal units, where broad 
spectrum antibiotics are frequently commenced on admission to hospital and the incidence 
rates of AAD and CDAD have been high. 
 
5.2  Methods 
5.2.1 Clinical setting 
The renal inpatient wards are a high-risk clinical setting for AAD and CDAD. Patient 
demographics and diagnoses on admission were recorded and used as baseline 
characteristics for patient randomisation and study analyses. A baseline stool sample was 
sent to the microbiology laboratory and stored frozen for retrospective analysis for C. 
difficile.  If CDAD developed in any patient, the baseline stool sample was retrospectively 
analysed using an alcohol-shock method followed by isolation on selective agar.  
Randomisation was stratified by age as this is a major risk factor for AAD with patients 
grouped by those aged younger than 65 or 65 and older at the time of randomisation. 
 
5.2.2 Subjects 
A. Inclusion criteria 
1. Inpatient in a renal ward and prescribed a course of antibiotic with the exception of 
vancomycin alone or metronidazole alone or in combination with another antibiotic 
2. aged 18 years or greater 
 
B. Exclusion criteria 
1. diarrhoea on randomisation or within the preceding week 
2. lactose intolerance or intolerance to dairy products 
3. regular probiotic use in the 4 weeks prior to randomisation 
4. antibiotic use in the 4 weeks prior to randomisation 
5. patients unable to give written consent within 48 hours of starting antibiotics 
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6. patients on induction dose immunosuppression (e.g. recent transplant or induction 
therapy of  vasculitis) 
7. active inflammatory bowel disease or bowel surgery less than 6 months prior to 
admission 
 
All patients were managed as per the hospital infection control recommendations to 
minimise the risk of developing or transferring infectious diarrhoea, for example, gowns 
and gloves and isolation rooms as deemed appropriate by the supervising clinician.  The 
principal stopping criterion was the development of lactobacillus bacteraemia in any 
patient suggesting systemic infection with the probiotic strain.    
 
5.2.3 Study protocol 
Patients commencing antibiotics were asked for informed consent within 48 hours of 
starting antibiotics. Patients were randomised to either probiotic milk drink (Yakult) twice 
daily or placebo solution twice daily within 48 hours of starting one or more of the above 
antibiotics and continued until 7 days after stopping antibiotics. Patients, nursing staff and 
investigators were blinded to which study product had been assigned to the patient. 
 
Randomisation was via an online portal designed by the Robertson Centre of Biostatistics, 
University of Glasgow.  Compliance with the randomised non-medicinal product (Yakult 
or placebo) was supervised by the renal unit medical and nursing staff.   
 
Stool samples were sent for culture to attempt to identify a specific cause in all patients 
who developed diarrhoea as per usual practice.  Cell culture method was used to diagnose 
the presence of CDAD. The frequency and duration of diarrhoea, identified aetiology (if 
any), and antimicrobial treatment of diarrhoea (if any), were recorded. Antimicrobial 
treatment adhered to local hospital guidelines on antibiotic treatment for Clostridium 
difficile and other enteric infections such as shigella and campylobacter.   
 
Patients were followed up for 12 weeks after recruitment with AAD, CDAD, further 
hospital admission and mortality documented.   
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The milk drinks were checked on arrival and storage refrigerators were checked regularly 
to ensure the desired temperature range was adhered to.  If the drinks were found to be too 
warm they were discarded.    
 
5.2.4 Study outcomes 
A. Primary outcome 
Incidence of AAD: 
AAD was assessed by daily monitoring of frequency of loose or semi-formed stools by 
renal nursing staff and development of abdominal pain. Diarrhoea was defined as 3 or 
more loose bowel motions in 24 hours according to the World Health Organisation 
definition.  Stool samples were sent following the diagnosis of AAD.     
 
B. Main secondary outcome 
Incidence of C. difficile diarrhoea: 
C. difficile cell culture and stool cultures were performed on all patients with undiagnosed 
diarrhoea to identify if enteric pathogens were present. 
 
C. Other secondary outcomes 
1. total days until discharge from hospital or patient death 
2. total treatment days on oral metronidazole or vancomycin 
3. adverse events attributable to Yakult or control solution 
4. significant differences in routine laboratory tests such as serum albumin 
 
5.2.5 Statistical analyses 
Data were analysed using an intention to treat analysis. Chi squared test, Mann Whitney U 
test and Student’s unpaired T test were used where appropriate. 
 
5.2.6 Power calculation 
With α=0.05 and a power of 90% to detect an absolute difference of 20% between the 
proportion of patients with antibiotic associated diarrhoea in the placebo (assumed at 30%) 
and probiotic (assumed at 10%) groups we estimated that we needed a sample size of 164 
(82 in each group). 
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5.2.7 Indemnity and ethical approval 
The study was conducted according to the guidelines laid down in the Declaration of 
Helsinki and was healthcare related research covered by NHS indemnity.  It was approved 
by the local Research and Development department and by NHS Greater Glasgow and 
Clyde research and ethics committee, (reference 08/S0704/4), on the 11th July 2008. 
 
5.3 Results 
During a 44 month period (01/03/2009 – 01/11/2012) 85 patients, who were admitted to 
the renal unit and met the inclusion and exclusion criteria, were recruited to this study 
within 2 days of starting antibiotics. Forty-four of the patients were randomised to 
probiotic milk drink and 41 to placebo.  Seven hundred and sixteen additional patients 
were screened.   
 
The main reasons why patients were not recruited were:  
• recent antibiotic use (n=220) 
• current metronidazole use (n=75) 
• declined to take part in the study (n=68) 
• antibiotic administration for >48 hours (n=65) 
• unable to give informed consent (n=59) 
• vancomycin prescribed as a single agent (n=51) 
• too unwell to participate (n=43) 
• diarrhoea (n=43) 
• long term antibiotic use (n=37) 
• high dose immunosuppression (n=36) 
• unknown (n=19)  
 
Figure 5-1 is a consort diagram illustrating the recruitment process of patients screened to 
take part in the study.  
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Figure 5-1 Consort diagram of the recruitment process of patients screened to take part in the probiotics study  
Patients screenedn=801
Patients ineligible for inclusionn=648
recent antibiotic use n=220current metronidazle n=75antibiotics for >48 hours n=65unable to consent n=59vancomycin as single agent n=51too unwell to participate n=43current diarrhoea n=43long term antibiotics n=37high dose immunosuppression n=36unknown n=19
Patients eligible for inclusionn=153
Patients recruited n=85
Patients randomised to probioticn=44
Patients completed coursen= 26
Patients did not complete course n=18
Patients randomised to placebon=45
Patients completed course n=33
Patients did not complete coursen=12
Patients declined to take part n=68
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Table 5-1 Patient characteristics at recruitment 
Characteristic Probiotic milk 
drink (n=44) 
Placebo  
(n=41) 
P value 
Age (mean, IQR*) 62.27 (52.02, 74.43) 62.49 (50.69, 
76.40) 
0.949 
 
   
Sex (% male) 27 (61.4) 26 (63.4) 0.845 
 
   
Renal replacement therapy    
emergency haemodialysis 2 4 0.352 
longterm haemodialysis 25 20 0.457 
peritoneal dialysis 4 5 0.643 
renal transplant 3 3 0.929 
    
Antibiotic duration (mean, IQR) 13.75 (7.0, 14.0) 11.40 (6.0, 10.75) 0.545 
 
   
Comorbidity    
diabetes mellitus 15 (34.09) 15 (36.59) 0.810 
ischaemic heart disease 16 (36.36) 16 (39.02) 0.800 
cerebrovascular disease 7 (15.91) 7 (17.07) 0.885 
hypertension 29 (65.91) 32 (78.05) 0.208 
asthma/COPD** 5 (11.36) 8 (19.51) 0.298 
malignancy 2 (4.55) 4 (9.76) 0.352 
vasculitis 0  2 (4.88) 0.147 
 
   
Previous CDAD 1 (2.27) 2 (4.88) 0.520 
 
   
Medications    
proton pump inhibitor 27 (61.36) 20 (48.78) 0.240 
antidiarrhoeal agents 0 1 (2.44) 0.311 
immunosuppression 8 (18.18) 6 (14.63) 0.658 
 
   
Laboratory parameters    
haemoglobin(mean, IQR) 10.5 (9.1, 11.9) 10.3 (8.7, 12.0) 0.378 
white cell count (mean, 
IQR) 
9.36 (6.79, 10.99) 10.97 (8.05, 12.45) 0.057 
platelet count (mean, IQR) 233 (154, 296) 233 (182, 280) 0.894 
C reactive protein (mean, 
IQR) 
109 (40, 163) 98 (17, 170) 0.555 
Serum albumin 28.8 (26.3, 33.0) 28.0 (23.5, 32.0) 0.550 
 
*interquartile range 
** chronic obstructive pulmonary disease 
 
Table 5-1 shows that there were no significant differences in patient baseline 
characteristics between the probiotic milk drink and placebo groups at the time of 
randomisation.  
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There was no significant difference in primary and secondary outcomes between those 
taking probiotic milk drink and placebo as illustrated by Table 5-2.  The only exception to 
this was improved compliance in the placebo group at the end of the antibiotic course 
(85.4% v 65.9%; p=0.031).  This difference was not maintained at completion of the study 
(p=0.123).  AAD occurred in 36.36% of cases in the probiotic milk drink group and 
34.14% in the placebo group.  There was no significant difference when non compliant 
patients were excluded from the analysis.  Only 2 patients developed CDAD during the 
study period.  Both of the patients with CDAD were in the placebo group.  Neither patient 
developed toxic megacolon or required colectomy. Both patients had baseline stool 
specimens submitted.  One of these specimens grew C. difficile ribotype 002.   
 
Nausea was the most common side-effect in both groups and was the predominant reason 
given for non compliance with the drinks.  Elevated tacrolimus levels were noted in 1 
patient who was in the placebo arm of the study.  
 
There was no significant change in laboratory parameters between probiotic and placebo 
groups although the study was not powered for this.   
 
47.7% patients in the probiotic group and 36.6% patients in the placebo group were 
readmitted to the renal unit during the 3 month follow up period (p=0.295).  13.3% and 
12.2% patients died during the 3 month follow-up period in the probiotic and placebo 
groups respectively (p=0.843).  This trend toward an increased rate of readmission may 
reflect an underlying increase in co-morbidity in the probiotic group that was not captured 
by the baseline characteristics recorded.  There was no significant difference in length of 
admission between the two groups, including when the analyses were censored for 
inpatient deaths and for deaths during follow-up.   
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Table 5-2 Comparison of patient outcomes between probiotic milk drink and placebo 
groups 
 Probiotic milk drink 
n=44 (%) 
Placebo 
 
n=41 (%) 
P value 
Antibiotic associated diarrhoea  16 (36.36) 14 (34.14) 0.831 
C. difficile diarrhoea 0 2 (4.87) 0.147 
 
   
Compliance    
2 days after starting 32 (72.73) 36 (87.80) 0.074 
at end of antibiotic course 29 (65.91) 35 (85.37) 0.031 
1 week after stopping antibiotic 28 (63.63) 
 
33 (80.49) 0.077 
 
   
Reasons for non compliance/ side 
effect 
   
nausea 7 (15.90) 
 
3 (7.31) 0.210 
change in immunosuppression 
levels 
0 1 (2.44) 0.311 
disruption in supply of drink 6 (13.63) 3 (7.31) 0.337 
deterioration in patient 
condition 
2 (4.54) 1 (2.44) 0.595 
patient changed their mind 
regarding taking part in study 
2 (4.54) 1 (2.44) 0.595 
 
   
Antibiotic associated diarrhoea in 
fully compliant patients 
9/26 (34.6%) 11/33 (33.3%) 0.918 
 
   
Change in laboratory parameters 
between randomisation and discharge 
(death censored) 
   
Hb (g/dl) (mean, IQR) -0.43 (-1.23, 0.13) -0.56 (-1.18, 0.48) 0.654 
WCC (mean, IQR) -0.74 (-3.15, 0.85) -2.24 (-3.93, 0.06) 0.089 
Platelet count (mean, IQR)  37 (18, 75) 37 (-3, 64) 0.951 
C reactive protein (mean, IQR)  -59 (-126, 0) -55 (-131, 2) 0.855 
Serum albumin (mean, IQR) -1.9 (-4.0, 0.25) -1.8, (-5.0, 1.0) 0.928 
 
   
Length of hospital admission (mean, 
IQR) 
10.16 (3, 12) 13.8 (6, 19) 0.104 
Readmitted during 3 month follow-up 21 (47.7) 15 (36.6) 0.295 
Died during hospital admission 2 (4.5) 1 (2.4) 0.595 
Died during 3 month follow-up 6 (13.3) 5 (12.2) 0.843 
Composite of AAD/ CDAD/ death  20 (45.5) 15 (36.7) 0.404 
 
Table 5-3 compares antibiotic burden between probiotic and placebo groups by the 
antibiotic choice at recruitment.  There was no significant difference in the proportion of 
patients taking 2 or more antibiotics at the time of recruitment.  There were more patients 
prescribed flucloxacillin and gentamicin in the probiotic group. These data are potential 
confounders as there is good evidence that antibiotic choice is associated with the 
development of AAD including CDAD.  It is notable that there was no difference between 
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the 2 groups in the proportion of patients prescribed high risk antibiotics such as co-
amoxiclav, cephalosporins and fluroquinolones.   
 
Table 5-3 Comparison of antibiotic choice at recruitment between probiotic and 
placebo groups 
 Probiotic  
n=44 (%) 
Placebo  
n=41 (%) 
P value 
Specific antibiotics    
amoxicillin  7 (15.9) 14 (33.3) 0.056 
benzylpenicillin  - 1 (2.4) 0.311 
ceftazidime  3 (6.8) 4 (9.5) 0.647 
ciprofloxacin  10 (22.7) 8 (19.0) 0.674 
clarithromycin  3 (6.8) 7 (16.7) 0.153 
clindamycin  - 1 (2.4) 0.311 
co-amoxiclav  3 (6.8) 3  (7.1) 0.953 
doxycycline  - 1 (2.4) 0.311 
flucloxacillin   10 (22.7) 3 (7.1) 0.037 
gentamicin  14 (31.8) 6 (14.3) 0.048 
levofloxacin  1 (2.3) - 0.312 
rifampicin  1 (2.3) - 0.312 
tazocin  2 (4.5) 3 (7.1) 0.608 
teicoplanin  - 1 (2.4) 0.311 
vancomycin  13 (29.5) 8 (19.0) 0.252 
number of patients prescribed 
2 or more antibiotics  
20 (45.5) 20 (47.6) 0.759 
 
 
Table 5-4 examines antibiotic use associated with AAD including CDAD.  There was no 
significant difference in the incidence of AAD between the probiotic milk drink and 
placebo groups in those prescribed 2 or more antibiotics.  There was more AAD in the 
placebo group in those prescribed flucloxacillin and gentamicin although caution is 
required in the interpretation of this given the small numbers involved and the tendency for 
these antibiotics to be prescribed concomitantly, particularly in the presence of gram 
positive infection.  All antibiotics prescribed during the follow-up period are included in 
these data.   
 
 
Chapter 5 
 
145
Table 5-4 Antibiotic associated diarrhoea including C. difficile associated diarrhoea 
by antibiotic 
 Probiotic milk drink  
no. of patients with 
AAD  
(% of total taking 
named antibiotic) 
Placebo 
no. of patients with 
AAD  
(% of total taking 
named antibiotic) 
P value 
amoxicillin 3 (30.0) 5 (27.8) 0.901 
benzylpenicillin 0 (0) 1 (100) n/a 
ceftazidime 2 (66.7) 0 n/a 
ciprofloxacin 4 (30.8) 4 (40.0) 0.646 
clarithromycin 2 (66.7) 1 (14.3) 0.083 
co-amoxiclav 2 (50.0) 2 (40.0) 0.764 
flucloxacillin 3 (23.1) 3 (75.0) 0.035 
gentamicin 4 (28.6) 5 (71.4) 0.040 
levofloxacin 1 (100) 0 (0) n/a 
rifampicin 0 (0) 1 (100) n/a 
tazocin 2 (66.7) 3 (75.0) 0.811 
vancomycin 5 (29.4) 3 (33.3) 0.838 
number of patients with AAD 
prescribed 2 or more 
antibiotics  
10 (66.7) 8 (57.1) 0.716 
 
 
Table 5-5 Site of infection at recruitment 
 Probiotic milk drink 
(n=44 patients) 
Placebo  
(n=41 patients) 
P value 
blood 1 0 0.312 
chest 9 13 0.235 
endocarditis 0 1 0.311 
line 7 3 0.210 
PD* peritonitis 3 4 0.624 
skin 10 5 0.195 
unknown 6 10 0.843 
urine 8 5 0.439 
 
*peritoneal dialysis 
 
Comparison of the site of infection between patients randomised to probiotic and patients 
randomised to placebo is illustrated in Table 5-5.  There were no significant differences in 
the site of infection between the 2 groups at initiation of treatment.   
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Table 5-3 Antibiotic associated diarrhoea by site of infection 
 Probiotic milk drink  
no. of patients with 
AAD (% total) 
Placebo 
no. of patients with 
AAD (% total) 
P value 
blood 0 (0) 0 (0) - 
chest 3 (33.3) 3 (23.1) 0.600 
endocarditis 0 (0) 1 (100) - 
line 3 (42.9) 1 (33.3) 0.773 
PD* peritonitis 2 (66.7) 0 (0) 0.014 
skin 3 (30.0) 0 (0) 0.038 
unknown 2 (33.3) 5 (50.0) 0.503 
urine 3 (37.5) 4 (80.0) 0.086 
 
 
Table 5-6 illustrates the percentage of patients with AAD separated into site of primary 
infection.  It suggests that those patients with PD associated peritonitis and randomised to 
probiotic milk were more likely to experience AAD but the number of cases was very 
small and there were no patients with PD peritonitis in the placebo group.  This difference 
is not maintained with the composite end point of AAD, CDAD and death (Table 5-7).   
 
Table 5-4 Antibiotic associated diarrhoea, CDAD or death by site of infection 
 Probiotic milk 
drink  
no. of patients with 
AAD/CDAD or 
died (% total) 
Placebo  
 
no. of patients with 
AAD/CDAD or 
died (% total) 
P value 
blood 0 (0) 0 (0)  
chest 5 (55.6) 3 (23.1) 0.109 
endocarditis 0 (0) 1 (100) - 
line 4 (57.1) 1 (33.3) 0.471 
pd peritonitis 3 (100) 0 (0) - 
skin 3 (30.0) 1 (20.0) 0.664 
unknown 2 (33.3) 5 (50.0) 0.503 
urine 4 (50.0) 4 (80.0) 0.233 
 
Patients were stratified according to age (younger than 65 or 65 and older) at the time of 
randomization.  When these groups are compared, there are no significant differences in 
outcome with the exception of increased compliance seen at the end of the antibiotic 
course in the placebo group aged younger than 65 as shown in Tables 5-8 and 5-9.  
However this higher compliance was not maintained at completion of the study 7 days 
after stopping antibiotics as was also noted when the patients younger than 65 or 65 and 
older were analysed as a single group in Table 5-2.  
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Table 5-5 Comparison of patient outcomes between probiotic milk drink and placebo 
groups in those aged younger than 65  
 Probiotic milk drink  
n=24 (%) 
Placebo 
 
n=20 (%) 
P value 
Antibiotic associated diarrhoea  8 (32.0) 8 (40.0) 0.648 
C. difficile diarrhoea 0 0  
 
   
Compliance    
2 days after starting 19 (76.0) 18 (90.0) 0.310 
at end of antibiotic course 15(60.0) 18 (90.0) 0.021 
1 week after stopping antibiotic 15 (60.0) 17 (85.0) 0.077 
 
   
Reasons for non compliance/ side 
effect 
   
nausea 5 (20.0) 1 (5.0) 0.100 
change in immunosuppression 
levels 
0 1 (5.0) 0.305 
disruption in supply of drink 4 (25.0) 0 0.020 
deterioration in patient 
condition 
0 1 (5.0) 0.305 
patient changed mind regarding 
taking part in study 
0 1 0.305 
 
   
Antibiotic associated diarrhoea in 
fully compliant patients 
3/15 (20.0%) 4/17 (23.53%) 0.809 
 
   
Readmitted during 3 month follow-up 10 (40.0) 8 (40.0) 1.000 
Died during hospital admission 0 0  
Died during 3 month follow-up 3 (12.0) 1 (5.0) 0.389 
Composite of AAD/ CDAD/ death  10 (40.0) 8 (40.0) 1.000 
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Table 5-6 Comparison of patient outcomes between probiotic milk drink and placebo 
groups in those aged 65 and older 
 Probiotic milk drink  
n=20 (%) 
Placebo 
 
n= 21 (%) 
P value 
Antibiotic associated diarrhoea  8 (40.0) 6 (28.6) 0.438 
C. difficile diarrhoea 0 2 (9.5) 0.137 
 
   
Compliance    
2 days after starting 13 (65.0) 18 (85.7) 0.114 
at end of antibiotic course 13 (65.0) 17 (81.0) 0.412 
1 week after stopping antibiotic 12 (60.0) 16 (76.2)  
 
   
Reasons for non compliance/ side 
effect 
   
nausea 2 (10.0) 2 (9.5) 0.959 
change in immunosuppression 
levels 
0 0 - 
disruption in supply of drink 2 (10.0) 2 (9.5) 0.959 
deterioration in patient 
condition 
2 (10.0) 1 (4.8) 0.972 
patient changed mind regarding 
taking part in study 
2 (10.0) 0 0.136 
 
   
Antibiotic associated diarrhoea in 
fully compliant patients 
4/12 4/16 0.632 
 
   
Readmitted during 3 month follow-up 10 (50.0) 7 (33.3) 0.273 
Died during hospital admission 1 (5.0) 1 (4.8) 0.972 
Died during 3 month follow-up 2 (10.0) 3 (14.3) 0.673 
Composite of AAD/ CDAD/ death  11 (55.0) 7 (33.3) 0.153 
 
 
Univariate binomial regression analysis was performed in order to determine factors 
associated with the development of AAD.  Univariate regression analysis is shown in 
Table 5-10.  No variable gave a statistically significant result suggesting either an 
increased or decreased risk of AAD.  
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Table 5-7 Univariate analysis of factors associated with antibiotic associated 
diarrhoea  
Variable Odds ratio Lower CI Upper CI P value 
age 1.01 0.98 1.04 0.647 
sex 1.68 0.65 4.32 0.279 
2 or more 
antibiotics 
1.33 0.53 3.38 0.543 
total antibiotics 
days 
1.03 0.99 1.07 0.102 
AKI 1.13 0.36 3.47 0.838 
Acute on CKD* 2.04 0.60 7.00 0.259 
CKD* not on 
RRT** 
1.41 0.55 3.62 0.476 
RRT** 0.53 0.20 1.36 0.185 
Diabetes mellitus 2.13 0.85 5.37 0.107 
IHD¥ 1.17 0.47 2.91 0.741 
Cerebrovascular 
disease 
0.69 0.20 2.43 0.559 
Hypertension 0.53 0.20 1.41 0.207 
Asthma/COPD¥¥ 1.18 0.35 3.97 0.796 
Malignancy 0.91 0.16 5.29 0.917 
Vasculitis 1.86 0.11 30.88 0.667 
Immunosuppressed 1.02 0.31 3.38 0.971 
Previous CDAD 3.86 0.34 44.41 0.261 
PPI use 2.07 0.82 5.23 0.117 
Antidiarrhoeals 0.00 0.00 - 0.356 
Laxatives 0.72 0.25 2.03 0.526 
Further admission 1.06 0.43 2.61 0.893 
Died during follow-
up period 
1.63 0.45 5.88 0.456 
 
* Chronic kidney disease 
** Renal replacement therapy 
¥ Ischaemic heart disease 
¥¥
 Chronic obstructive pulmonary disease 
 
 
The univariate analysis was repeated using a composite end point of AAD, CDAD and 
death as illustrated in Table 5-11.  Proton pump inhibitor (PPI) use was the only variable 
identified to be significantly associated with an increased risk of AAD, CDAD and death 
with an odds ratio of 2.79 (P= 0.23).  Total number of days on antibiotics was also 
associated with increased risk with odds ratio 1.05 (P=0.017).  Requiring long-term RRT 
appeared to be protective with odds ratio 0.42 although this did not reach statistical 
significance (p= 0.066). 
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Table 5-8 Univariate analysis of factors associated with antibiotic associated 
diarrhoea, CDAD and death 
Variable Odds ratio Lower CI Upper CI P value 
age 1.02 0.99 1.05 0.183 
sex 1.12 0.46 2.73 0.802 
2 or more 
antibiotics 
1.12 0.46 2.73 0.802 
total antibiotics 
days 
1.05 1.00 1.11 0.017 
AKI 2.00 0.67 6.01 0.214 
Acute on CKD 2.12 0.61 7.34 0.230 
CKD not on RRT 1.41 0.56 3.55 0.462 
RRT 0.42 0.16 1.07 0.066 
Diabetes mellitus 2.00 0.81 4.94 0.131 
IHD 1.34 0.55 3.26 0.513 
Cerebrovascular 
disease 
1.45 0.46 4.57 0.528 
Hypertension 0.82 0.32 2.13 0.684 
Asthma/COPD 0.83 0.25 2.77 0.757 
Malignancy 0.66 0.11 3.83 0.639 
Vasculitis 1.37 0.08 22.69 0.826 
Immunosuppressed 1.02 0.32 3.26 0.967 
Previous CDAD 2.82 0.25 32.41 0.388 
PPI use 2.79 1.13 6.90 0.023 
Antidiarrhoeal 
agents 
0.00 0.00 - 0.292 
Laxatives 0.76 0.28 2.04 0.579 
Further admission 0.95 0.40 2.28 0.913 
 
 
Multivariate binomial regression analysis for a composite of AAD, CDAD and death was 
performed using a backwards selection method for those with p values < 0.2 (Table 5-12). 
Patients requiring renal replacement therapy appear to have reduced risk of AAD, CDAD 
and death as a composite end point (OR 0.33, P= 0.054).  PPI use was associated with 
significantly increased risk of meeting the composite end point with OR 2.64.  (P= 0.003). 
 
Table 5-9 Multivariate analysis of factors associated with antibiotic associated 
diarrhoea, CDAD and death  
Variable Univariate analysis Multivariate analysis 
 Odds 
ratio 
Confidence 
Interval 
P 
value 
Odds 
ratio 
Confidence 
Interval 
P 
value 
Age 1.02 0.99, 1.05 0.183   ns 
Diabetes mellitus 2.00 0.81, 4.94 0.131   ns 
Total antibiotic 
days 
1.05 1.00, 1.11 1.05   ns 
RRT 0.42 0.16, 1.07 0.066 0.33 0.12, 0.92 0.054 
PPI 2.79 1.13, 6.90 0.023 2.64 0.99, 7.03 0.003 
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5.4 Discussion 
This double blind, randomized placebo controlled study of high risk renal inpatients has 
shown no evidence of a decreased incidence of AAD or CDAD when prescribed a 
commercially available probiotic milk drink twice daily within 2 days of starting a course 
of antibiotics (Table 5-2).  However, there was a much lower incidence of CDAD in the 
current study than in previously reported studies and the Cochrane Review. Only 2 (2.4%) 
of the 84 patients recruited to this study developed symptomatic CDAD, whereas there was 
a high incidence of AAD in both the probiotic milk drink and placebo groups.  The 
Cochrane Systematic Review found a much higher CDAD incidence of 12.6% in the 
probiotic groups and 12.7% in placebo groups in 13 studies (n=961) (183).  The WHO 
definition of diarrhoea was chosen to give a formal definition to be used by clinicians, 
however, it is limited by the lack of clarity in what constitutes “loose stool”.    
 
Clostridium difficile cases in Scotland were falling consistently throughout the duration of 
the study from 1.29 per 1000 occupied bed days in 2007-8 to 0.296 per 1000 occupied bed 
days in 2011-12.  Cases of CDAD in the Glasgow Renal Units also fell between 2008 and 
2013 with 43 cases in 2008 compared to 8 in 2012 with no significant difference in the 
total number of renal inpatient beds or bed occupancy rates.  The results of this study 
therefore need to be interpreted in the knowledge that the study was performed during a 
period of time when a bundle of measures was introduced to reduce the incidence of 
CDAD to rates much below the incidence reported in previous clinical trials. 
 
A range of preventive measures for CDAD was instituted locally and nationally during the 
study time period after a well publicised outbreak of CDAD infection and associated 
increase in mortality was reported in a specific hospital in NHS Greater Glasgow and 
Clyde.  Firstly, antibiotic guidelines were changed to restrict the use of high-risk 
antibiotics, in particular, co-amoxiclav and cephalosporins, and the subsequent reduction in 
the use of antibiotics at higher risk of inducing CDAD is shown in the data below provided 
by the Greater Glasgow and Clyde Antimicrobial Prescribing Group (Figure 5-2).  Defined 
daily dose (DDD) of cephalosporins per 1000 occupied bed days in NHS GGC fell from a 
peak of 78 between April and June 2008 to 30 between July and September 2009.  Co-
amoxiclav use also halved over a similar time period.   
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Figure 5-2 Antibiotic use before and after change in empirical antibiotic guidelines in 
August 2008 
 
Antibiotic protocols for NHS Greater Glasgow and Clyde before and after the changes 
instituted to reduce CDAD are illustrated in Figures 5-4 and 5-5 below. It is not always 
possible to adhere to empirical antibiotic guidelines and avoid the use of antibiotics at high 
risk of CDAD in the renal unit population.  For example trimethoprim or gentamicin may 
need to be avoided due to the risks of increasing serum potassium and/or serum creatinine 
concentrations in patients with severe renal impairment (264) and there is a risk of drug 
interactions in those patients taking immunosuppressive medications and antibiotics such 
as rifampicin and clarithromycin. 
 
Secondly, an infection control nursing care plan was put in place for patients with loose 
stool of unknown origin.  It covered multiple aspects of care including appropriate 
accommodation for patients with diarrhoea, attention to hand hygiene, personal protective 
equipment, decontamination of patient equipment, appropriate collection of stool 
specimens, laundry, waste disposal, environmental cleaning, and toileting facilities.  The 
care plan for patients with confirmed CDAD also stressed the requirement for appropriate 
hand hygiene and reinforced that alcohol gel was ineffective against CDAD spores.  It also 
stated that patients should not be transferred to other hospital wards or departments with 
confirmed CDAD until they were 48 hours free of symptoms and have had a formed stool.   
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With this extensive bundle of preventive measures the targets for a reduction in CDAD 
incidence rates were achieved as shown by Figure 5-3 below.  For the year ending March 
2013, the CDAD rate across NHS Scotland was 0.37 per 1,000 occupied bed days among 
patients aged 65 and over.  The current HEAT target is to reduce CDAD cases to 
0.32 cases or less per 1,000 total occupied bed days by March 2015.      
 
 
Figure 5-3 National performance for CDAD cases March 2008- March 2013 
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Figure 5-4 Empirical antibiotic guidelines in Greater Glasgow and Clyde pre June 2008 
 
Chapter 5 
 
155
 
Figure 5-3 Empirical antibiotic guidelines in Greater Glasgow and Clyde post June 2008
Chapter 5 
 
156
 
Recruitment to this study did not meet the total number required from the power 
calculation but there was not even a trend towards a reduction in AAD in the probiotic 
group. Indeed there was a 2% increase in AAD in the probiotic group compared with the 
placebo group.  The low incidence rates of CDAD observed in both groups in the current 
study were most likely related to a bundle of preventive measures introduced in all hospital 
patients during the study period.  As a consequence of the falling background CDAD rate 
during the study period, the initial power calculation was no longer valid.  Recruitment was 
slower than projected due to a number of factors including delays in transferring patients to 
the tertiary unit resulting in antibiotic use for longer than 48 hours prior to admission to the 
renal unit and higher than expected community antibiotic use.    
 
There is some recent evidence from the USA that a higher cumulative antibiotic dose is 
associated with an increased risk of CDAD.  Stevens et al conducted a retrospective cohort 
study of over 10 000 hospital admissions and found that cumulative dose, number and 
duration of antibiotic use were associated with an increased risk of the development of 
CDAD across all classes of antibiotics although those taking cephalosporins, β-lactamase 
inhibitor combinations, fluoroquinolones, sulphonamides, and intravenous vancomycin 
were significantly more likely to develop CDAD compared with patients who did not 
receive these antibiotics, regardless  of  any other antibiotics that were prescribed.  Those 
patients taking fluoroquinolones were at the highest risk (265).  In a paediatric population 
co-amoxiclav was more frequently associated with the development of AAD than other 
antibiotics (266).  This study highlighted that it is important to recognize the patient 
burden associated with AAD as well as CDAD. 
 
The recent Cochrane Systematic Review evaluated the effect of probiotics on prevention of 
AAD and CDAD and identified 23 randomized controlled trials reporting on a total of 
4213 patients (183). It found that the incidence of CDAD was 2.0% in the probiotic group 
compared to 5.5% in the placebo or no treatment control group with a relative risk of 0.36 
(95% CI 0.26 to 0.51) and rated the quality of this evidence as moderate.  Evidence for the 
effect of probiotics on AAD was found to be less robust and rated as low quality.  In 
twenty-five studies with a total of 4097 patients 13% of the participants in the probiotics 
group developed AAD compared to 21% of the placebo or no treatment control groups 
with a relative risk of 0.60 (95% CI 0.49 to 0.72).  The studies on AAD were heterogenous 
with a high proportion of missing data and, if this was taken into account, there was no 
longer a statistically significant reduction in AAD in those taking a probiotic (RR 0.90; 
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95% CI 0.69 to 1.18).   
Data in press or published recently continue to provide support for the concurrent use of 
probiotics in prevention of AAD and CDAD. A Lactobacillus casei Shirota (LcS) 
preparation was used in a randomized study in a total of 164 patients with spinal cord 
injuries within 24 hours of starting antibiotics (267).  The incidence of AAD in the LcS 
group was 17.1% compared with 54.8% in the control group (p<0.001). Patients at risk of 
undernutrition were at higher risk of developing AAD and patients taking a PPI were also 
at increased risk of AAD as was shown in the current study.  The high incidence of AAD 
was attributed to the relatively prolonged follow-up period of 30 days and this may also be 
relevant to the current study, which documented the incidence of AAD for the duration of 
antibiotic therapy and up to 12 weeks after study recruitment.  
Probiotic therapy may also reduce recurrent CDAD (268).  A single site cohort controlled 
study of patients with CDAD treated with antibiotics alone or antibiotics in conjunction 
with LcS found that recurrent CDAD was significantly lower in the cohort taking 
probiotics (3.2% v 20.0%, p=0.007).  This study is limited by its small sample size (66 
patients in total) and its retrospective non-randomised design.     
A large non-randomised study of 340 patients has compared the incidence of AAD after 
administration of LcS to an entire hospital ward including the staff and an adjacent ward 
given routine clinical care (269).  Only patients prescribed antibiotics on either ward were 
included in an analysis of AAD incidence.  The incidence of AAD in the intervention 
group was 5% compared to 18.6% in the control group (p<0.001).  Analysis of stool 
diversity showed a reduction in bacterial diversity and short chain fatty acid production in 
the routine care group.   
The PLACIDE trial is the largest trial of probiotic use in AAD to date.  It is a multicentre 
phase 3 trial of probiotic against placebo in patients aged 65 years or older (184).  The 
study recruited 2974 patients from 17 420 patients screened.  It differs from this current 
study as it recruited patients aged >65 years only.  Patients were included if they had been 
prescribed antibiotics within 7 days prior to recruitment.  There was no specific exclusion 
of recent antibiotic therapy.  The probiotic supplement was continued for 21 days 
regardless of antibiotic therapy duration.  Patients already taking probiotic supplements 
were included if they were willing to discontinue them at study entry.  Patients with 
suspected acute pancreatitis or a history of mesenteric ischaemia were excluded from the 
PLACIDE study in light of the PROPATRIA trial (144), which found that probiotic 
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administration was associated with a worse outcome in those with acute severe 
pancreatitis.  No patients with pancreatitis were included in our trial.   
 
The PLACIDE study in patients > 65 years found no evidence of a reduction in AAD or 
CDAD with the addition of a freeze dried powder in a vegetarian capsule containing 6 × 
1010 live bacteria: two strains of Lactobacillus acidophilus and two strains of 
bifidobacterium.  AAD occurred in 12.9% of the probiotic group and 11.7% of the placebo 
group.  In the current study no difference in the incidence of AAD was observed between 
patients greater and less than 65 years old (Tables 8 and 9).  Although this study showed 
no reduction in AAD with a probiotic and it was a large randomized study, it had several 
limitations: 
 
• study recruitment was permitted in subjects already using antibiotics for up to 7 
days, and so these patients may have had alterations in gut microbiota prior to 
recruitment  
• heterogeneity of antibiotic use with both intravenous and oral antibiotics being 
prescribed 
• fixed duration of probiotic administration resulting in some subjects not taking 
probiotics for the duration of antibiotic therapy 
• lower incidence of AAD and CDAD than expected resulting in the study being 
underpowered  
     
There is evidence that patients with chronic kidney disease may have differences in gut 
flora compared with the general population (270). This results in differences in gut barrier 
function and may result in bacterial translocation (271) (272).  These differences in gut 
flora may influence the effect of probiotics and make data from a general population 
difficult to extrapolate to renal patients.  Out of all the studies described above, only the 
current study investigates the effect of probiotics on the prevention of AAD and CDAD in 
renal patients.    
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5.5 Conclusions 
The role of probiotics in AAD is complex and is not fully understood.  This double-blind 
randomized controlled study has failed to demonstrate any reduction in AAD or CDAD in 
patients with kidney disease who have commenced antibiotics within the previous 2 days.    
However, the study was underpowered which may result in small differences in AAD 
between the probiotic and placebo groups not being identified in this population.  As 
recommended by the Cochrane Systematic Review, more research is required in this area, 
particularly in relation to probiotics and the prevention of AAD rather than CDAD alone.   
 
Larger, multicentre studies are required in renal patients. Such studies should be at low risk 
to the study population as the current pilot study showed that there were no significant 
adverse events and in particular there were no episodes of lactobacillus bacteraemia during 
the study period, despite the high comorbidity and relative immunosuppression of the renal 
inpatient population. 
 
 
5.6 Suggestions for further research  
 
Further research is required into the immunomodulatory effects of probiotics with 
particular attention to genus and strain specific effects.  Current research is difficult to 
compare due to differences in the probiotic intervention studied with yeasts, lactobacilli 
and preparations containing multiple strains included in meta-analyses.   
 
The Human Microbiome Project has analysed the normal flora of the intestinal microbiota 
of 242 adults (273).  It found that stool specimens displayed higher diversity than expected 
based on previous research although the gut microbiota seems to be a stable community in 
healthy subjects (274)..  It has been hypothesised that changes in microbiota over time in 
the developed world has contributed to an increase in autoimmune disease such as asthma 
as part of the “hygiene hypothesis” although definitive research is lacking (275) (276).    
 
Knowledge of the healthy microbiota may help our understanding of its role in disease 
states and therefore facilitate its manipulation for therapeutic purposes.  Current research 
suggests decreased diversity of the gut microbiota in obesity although this may be 
accounted for by a high fat diet(277) (278).  There is also emerging evidence that the 
Chapter 5 
 
160
microbiota can be implicated in carcinogenesis in addition to more well established 
research showing a role in inflammatory bowel disease(279)(280).  It is unclear whether 
these changes are causative in the pathogenesis of inflammatory bowel disease or 
secondary to underlying inflammation.  The interaction of the microbiome and potential 
manipulation by probiotics or antibiotics requires further attention.     
 
 
 
  
Chapter 6: Discussion and conclusions 
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The primary aim of this thesis was to further examine clinical problems in nephrology 
patients arising as a result of antibiotic use and infection.   
 
6.1 Acute kidney injury before and after a change in 
antibiotic policy 
The work detailed in Chapter 2 was a retrospective analysis of patients with acute kidney 
injury (AKI) requiring renal replacement therapy (RRT).  We hypothesized that a change 
in antimicrobial guidance policies after an increase in Clostridium difficile associated 
disease (CDAD) cases and subsequent increase in gentamicin prescribing, could result in a 
rise in cases of gentamicin associated AKI who required renal replacement therapy (RRT).   
 
The changes to antimicrobial guidelines were instituted in June 2008.  Administered 
gentamicin doubled between August 2008 and August 2009 from 20 to 40 defined daily 
doses per 1000 bed days.    The time periods analysed (Period 1 was 01/08/2007-
31/01/2008 and Period 2 was 01/08/2008-31/01/2009) were chosen in order to minimize 
seasonal bias and to allow a “run in” period for the new guidelines.     
 
Patients were identified retrospectively using the prospectively maintained intensive care 
unit and renal unit electronic patient records thus giving a full dataset of all patients 
receiving RRT for AKI within NHS Greater Glasgow and Clyde.  There were no 
significant differences between the patient populations.  In particular, the same proportion 
(43% patients) were prescribed gentamicin at any time during their admission to hospital 
and in fact, shorter courses of gentamicin were utilized during Period 2, perhaps reflecting 
increased antimicrobial stewardship and specific advice from the new antimicrobial 
guidelines to limit gentamicin prescribing to short courses only.  There was no significant 
increase in gentamicin associated AKI requiring RRT between Period 1 and Period 2.   
 
The data were further analysed as a whole in order to identify risk factors for gentamicin 
associated AKI.  Patients were more likely to have undergone RRT in an ITU, have 
undergone surgery and had a more prolonged admission.  Despite these adverse prognostic 
markers, there was no difference in mortality in those with gentamicin associated AKI and 
the remainder of the cohort.   
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Factors associated with deterioration in renal function from baseline were determined by 
binomial univariate then multivariate analysis of the entire cohort.  Pre-existing renal 
impairment was associated with residual deterioration from baseline renal function 
following the episode of AKI.  Patients who received RRT in a renal unit only were more 
likely to have deterioration from baseline renal function at discharge from hospital.  This 
may reflect a difference in characteristics in these patients with an increased prevalence of 
patients with a primary renal disease such as glomerulonephritis.  Gentamicin associated 
AKI was not associated with adverse renal outcomes. 
 
Finally, the entire cohort was studied by univariate then multivariate regression analysis to 
establish risk factors for increased inpatient mortality.  ITU admission and increasing age 
were independently associated with increased mortality whereas prior angiotensin 
converting enzyme inhibitor or angiotensin 2 receptor blocker use were associated with 
decreased risk of death on multivariate analysis.  There was no association between 
gentamicin associated AKI and mortality although gentamicin use at any time was 
associated with an increased risk of death on univariate analysis.  Patients with diabetes 
were associated with decreased risk of death on univariate analysis.  Diabetic patients in 
this cohort were part of a highly selected subgroup judged as suitable for admission to 
either a renal unit or critical care unit and therefore are unlikely to be representative of the 
diabetic population as a whole.           
 
These data support existing observational research that patients with pre-existing renal 
impairment are less likely to fully recover renal function after an episode of AKI and that 
requiring RRT in an ITU setting is associated with an increased risk of mortality.  It is 
unique in its analysis of the effect of increased gentamicin prescribing in the hospital 
environment on a small group of critically ill patients.      
 
One limitation of this study is that it was retrospective using an earlier time period as a 
control group in the initial analysis.  Prospective research in this area would be very 
difficult due the unknown effects of omitting gentamicin or replacing it for an alternative 
antimicrobial.  The requirement for gentamicin monitoring would result in blinding being 
impossible.   
 
Comparison with other research is difficult due to varying definitions of AKI and the lack 
of a consensus on what constitutes gentamicin associated AKI.  Gentamicin associated 
AKI in this study was defined as commencing gentamicin between 1 and 10 days prior to 
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requiring RRT and this population is unique as the main inclusion criterion is the 
requirement for RRT.  As a result, only patients with the most severe AKI were included.  
Existing research of patients receiving gentamicin suggests that less than 5% patients 
require RRT for AKI in this context with 25% patients developing AKI of any severity.   
This study did not include patients with less severe gentamicin associated AKI which 
resolved without requiring RRT or those who developed AKI but were unsuitable for renal 
unit or critical care unit admission. Therefore, further research on the development of all 
forms of AKI in association with gentamicin use is required in order to assess the total risk 
of AKI associated with an increased use of gentamicin in the empiric treatment of sepsis in 
this era of increasing antibiotic resistance.   
 
6.2 Staphylococcal bacteraemia in the renal unit.   
Sepsis is second only to cardiovascular disease as the leading cause of death in HD patients 
and staphylococcal bacteraemia is the most common cause of bacteraemia in the renal 
inpatient unit and outpatient HD unit.  Chapter 3 retrospectively compares the outcomes of 
patients with staphylococcal bacteraemia (methicillin sensitive Staphylococcus aureus 
(MSSA), methicillin resistant Staphylococcus aureus (MRSA) and coagulase negative 
staphylococcal bacteraemia) in a renal inpatient population during 2010 and 2011 and 
compares the efficacy of different antibiotic regimens in the treatment of MSSA 
bacteraemia.  The epidemiology of the Staphylococcus aureus bacteraemias in the patients 
in this study were examined using spa gene typing. 
 
Bacteraemia in HD patients occurred at a similar rate to previous datasets.  The majority 
(62.6%) of staphylococcal bacteraemias occurred in patients dialysing via tunnelled central 
venous catheters (TCVCs).  TCVC use was associated with a higher risk of developing all 
forms of staphylococcal bacteraemia (MSSA, MRSA and coagulase negative 
staphylococcus bacteraemia).  Sixty-five of the 248 (26.2%) patients from the cohort died 
within 6 months of a first episode of staphylococcal bacteraemia.  Renal transplant 
recipients were less likely to die in the 6 months after a first episode of staphylococcal 
bacteraemia compared to patients requiring regular HD reflecting their better “prior to 
bacteraemia” life expectancy than patients requiring other forms of RRT.   
 
Patients with MSSA bacteraemia had more frequent and more prolonged hospital stays in 
the 6 months following bacteraemia compared to MRSA bacteraemia although there were 
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no differences in the number of vascular access interventions, metastatic infection or 
mortality.  This is in contrast to previous literature which reported increased mortality and 
higher healthcare costs associated with MRSA bacteraemia compared to MSSA.  Although 
MRSA bacteraemia incidence is falling, MSSA bacteraemia incidence has remained 
relatively static and forms part of a current HEAT target for the reduction of healthcare 
associated infection (HCAI).       
 
No difference in outcomes for MSSA bacteraemia treated with flucloxacillin or 
vancomycin (monotherapy or in conjunction with another antibiotic) was observed in this 
study.  Vancomycin is often selected for its convenience in dosing in HD patients, as it can 
be administered intermittently on HD, thus avoiding a prolonged admission to hospital.   
 
This study had several limitations. Firstly, retrospective interpretation of the analyses of 
coagulase negative staphylococcal bacteraemia was difficult due to bacteraemia being 
defined only on the basis of positive blood culture with no requirement for a systemic 
inflammatory response. Secondly the duration of antimicrobial therapy was confounded as 
patients who developed evidence of metastatic infection would be much more likely to be 
prescribed prolonged courses of antibiotic.  Thirdly the small sample sizes  of 
subpopulations in this analysis may have led to false negative results.  Finally, although 
this study was limited by being retrospective, there are no prospective data comparing the 
efficacy of flucloxacillin and vancomycin in vivo on MSSA bacteraemia.  Treatment 
selection and patient outcomes in different forms of staphylococcal bacteraemia should be 
an important focus for future research. 
 
Spa gene typing showed that patients with recurrent SAB mostly become re-infected with 
the same genetic strain of S. aureus.  This supports existing data suggesting that individual 
patients tend to be colonised with the same strain of S. aureus.   
 
These data add to existing research confirming the increased risk of bacteraemia associated 
with TCVC use and support data suggesting consistent colonisation with the same strain of 
S. aureus may repeatedly causing disease in some patients. The need to achieve a reduction 
in the incidence of MSSA bacteraemia in renal units should become an increasing focus of 
care in the next few years.  The first objective should be to achieve a higher rate of AVF 
use in incident and prevalent HD patients and reduce reliance on TCVCs.  The second 
objective should be to develop more effective bundles of care in the prevention of MSSA 
bacteraemia in renal units and especially in HD patients with TCVCs.  Future research 
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should consider the optimum combination of infection prevention strategies in this 
vulnerable patient group.   
 
6.3 Staphylococcus aureus toxin gene positivity in 
colonisation and disease 
Toxin gene positivity may be one of the factors accounting for increased virulence and 
disease severity of some strains of S. aureus.  Disease secondary to S. aureus toxin genes 
can result in severe skin infection, necrotising pneumonia and desquamation of large areas 
of skin.   
 
The data presented in Chapter 4 further examines the role of toxin gene positivity in two 
populations colonised by S. aureus (HD patients and healthy controls) and two populations 
with S. aureus disease (general practice patients with skin infections and patients with S. 
aureus bacteraemia).  The prevalence of toxin gene positive S. aureus colonisation in the 
community is unknown, as is the proportion of disease caused by toxin gene positive S. 
aureus.  The spa gene allows an epidemiological analysis of S. aureus to be performed.  
Different toxin genes are associated with specific spa types.    
 
HD patients and healthy controls were prospectively screened for S. aureus by swabbing of 
the anterior nares into charcoal medium.  S. aureus was confirmed using SAID agar plates 
forming distinctive green colonies then confirmed using latex agglutination.     
 
Methicillin and mupirocin sensitivity was assessed in all samples using standard horse 
blood agar and antibiotic discs.  Polymerase chain reaction followed by gel electrophoresis 
was performed to confirm findings.  Toxin gene analysis was performed on all samples 
followed by spa gene analysis. 
 
Overall, 30.3% of HD patients and 27.2% of healthy controls were colonised with S. 
aureus in the anterior nares.  9.1% of HD patients who were positive for S. aureus 
colonisation were colonised with MRSA and 2.9% of healthy controls positive for S. 
aureus colonisation were colonised with MRSA.  13.8% of the general practice skin 
samples were MRSA positive and 21.9% of the S. aureus bacteraemias were MRSA 
positive.  There was evidence of recent medical intervention in many of the general 
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practice samples based on the source of infection given on the request form as either drain 
or surgical wound sites.    
 
Toxin gene positivity was present in 15.0% of all S. aureus positive samples.  There was a 
single PVL positive sample from a MSSA bacteraemia.  There was a trend towards 
increased toxin gene positivity in patients with S. aureus infection and decreased toxin 
gene positivity in the healthy controls although there were no statistically significant 
results due to the small numbers involved.  There was no significant difference in 
deprivation index between the four groups studied or between those colonised with S. 
aureus compared to those not colonised with S. aureus.   
 
Spa gene analysis was compared in colonised and infected patients.  There was no 
significant difference in genetic diversity between the groups.  Genetic diversity in this 
population was similar to that reported in the literature.   
 
The prevalence of S. aureus colonisation in these data is consistent with existing research 
data and, although it did not show a higher prevalence of S. aureus colonisation in HD 
patients, it was not powered for this purpose.  It adds to current evidence that toxin gene 
positivity varies in different populations and larger prospective trials are required to give a 
true estimate of toxin gene positivity in S. aureus colonisation.  Data from elsewhere in the 
UK suggests that colonisation with PVL positive MRSA in the community is rising 
although there was no evidence that this had occurred in this dataset.  There was no 
convincing evidence of toxin gene positivity being associated with disease compared to 
colonised patients.   
 
This study contributes to existing data suggesting that current understanding of the role of 
colonisation in invasive disease is far from complete.  Its small size limits interpretation of 
results.  Toxin gene positivity was low in this population and, although toxin genes are 
associated with disease, their role in causing infection requires further study.   
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6.4 Prevention of antibiotic associated diarrhoea using 
probiotic milk drink 
The double blind randomised controlled trial presented in Chapter 5 examines the effect of 
a commercially available probiotic milk drink on the incidence of antibiotic associated 
diarrhoea (AAD) and Clostridium difficile associated disease (CDAD) in renal unit 
inpatients prescribed antibiotics.  Patients were randomised to twice daily probiotic milk 
drink or placebo for the duration of antibiotic therapy continued for one week after 
completion of antibiotics.  Forty- four patients were randomised to probiotic and 41 to 
placebo.  There were no significant differences in baseline patient characteristics at 
randomisation.     
 
This study did not show any evidence of a reduction in either AAD or CDAD in the 
probiotic study population.  The incidence of AAD in the probiotic group was 36.36% 
compared to 34.14% in the placebo group.  There were differences in which antibiotics 
were prescribed to the probiotic and placebo groups, but these difference were low risk 
antibiotics for AAD and CDAD and not higher-risk fluroquinolones, co-amoxiclav or 
cephalosporins.  Patients prescribed proton pump inhibitor therapy were at higher risk of 
developing AAD on multivariate analysis in keeping with other studies.     
 
Interpretation of the results of this randomised controlled trial was confounded by under-
recruitment which resulted in the study being underpowered.  Furthermore the power 
calculations for this study were performed using baseline CDAD rates which were higher 
than the CDAD rates observed in both the probiotic and control groups during the study 
period and in the general population..  This fall in CDAD rates in the renal and general 
patient population occurred as a result of changes in antibiotic prescribing during the study 
period and the introduction a bundle of preventive care measures for patients who 
developed loose stool of unknown cause.   
 
Research into the effects of probiotic on AAD has increased dramatically since the study 
described in Chapter 5 began recruitment and there have been eight double blind 
randomised controlled trials published in the past 5 years.  Data on the efficacy of 
probiotics in prevention of AAD and CDAD remains equivocal and is summarised in 
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Tables 6-1 and 6-2 below with the data from Chapter 5 included to allow comparison. 
From Table 6-1, it is clear that the studies are heterogenous and most of the studies were 
small.  The majority of studies involved hospital inpatients with some studies limited to the 
elderly as they are known to be at increased risk of AAD.  Agents used as the probiotic 
intervention were also variable with some studies using the yeast, S. boulardii and some 
using multiple preparations.  Duration of probiotic therapy was variable, ranging from the 
duration of antibiotic therapy to two weeks after the antibiotic course was complete.  Some 
studies continued probiotic therapy for a specified period of time regardless of antibiotic 
course duration.  All studies were double blind with the exception of Hickson et al 2007, 
which was single blind.  A placebo yogurt was administered by nursing staff in a medicine 
administration cup which was identical to that used for the intervention.     
 
Table 6-2 examines outcomes in the study populations.  The incidence of AAD in the 
control groups varied widely from 6.0% to 35.5%.  Of the 17 studies, 7 had an incidence of 
AAD of less than 15% in the control group and 7 had an incidence of AAD of greater than 
25%.  There appears to be a trend towards higher AAD incidence in studies with a more 
prolonged follow-up period.   This may partly explain the relatively high incidence of 
AAD in the study described in Chapter 5. 
 
There were also highly variable background CDAD rates in the study populations with the 
incidence of CDAD in control groups ranging from 0 to 23.8%.  This is difficult to 
interpret due to varying definitions of C. difficile positivity in the different studiess as some 
studies did not differentiate between positive C. difficile culture from solid stool in an 
asymptomatic patient and symptomatic CDAD.  There was no definite trend of falling 
CDAD rates in these more recently reported studies.   
 
There was no evidence of any trend in reducing the incidence of AAD or CDAD in the 
study described in Chapter 5.  However the study was unique in studying renal inpatients 
which is a subgroup of hospitalised patients known to be at high risk of AAD and CDAD.  
The study was limited by its small sample size.  The incidence of AAD, although high, is 
in keeping with some of the other studies published recently (Table 6-2).  Further research 
into the role of probiotics in the prevention of either AAD or CDAD should focus on high 
risk patient populations and will need to be large multicentre studies if the studies are to 
provide an adequately powered study now that background CDAD rates are much lower 
than previously. 
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Table 6-1 Randomised controlled studies of probiotic against placebo in prevention of 
AAD: Patient characteristics, recruitment numbers, agent used and duration of 
intervention (181, 184) (281, 282), (283) (284) (285, 286) (287) (288, 289) (290) (291) 
(292) 
Study 
Year 
No. of patients Clinical setting Agent 
  
Duration of intervention 
  
Study Control 
Surawicz 
1989 
120 64 Hospital inpatients S boulardii,  Within 48h of starting 
antibiotics continued for 2 
weeks after course 
complete 
McFarland 
1995 
97 96 Hospital inpatients 
taking beta lactam 
antibiotics 
S boulardii  Within 72h of starting 
antibiotics continued for 3 
days after stopping 
Lewis  
1998 
33 36 Hospital inpatients 
aged >65 
S. boulardii  Duration of antibiotics 
 
Thomas  
2001 
133 134 Hospital inpatients  Lactobacillus 
GG 
Within 24h of antibiotics 
then for 14 days 
Plummer 
2004 
69 69 Hospital inpatients 
aged >65 
lactobacillus and 
bifidobacterium 
Within 72h of starting 
antibiotics, continued for 
20 days 
Can  
2006 
78 73 Hospitalised patients 
with no chronic 
illnesses 
S. boulardii  Within 48h of antibiotic 
then during course 
Beausoleil 
2007 
44 45 Hospital inpatients L acidophilus, L 
casei 
Within 48h of antibiotic 
then during course 
Hickson 
2007 
69 66 Hospital inpatients L. casei, L. 
bulgaricus, S. 
thermophilus  
Within 48h of antibiotic 
continued for 1 week after 
course complete 
Bravo 2008 41 45 Outpatients S. boulardii  12 days 
Safdar  
2008 
23 17 Hospitalised military 
veterans 
L. acidophilus 14 days after stopping 
antibiotic 
Wenus  
2008 
46 41 Hospital inpatients L. rhamnosus 
GG, L. 
acidophilus, 
Bifidobacterium 
Within 72h of starting 
antibiotics for 14 days 
Gao  
2010 
171 84 Hospital inpatients 
of Asian ethnicity 
L. acidophilus, 
L. casei 
Within 36h of starting 
antibiotics continued for 5 
days after antibiotic 
completed 
Lonnermar
k 2010 
80 83 Mix of hospital 
inpatients and 
outpatients 
L. plantarum Within 48h of starting 
antibiotics continued until 
a week after course 
complete 
Psaradellis 
2010 
216 221 Hospital inpatients L. acidophilus, 
L. casei 
Within 24h of starting 
antibiotics continued for 5 
days after course complete 
Pozzoni 
2012 
141 134 Hospital inpatients 
aged >50 
S. boulardii  Within 48h of starting 
antibiotics continued for 7 
days after course complete 
Allen  
2013 
1493 1488 Hospital inpatients 
aged >65 
L. acidophilus, 
Bifidobacterium 
Within 7 days of starting 
antibiotic continued for 21 
days 
Helps  
2013 
44 41 Renal unit inpatients L. casei Within 48h of starting 
antibiotics continued for 7 
days after course complete 
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Table 6-2 Randomised controlled studies of probiotic against placebo in prevention of 
AAD: incidence of AAD and CDAD with duration of follow-up  (181, 184) (182, 281, 
282) (283) (284) (285, 286) (287) (288, 289) (290) (291) (292) 
Study 
Year 
AAD CDAD Follow up 
  Probiotic Control Probiotic Control 
Surawicz 
1989 
11  
(9.2%) 
14 
(21.9%) 
5  
(4.2%) 
5  
(7.8%) 
Up to 25 days after 
stopping antibiotics 
McFarland 
1995 
7 
(7.2%) 
14 
(14.6%) 
Not assessed 
  
7 weeks after stopping 
antibiotic 
Lewis  
1998 
7  
(21.2%) 
5 (13.9%) 5  
(15.2%) 
3  
(8.3%) 
Antibiotic duration 
Thomas  
2001 
39  
(29.3%) 
40 
(29.9%) 
not assessed 
  
7 days after last study dose 
Plummer  
2004 
15  
(23.1%) 
15 
(23.1%) 
2  
(2.9%) 
5 
(7.3%) 
Not specified 
Can  
2006 
1  
(1.4%) 
7  
(9%) 
0  
 
2  
(3%) 
4 weeks after stopping 
antibiotics 
Beausoleil  
2007 
7  
(15.9%) 
16 
(35.5%) 
1  
(2.3%) 
7 (15.6%) 21 days after last antibiotic 
dose 
Hickson  
2007 
7  
(10.1%) 
19 
(28.8%) 
0 9 (13.6%) 5 weeks after stopping 
antibiotic 
Bravo  
2008 
4  
(9.8%) 
5 (11.1%) not assessed 
  
9 days after last study drug 
dose 
Safdar  
2008 
4  
(17.%) 
6  
(35.3%) 
0 1  
(5.6%) 
Not specified 
Wenus  
2008 
2  
(5.9%) 
8 (27.6%) 0 1  
(2.4%) 
Not specified 
Gao  
2010 
37 (44.0%) 37 
(21.6%) 
9  
(5.3%) 
20 
(23.8%) 
26 days after stopping 
antibiotics 
Lonnermark 
2010 
6  
(7.5%) 
5  
(6.0%) 
1  
(1.3%) 
0 7-10 days after stopping 
antibiotics 
Psaradellis 
2010 
47 (21.8%) 70 
(31.7%) 
1  
(6.2%) 
4 (13.3%) 26 days after stopping 
antibiotics 
Pozzoni  
2012 
16 (11.3%) 13 (9.7%) 3  
(2.1%) 
2 ( 
1.5%) 
4 weeks after stopping 
antibiotics 
Allen  
2013 
159 
(10.8%) 
153 
(10.4%) 
12  
(0.8%) 
17 (1.2%) 8 weeks after recruitment 
Helps  
2013 
16 
(36.36%) 
14 
(34.1%) 
0 2  
(5.0%) 
12 weeks after recruitment 
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6.5 Conclusion 
Sepsis remains second to cardiovascular disease in the reported causes of death in the RRT 
population.  The prevention of infection and avoidance of harm secondary to the treatment 
of infection are particularly relevant to the renal unit population due to the high incidence 
of infective complications in this patient group.    
 
This thesis has shown that the wider use of empiric gentamicin in hospitalized patients did 
not result in an increased incidence of dialysis dependent antibiotic associated AKI, which 
is reassuring. In contrast, the persistent, high rates of different forms of Staphylococcal 
bacteraemia in renal inpatients is disappointing given the efforts which have been made in 
attempting to increase the proportion of patients using an AVF for HD and the provision of 
bundles of care aimed at prevention of infection, especially in patients using a TCVC for 
vascular access for HD. 
 
The study of the role of toxin gene positivity in patients colonised by S. aureus (HD 
patients and healthy controls) and patients with S. aureus disease (general practice patients 
with skin infections and patients with S. aureus bacteraemia) found that the frequency of 
toxin gene positivity did not differ significantly among the different patient populations. 
The role of the gut microbiome in the prevention and causation of disease is poorly 
understood but the use of probiotics in optimizing the gut flora seems intuitive. A small 
randomized double blind trial has failed to show any trend for a reduction in AAD or 
CDAD in a renal inpatient population commencing antibiotics within 2 days of starting a 
probiotic. When this study is added to other randomized controlled trials definitive 
evidence of benefit of probiotic therapy in the prevention of AAD and CDAD or in its 
treatment remains unproven. 
 
This thesis adds to the growing body of work towards safer prescribing and reduction in 
risk associated with treatment of infection.  Questions remain regarding the optimum 
approaches in preventing S. aureus bacteraemia and AAD and CDAD in the renal patient 
population.  Future research is likely to focus on the ideal bundle of measures for 
maximum risk reduction in addition to novel approaches such as vaccination and 
decolonization strategies.  
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Appendices 
8.1 Patient characteristics and toxin gene positivity of S. 
aureus isolates originating from the community.   
Patient 
number 
Age swab location sex MRSA PVL ETA ETB TST 
1 57 shoulder F 0 0 1 1 0 
2 59 ankle M 0 0 1 0 0 
3 43 abdominal 
wound 
F 0 0 1 0 0 
4 81 hip F 0 0 0 0 1 
5 69 skin F 0 0 0 0 1 
6 69 stump site F 0 0 0 0 1 
7 51 abdominal 
wound 
F 0 0 0 0 1 
8 29 toe F 0 0 0 0 1 
9 28 ear M 0 0 0 0 0 
10 22 pilonidal sinus M 0 0 0 0 0 
11 78 wound F 0 0 0 0 0 
12 80 leg ulcer F 0 0 0 0 0 
13 39 ear F 0 0 0 0 0 
14 72 PEG* tube F 1 0 0 0 0 
15 56 leg ulcer M 0 0 0 0 0 
16 71 ear M 0 0 0 0 0 
17 92 great toe F 0 0 0 0 0 
18 89 calf wound F 0 0 0 0 0 
19 75 foot M 0 0 0 0 0 
20 40 finger F 0 0 0 0 0 
21 54 abdominal 
wound 
M 0 0 0 0 0 
22 95 NK F 0 0 0 0 0 
23 63 ear M 0 0 0 0 0 
24 36 heel M 0 0 0 0 0 
25 32 pilonidal sinus M 0 0 0 0 0 
26 57 toe M 0 0 0 0 0 
27 53 ear M 0 0 0 0 0 
28 74 leg wound F 0 0 0 0 0 
29 62 wrist F 0 0 0 0 0 
30 80 wound F 0 0 0 0 0 
31 55 ear M 0 0 0 0 0 
32 39 heel F 1 0 0 0 0 
33 38 wound F 0 0 0 0 0 
34 74 wound F 0 0 0 0 0 
35 77 sacral wound F 0 0 0 0 0 
36 48 nail bed F 0 0 0 0 0 
37 63 leg ulcer M 0 0 0 0 0 
38 30 nk F 0 0 0 0 0 
39 79 leg F 0 0 0 0 0 
40 74 foot F 0 0 0 0 0 
41 28 head M 0 0 0 0 0 
42 45 wound M 0 0 0 0 0 
43 42 skin F 0 0 0 0 0 
44 64 ankle F 1 0 0 0 0 
45 74 leg wound F 0 0 0 0 0 
46 56 groin F 0 0 0 0 0 
47 83 wound M 0 0 0 0 0 
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48 80 leg ulcer M 0 0 0 0 0 
49 72 nose F 1 0 0 0 0 
50 66 chest drain site M 1 0 0 0 0 
51 55 abdominal 
wound 
F 1 0 0 0 0 
52 30 toe M 0 0 0 0 0 
53 64 foot M 1 0 0 0 0 
54 82 heel pressure sore F 0 0 0 0 0 
55 22 ankle F 0 0 0 0 0 
56 46 leg M 0 0 0 0 0 
57 66 leg wound F 0 0 0 0 0 
58 38 spine wound F 1 0 0 0 0 
 
* Percutaneous endoscopic gastrostomy  
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8.2 Clinical Research Form: Probiotics study Chapter 6 
Patient Information 
Sticker  
Randomisation number: 
Date: 
Location: 
Telephone number: 
Alternative contact: 
        
Inclusion criteria: 
1 Aged over 18  
2 Inpatient in renal unit  
3 To start or has started a course of antibiotic other than metronidazole or vancomycin in the 
past 48h 
 
Exclusion criteria: 
1 Diarrhoea on admission or in the previous week (3 or more loose bowel motions in 24h) 
 
2 Lactose intolerance or intolerance to dairy products 
 
3 Regular probiotic use in the 4 weeks prior to admission  
 
4 Unable to give consent within 48h of starting antibiotics 
 
5 Antibiotic use in the past 4 weeks 
 
6 Induction dose immunosuppression 
 
7 Active inflammatory bowel disease or bowel surgery less than 6 months ago 
 
 
Consent form completed x3 (copy overleaf)     Y/N 
Baseline patient characteristics: 
Underlying renal disease: _______________________________________ 
RRT:       Haemodialysis/PD/transplant    ________ duration 
    HD access:   TCVC/Temp line/Graft/AVF 
    Duration on current mode of RRT 
Co-morbidity:   Hypertension     Y/N 
    IHD      Y/N 
    Cerebrovascular disease   Y/N 
    Diabetes mellitus    Y/N 
     Type 1 or type 2? ___________________ 
     Insulin     Y/N 
    Valvular heart disease    Y/N 
    Asthma/COPD    Y/N 
    Vasculitis     Y/N 
     Details____________________________ 
    Malignancy     Y/N 
     Details____________________________ 
    Previous C. difficile diarrhoea  Y/N 
     When_____________________________ 
    Other            _____________________________ 
Medications:   Immunosuppression    Y/N 
     Details____________________________ 
    PPI      Y/N 
     Preparation/dose ___________________ 
    Laxatives     Y/N 
    Anti diarrhoeal (loperamide, codeine etc) Y/N 
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Current admission 
Initial stool sample sent for reference?  Y/N    Date:_____________ 
 
Site of infection:      
Antibiotic Dose Start date Stop date Reason for change 
 
 
    
 
 
    
 
 
    
 
Microbiology results: 
Date taken Site of culture Date of result Organism Sensitivities  
     
 
     
 
     
 
Diarrhoea: defined as 3 or more loose bowel motions in 24 hours 
Present during antibiotics?       Y/N 
 Date: ____________ 
 
Culture results:   
Date Result Action taken  
   
 
   
 
   
 
Present after finishing antibiotics? 
 Date:         Y/N 
Culture results: 
Date Result Action taken 
 
 
  
 
 
  
 
 
  
 
Follow up: 
1 week after stopping antibiotics 
Compliance with milk drink Y/N  Presence of diarrhoea  Y/N 
Culture sent if required Y/N  Culture result _____________________ 
2 weeks after stopping antibiotics 
Presence of diarrhoea  Y/N  Start date:_____   End date: _______ 
Culture sent if required Y/N  Culture result _____________________ 
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8.3 Patient Information Sheet: Probiotics Study Chapter 6 
Study Title: Prospective randomised double blind study of efficacy of probiotic milk 
drink in reducing the incidence of antibiotic associated diarrrhoea and Clostridium 
difficile 
 
(Does probiotic milk drink reduce antibiotic associated diarrhoea?) 
 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. Talk to others about the study if you wish.  
(Part 1 tells you the purpose of this study and what will happen to you if you take part.  
Part 2 gives you more detailed information about the conduct of the study).  
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
 
What is the purpose of the study? 
It is known that Antibiotic Associated Diarrhoea (AAD) and in particular Clostridium 
Difficile (C. difficile) is common in hospital patients, especially those started on broad-
spectrum antibiotics, such as co-amoxiclav (augmentin) or ciprofloxacin.  As many as a 
quarter of those prescribed these antibiotics may experience AAD or C. difficile.   
 
There is some evidence from scientific studies which suggests that probiotic drinks might 
help reduce the incidence of antibiotic associated infections and C. difficile infections 
although these are not conclusive.   
 
Why have I been invited? 
We are asking all patients who are admitted to the Renal Wards and are prescribed certain 
antibiotics and are over 18 to participate in a study of whether probiotic drinks will reduce 
the incidence of antibiotic associated diarrhoea and c difficile. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you decide 
to take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive. 
 
What will happen to me if I take part? 
If you agree to take part you will be asked to take either Yakult (a probiotic milk drink) or 
sterile milk drink twice daily.  There should be no way to tell which type of drink you will 
be drinking and the doctors and nurses will not know either.  This will start within 48h of 
starting the antibiotic and continue for 7 days after stopping the antibiotic.   
We will also obtain some basic medical information from your hospital records. One of the 
doctors will also ask you some additional questions and to make a decision whether you 
are suitable for the study.   
 
What will I have to do? 
Other than take the drink two times per day, there will be very little else for you to do.  If 
you develop diarrhoea while in hospital, there will be samples sent to the laboratory 
looking for C. difficile.  We will take a stool sample from you at the beginning of the study 
so that it can be analysed later if you develop diarrhoea.  If you develop diarrhoea while at 
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home, we will ask you to let us know, so that samples can be sent for analysis.  We will 
ask you to keep taking the drink for 7 days after stopping antibiotics.   
 
 
What are the alternatives? 
If you choose, you can stop taking the drink at any time.  This will not affect your 
treatment while in hospital or afterwards.       
 
What are the possible disadvantages and risks of taking part? 
You may find that you do not like the milkshake or are intolerant of the lactose it contains.  
There have been some case reports of people possibly developing infections as a result of 
probiotic yogurts.  Those on high doses of medications to suppress the immune system are 
not being included in this study.    
 
What are the side-effects of any treatment received while taking part? 
Other than those mentioned above, there are no additional side-effects.   
 
What are the possible benefits of taking part? 
It is hoped that the incidence of antibiotic associated diarrhoea will be reduced by the use 
of probiotic yogurt although you may not benefit personally from this study.  We hope to 
use the information gathered to find out if probiotic drinks reduce the incidence of 
antibiotic associated diarrhoea and clostridium difficile in patients in the Renal Unit.  If 
you do develop AAD or C. difficile, you will, of course, be treated in the conventional 
way.    
 
What happens when the research study stops? 
When the study stops, we hope to have developed a policy for the use of probiotic yogurts 
in the renal unit.  You will have been contacted 1 month and 6 months after starting the 
study to check there have not been any problems in the meantime.     
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in Part 
2.  
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2.  
 
This completes Part 1.  If the information in Part 1 has interested you and you are 
considering participation, please read the additional information in Part 2 before making 
any decision.  
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PART 2 
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, your 
research doctor will tell you and discuss whether you should continue in the study. If you 
decide not to carry on, your research doctor will make arrangements for your care to 
continue. If you decide to continue in the study he may ask you to sign an updated consent 
form. If this happens, your research doctor might consider you should withdraw from the 
study. He/she will explain the reasons and arrange for your care to continue. If the study is 
stopped for any other reason, we will tell you and arrange your continuing care.   
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from treatment at any time.  This will not affect the care you receive.  
Information collected may still be used. Any stored blood or tissue samples that can still be 
identified as yours will be destroyed if you wish.    
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (contact number supplied). If 
you remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital.   
 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, and any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised. Your GP will be 
notified that you are taking part in this study as part of your hospital discharge letter.   
 
What will happen to any samples I give? 
An initial sample of your bowel motions will be taken and stored in the microbiology 
department so that it can be analysed if you develop diarrhoea to confirm that any bacteria 
found are new.  If you develop diarrhoea, samples of your diarrhoea will be analysed by 
the microbiology laboratory and disposed of in the usual way.    
 
What will happen to the results of the research study? 
We plan to publish the results of this study in a medical journal.   
 
Who is organising and funding the research? 
Renal Unit doctors of the Glasgow Royal Infirmary designed this study.  There is no 
external funding for the study and none of your doctors will be paid for including you in 
the study.   
The study design has been assessed and passed by the independent Local Research Ethics 
Committee of Glasgow Royal Infirmary. 
 
Further information and contact details: 
Dr Aileen Helps, Research Fellow, or Dr Robert Mactier, Consultant Nephrologist 
Both contactable at 0141-211 0566 
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Study Title: Prospective randomised double blind study of efficacy of probiotic milk drink 
(Yakult) in reducing the incidence of antibiotic associated diarrhoea and Clostridium 
difficile 
 
(Does probiotic milk drink reduce antibiotic associated diarrhoea?) 
 
Name of Researchers:  Dr R.A. Mactier, Dr A Helps 
 
Please initial box 
 
1. I confirm that I have read and understand the information sheet dated                                    
25th February 2009 (version 4) for the above study and have had the                               
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to    
 withdraw at any time, without giving any reason, without my medical  
 care or legal rights being affected. 
 
3.    I agree to take part in the above study.       
 
 
 
 
           
Name of Patient Date Signature 
 
    
Name of Person taking consent  Date Signature 
(if different from researcher) 
 
   
Researcher Date Signature 
 
 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
 
 
 
 
 
 
 
